 EXHIBIT 2.1        

Exhibit 2.1

  

  

 


 

  


 

  

AGREEMENT AND PLAN OF MERGER

  


 

  

BY AND AMONG

  


 

  

VALEANT PHARMACEUTICALS INTERNATIONAL

  


 

  

BLUE SUBSIDIARY CORP.

  


 

  

AND

  


 

  

SYNERGETICS USA, INC.

  


 

  

DATED AS OF SEPTEMBER 1, 2015

    

  

TABLE OF CONTENTS

  


 

      |  |  

 _PAGE_

   
---|---|--- 
     |  |   
     |  

Article I

  |   
     |  |   
     |  

THE OFFER

  |   
     |  |   
    

Section 1.1

  |  

The Offer

  |  

2

   
     |  |   
    

Section 1.2

  |  

Company Actions

  |  

5

   
     |  |   
     |  

Article II

  |   
     |  |   
     |  

THE MERGER

  |   
     |  |   
    

Section 2.1

  |  

The Merger

  |  

6

   
    

Section 2.2

  |  

Closing; Effective Time

  |  

6

   
    

Section 2.3

  |  

Effect of the Merger

  |  

6

   
    

Section 2.4

  |  

Organizational Documents of the Surviving Corporation

  |  

7

   
    

Section 2.5

  |  

Directors of the Surviving Corporation

  |  

7

   
    

Section 2.6

  |  

Officers of the Surviving Corporation

  |  

7

   
     |  

Article III

  |   
     |  |   
     |  

EFFECTS OF THE MERGER; EXCHANGE OF CERTIFICATES

  |   
    

Section 3.1

  |  

Effect on Capital Stock

  |  

7

   
    

Section 3.2

  |  

Exchange of Shares and Certificates

  |  

8

   
    

Section 3.3

  |  

Dissenting Shares

  |  

11

   
    

Section 3.4

  |  

Treatment of Company Options and Company Restricted Stock Awards.

  |  

11

   
     |  

Article IV

  |   
     |  |   
     |  

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  |   
    

Section 4.1

  |  

Organization, Standing and Corporate Power

  |  

12

   
    

Section 4.2

  |  

Capitalization

  |  

13

   
    

Section 4.3

  |  

Authority

  |  

15

   
    

Section 4.4

  |  

Opinion of Financial Advisor

  |  

16

   
    

Section 4.5

  |  

No Conflict

  |  

16

   
    

Section 4.6

  |  

Required Filings and Consents

  |  

16

   
    

Section 4.7

  |  

Compliance with Laws

  |  

17

   
    

Section 4.8

  |  

Regulatory Compliance.

  |  

18

   
    

Section 4.9

  |  

SEC Filings; Financial Statements

  |  

21

   
    

Section 4.10

  |  

Absence of Certain Changes or Events

  |  

23

   
    

Section 4.11

  |  

Taxes

  |  

23

   
    

Section 4.12

  |  

Litigation

  |  

25

   
   


 

  

 

i  

     

Section 4.13

  |  

Product Liability and Recalls

  |  

25

   
---|---|--- 
    

Section 4.14

  |  

Material Contracts

  |  

26

   
    

Section 4.15

  |  

Employee Benefit Plans

  |  

29

   
    

Section 4.16

  |  

Labor and Employment Matters

  |  

32

   
    

Section 4.17

  |  

Title to Personal Properties

  |  

33

   
    

Section 4.18

  |  

Real Property

  |  

34

   
    

Section 4.19

  |  

Environmental Matters

  |  

35

   
    

Section 4.20

  |  

Intellectual Property

  |  

36

   
    

Section 4.21

  |  

Brokers

  |  

39

   
    

Section 4.22

  |  

Insurance

  |  

39

   
    

Section 4.23

  |  

Information Supplied

  |  

39

   
    

Section 4.24

  |  

Related Party Transactions

  |  

39

   
    

Section 4.25

  |  

Certain Business Practices.

  |  

40

   
    

Section 4.26

  |  

Takeover Statutes

  |  

40

   
     |  |   
     |  

Article V

  |   
     |  |   
     |  

REPRESENTATIONS AND WARRANTIES

  |   
     |  

OF PARENT AND MERGER SUB

  |   
     |  |   
    

Section 5.1

  |  

Organization and Good Standing

  |  

40

   
    

Section 5.2

  |  

Authority

  |  

41

   
    

Section 5.3

  |  

No Conflict

  |  

41

   
    

Section 5.4

  |  

Required Filings and Consents

  |  

42

   
    

Section 5.5

  |  

Ownership and Operations of Merger Sub

  |  

42

   
    

Section 5.6

  |  

Sufficiency of Funds

  |  

42

   
    

Section 5.7

  |  

Litigation

  |  

42

   
    

Section 5.8

  |  

Ownership of Company Common Stock.

  |  

42

   
    

Section 5.9

  |  

Brokers

  |  

43

   
    

Section 5.10

  |  

Information Supplied

  |  

43

   
     |  |   
     |  

Article VI

  |   
     |  |   
     |  

COVENANTS

  |   
     |  |   
    

Section 6.1

  |  

Conduct of Company's Business Pending the Merger

  |  

43

   
    

Section 6.2

  |  

Access to Information; Confidentiality

  |  

47

   
    

Section 6.3

  |  

Notification of Certain Matters

  |  

47

   
    

Section 6.4

  |  

Antitrust Filings; Reasonable Best Efforts

  |  

48

   
    

Section 6.5

  |  

No Solicitation; Company Recommendation

  |  

50

   
    

Section 6.6

  |  

Stockholder Litigation

  |  

54

   
     |  |   
    

Section 6.7

  |  

Indemnification; Director and Officer Insurance

  |  

54

   
    

Section 6.8

  |  

Public Announcements

  |  

55

   
    

Section 6.9

  |  

Employees

  |  

55

   
    

Section 6.10

  |  

Rule 16b-3

  |  

57

   
    

Section 6.11

  |  

Takeover Statutes

  |  

57

   
    

Section 6.12

  |  

Termination of Credit Agreements.

  |  

57

   
   


 

  

 

ii  

     

Section 6.13

  |  

Deregistration; Stock Exchange Delisting

  |  

58

   
---|---|--- 
     |  |   
    

Section 6.14

  |  

Merger

  |  

58

   
     |  |   
    

Section 6.15

  |  

Nonregistrable CVRs

  |  

58

   
     |  |   
     |  

Article VII

  |   
     |  |   
     |  

CONDITIONS

  |   
     |  |   
    

Section 7.1

  |  

Conditions to the Obligation of Each Party

  |  

58

   
     |  |   
     |  

Article VIII

  |   
     |  |   
     |  

TERMINATION

  |   
     |  |   
    

Section 8.1

  |  

Termination

  |  

59

   
    

Section 8.2

  |  

Effect of Termination

  |  

60

   
    

Section 8.3

  |  

Fees and Expenses

  |  

61

   
     |  |   
     |  

Article IX

  |   
     |  |   
     |  

GENERAL PROVISIONS

  |   
     |  |   
    

Section 9.1

  |  

Nonsurvival of Representations and Warranties

  |  

62

   
    

Section 9.2

  |  

Notices

  |  

62

   
    

Section 9.3

  |  

Interpretation

  |  

63

   
    

Section 9.4

  |  

Entire Agreement; No Third-Party Beneficiaries

  |  

64

   
    

Section 9.5

  |  

Assignment

  |  

64

   
    

Section 9.6

  |  

Amendments

  |  

64

   
    

Section 9.7

  |  

Waiver; Remedies Cumulative

  |  

64

   
    

Section 9.8

  |  

Governing Law

  |  

65

   
    

Section 9.9

  |  

Consent to Jurisdiction; Service of Process; Venue

  |  

65

   
    

Section 9.10

  |  

Waiver of Jury Trial

  |  

65

   
    

Section 9.11

  |  

Specific Performance

  |  

65

   
    

Section 9.12

  |  

Further Assurances

  |  

66

   
    

Section 9.13

  |  

Severability

  |  

66

   
    

Section 9.14

  |  

Headings

  |  

66

   
    

Section 9.15

  |  

Counterparts

  |  

66

   
    

Section 9.16

  |  

Certain Definitions

  |  

66

   
   


 

  

EXHIBIT A Conditions of the Offer

  

EXHIBIT B Form of Contingent Value Rights Agreement

  

 

iii  

  

INDEX OF DEFINED TERMS

  


 

     

Adverse Regulatory Requirement

  |  

6.4(c)

   
---|--- 
    

Affiliate

  |  

9.16(a)

   
    

Agreement

  |  

Preamble

   
    

Anti-Corruption Laws

  |  

1.1(a)

   
    

Assets

  |  

4.17

   
    

Associate

  |  

9.16(a)

   
    

Business Day

  |  

9.16(b)

   
    

Cash Consideration

  |  

Recitals

   
    

Certificate of Merger

  |  

2.2(b)

   
    

Certificates

  |  

3.2(b)

   
    

Closing

  |  

2.2(a)

   
    

Closing Date

  |  

2.2(a)

   
    

Code

  |  

3.2(h)

   
    

Collective Bargaining Agreement

  |  

4.16(a)

   
    

Commonly Controlled Entity

  |  

9.16(c)

   
    

Company

  |  

Preamble

   
    

Company Acquisition Agreement

  |  

6.5(c)

   
    

Company Adverse Recommendation Change

  |  

6.5(c)

   
    

Company Benefit Agreements

  |  

9.16(d)

   
    

Company Benefit Plans

  |  

9.16(e)

   
    

Company Board

  |  

Recitals

   
    

Company Bylaws

  |  

4.1(c)

   
    

Company Certificate of Incorporation

  |  

4.1(c)

   
    

Company Common Stock

  |  

Recitals

   
    

Company Disclosure Letter

  |  

Article IV

   
    

Company Financial Statements

  |  

4.9(b)

   
    

Company Leases

  |  

4.18(b)

   
    

Company Material Adverse Effect

  |  

9.16(f)

   
    

Company Material Contract

  |  

4.14(b)

   
    

Company Notice of Adverse Recommendation

  |  

6.5(e)

   
    

Company Option

  |  

3.4(a)

   
    

Company Organizational Documents

  |  

4.1(c)

   
    

Company Participant

  |  

4.15(i)

   
    

Company Products

  |  

4.8(a)

   
    

Company Recommendation

  |  

4.3(b)

   
    

Company Restricted Stock Award

  |  

3.4(b)

   
    

Company SEC Reports

  |  

4.9(a)

   
    

Company Securities

  |  

4.2(b)

   
    

Company Stock Plans

  |  

9.16(g)

   
    

Company Subsidiaries

  |  

4.2(d)

   
    

Company Subsidiary

  |  

4.2(d)

   
    

Company Takeover Proposal

  |  

6.5(g)

   
    

Competition Law

  |  

4.6

   
    

Competition Laws

  |  

4.6

   
    

Confidentiality Agreement

  |  

6.2

   
   


 

  

 

iv  

     

Contingent Consideration

  |  

Recitals

   
---|--- 
    

Contract

  |  

9.16(h)

   
    

Copyrights

  |  

9.16(o)

   
    

Covered Employees

  |  

6.9(a)

   
    

Credit Agreement

  |  

6.12(a)

   
    

CVR

  |  

Recitals

   
    

CVR Agreement

  |  

Recitals

   
    

DandO Insurance

  |  

6.7

   
    

Debt Payoff Letter

  |  

6.12(a)

   
    

Debt Payoff Letters

  |  

6.12(a)

   
    

DGCL

  |  

Recitals

   
    

Dissenting Shares

  |  

3.3

   
    

Effective Time

  |  

2.2(b)

   
    

Environmental Claim

  |  

9.16(i)

   
    

Environmental Law

  |  

9.16(j)

   
    

Environmental Permits

  |  

9.16(k)

   
    

ERISA

  |  

9.16(l)

   
    

Exchange Act

  |  

1.1(a)

   
    

Exchange Fund

  |  

3.2(a)

   
    

Expiration Time

  |  

1.1(b)

   
    

FDA

  |  

4.6

   
    

FDCA

  |  

4.8(a)

   
    

FTC

  |  

4.6

   
    

GAAP

  |  

4.9(b)

   
    

Governmental Entity

  |  

4.6

   
    

Hazardous Substances

  |  

9.16(m)

   
    

HSR Act

  |  

4.6

   
    

Indebtedness

  |  

9.16(n)

   
    

Intellectual Property

  |  

9.16(o)

   
    

IP Contracts

  |  

4.14(a)(xi)

   
    

IRS

  |  

4.15(b)

   
    

known to Company

  |  

9.16(z)

   
    

Law

  |  

4.5

   
    

Leased Real Property

  |  

4.18(b)

   
    

Liability

  |  

9.16(p)

   
    

Liens

  |  

4.2(d)

   
    

Litigation

  |  

4.12(a)

   
    

Material Intellectual Property

  |  

4.18(b)

   
    

Merger

  |  

Recitals

   
    

Merger Consideration

  |  

3.1(a)

   
    

Merger Sub

  |  

Preamble

   
    

Merger Sub Common Stock

  |  

3.1(b)

   
    

Minimum Tender Condition

  |  

Exhibit A-1

   
    

NASDAQ

  |  

1.1(b)

   
    

New Plan

  |  

6.9(c)

   
    

Notice Period

  |  

6.5(e)

   
   


 

  

 

v  

     

Offer

  |  

Recitals

   
---|--- 
    

Offer Closing

  |  

1.1(c)

   
    

Offer Closing Date

  |  

1.1(c)

   
    

Offer Conditions

  |  

1.1(a)

   
    

Offer Documents

  |  

1.1(d)

   
    

Offer Price

  |  

Recitals

   
    

Order

  |  

4.5

   
    

Outside Date

  |  

8.1(b)(i)

   
    

Owned Intellectual Property

  |  

4.20(a)

   
    

Owned Real Property

  |  

4.18(a)

   
    

Parent

  |  

Preamble

   
    

Patents

  |  

9.16(o)

   
    

Paying Agent

  |  

3.2(a)

   
    

Payoff Amount

  |  

6.12(a)

   
    

Permitted Liens

  |  

9.16(q)

   
    

Person

  |  

9.16(r)

   
    

Privacy Laws

  |  

4.8(l)

   
    

Regulatory Authority

  |  

4.6

   
    

Regulatory Authorizations

  |  

9.16(s)

   
    

Regulatory Laws

  |  

4.8(a)

   
    

Release

  |  

9.16(t)

   
    

Representatives

  |  

9.16(u), 6.5(h)

   
    

Required Regulatory Authorizations

  |  

9.16(v)

   
    

Rights Agent

  |  

Recitals

   
    

Sarbanes-Oxley Act

  |  

4.9(a)

   
    

Schedule 14D-9

  |  

1.2(b)

   
    

Schedule TO

  |  

1.1(d)

   
    

SEC

  |  

1.1(b)

   
    

Securities Act

  |  

4.9(a)

   
    

Software

  |  

9.16(o)

   
    

Subsidiary

  |  

9.16(w)

   
    

Superior Proposal

  |  

6.5(g)

   
    

Surviving Corporation

  |  

2.1

   
    

Takeover Statutes

  |  

4.26

   
    

Tax Return

  |  

9.16(y)

   
    

Taxes

  |  

9.16(x)

   
    

Tender Agreements

  |  

Recitals

   
    

Termination Fee

  |  

8.3(b)(i)

   
    

to the knowledge of the Company

  |  

9.16(z)

   
    

Trade Secrets

  |  

9.16(o)

   
    

Trademarks

  |  

9.16(o)

   
    

Transactions

  |  

Recitals

   
    

Uncertificated Shares

  |  

3.2(b)

   
    

United States

  |  

9.16(aa)

   
   


 

  

 

vi  

  

AGREEMENT AND PLAN OF MERGER

  


 

  

THIS AGREEMENT AND PLAN OF MERGER (this " _Agreement_ "), dated as of
September 1, 2015, is by and among Valeant Pharmaceuticals International, a
Delaware corporation (" _Parent_ "), Blue Subsidiary Corp., a Delaware
corporation and a wholly owned Subsidiary of Parent (" _Merger Sub_ "), and
Synergetics USA, Inc., a Delaware corporation (the " _Company_ ").

  


 

  

W I T N E S S E T H:

  


 

  

WHEREAS, Parent desires to acquire the Company on the terms and subject to the
conditions set forth in this Agreement;

  


 

  

WHEREAS, in furtherance of the acquisition of the Company by Parent, Parent
proposes to cause Merger Sub to commence an offer (as it may be amended from
time to time as permitted under this Agreement, the " _Offer_ ") to purchase
all of the outstanding shares of common stock, $0.001 par value, of the
Company (" _Company Common Stock_ ") at a price per share of Company Common
Stock of (a) $6.50 net to the holder thereof in cash, subject to reduction for
any applicable withholding taxes in respect thereof, without interest (such
consideration, as it may from time to time be amended in accordance with this
Agreement, the " _Cash Consideration_ "), plus one contractual contingent
value right per share of Company Common Stock (each, a " _CVR_ "), which shall
represent the right to receive up to two contingent payments, if any, of up to
$1.00 in the aggregate, upon the achievement of certain milestones at the
times and subject to the terms and conditions of the CVR Agreement (as defined
below), net to the holder thereof in cash, subject to reduction for any
applicable withholding taxes in respect thereof, without interest (the "
_Contingent Consideration_ " and together with the Cash Consideration, the "
_Offer Price_ "), upon the terms and subject to the conditions set forth in
this Agreement;

  


 

  

WHEREAS, it is proposed that, on the terms and subject to the conditions set
forth in this Agreement and in accordance with the provisions of Section
251(h) of the General Corporation Law of the State of Delaware (the " _DGCL_
"), as soon as practicable following the purchase of the Company Common Stock
in the Offer, Merger Sub shall merge with and into the Company (the " _Merger_
"), with the Company surviving the Merger as a wholly owned Subsidiary of
Parent, and each outstanding share of Company Common Stock shall be converted
into the right to receive the Merger Consideration, without interest and
subject to any required withholding tax, except for (i) shares of Company
Common Stock held in the treasury of the Company or owned by Parent, Merger
Sub or any wholly owned Subsidiary of Parent and (ii) the Dissenting Shares;

  


 

  

WHEREAS, the board of directors of the Company (the " _Company Board_ ") has
unanimously (a) approved and declared the advisability of this Agreement, the
Tender Agreements, the CVR Agreement, the Offer, the Merger and the other
transactions contemplated by this Agreement (the Offer, the Merger and the
other transactions contemplated by this Agreement and the CVR Agreement,
collectively, the " _Transactions_ "), (b) declared that it is in the best
interests of the Company and the stockholders of the Company (other than
Parent and its Subsidiaries) that the Company enter into this Agreement and
consummate the Merger and the other transactions contemplated by this
Agreement and that the stockholders of the Company tender their shares of
Company Common Stock pursuant to the Offer, in each case on the terms and
subject to the conditions set forth herein, (c) declared that the terms of the
Offer and the Merger are fair to the Company and the Company's stockholders
(other than Parent and its Subsidiaries) and (d) resolved to recommend that
the Company's stockholders accept the Offer and tender their shares of Company
Common Stock pursuant to the Offer;

  

   

  

WHEREAS, the board of directors of Merger Sub has approved and declared it
advisable for Merger Sub to enter into this Agreement, the Tender Agreements
and to consummate the Transactions upon the terms and subject to the
conditions set forth herein;

  


 

  

WHEREAS, the board of directors of Parent has approved this Agreement, the
Tender Agreements, the CVR Agreement and the Transactions upon the terms and
subject to the conditions set forth herein;

  


 

  

WHEREAS, subject to the terms and conditions of this Agreement, at or prior to
the Offer Closing Date, Parent and a rights agent mutually agreeable to Parent
and the Company (the " _Rights Agent_ ") will enter into a Contingent Value
Rights Agreement in substantially the form attached hereto as _Exhibit B_
(subject to changes permitted by _Section 1.1(e)_ ) (the " _CVR Agreement_ ");
and

  


 

  

WHEREAS, concurrently with the execution and delivery of this Agreement, and
as a condition and inducement to the willingness of Parent and Merger Sub to
enter into this Agreement, certain stockholders of the Company are entering
into tender agreements with Parent and Merger Sub dated as of the date hereof
(the " _Tender Agreements_ "), pursuant to which, among other things, such
holders are agreeing to tender their respective shares of Company Common Stock
in the Offer, upon the terms and subject to the conditions set forth therein.

  


 

  

NOW, THEREFORE, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements contained in this
Agreement and intending to be legally bound hereby, the parties hereto agree
as follows:

  


 

  

ARTICLE I

  


 

  

 _THE OFFER_

  


 

  

Section 1.1 _The Offer_

  


 

  

(a) _Commencement of the Offer_. Subject to the terms and conditions of this
Agreement, within ten (10) Business Days after the date hereof, Merger Sub
shall, and Parent shall cause Merger Sub to, commence, within the meaning of
Rule 14d-2 under the Securities Exchange Act of 1934, as amended (together
with the rules and regulations promulgated thereunder, the " _Exchange Act_
"), the Offer; _provided_ , that the Company agrees that no shares of Company
Common Stock owned by the Company or any Company Subsidiary will be tendered
pursuant to the Offer. The obligations of Merger Sub to, and of Parent to
cause Merger Sub to, accept for payment, and pay for, any shares of Company
Common Stock tendered pursuant to the Offer are subject only to the
satisfaction or waiver (to the extent permitted under this Agreement) of the
conditions set forth in _Exhibit A_ (as they may be amended in accordance with
this Agreement, the " _Offer Conditions_ "). Merger Sub expressly reserves the
right, at any time, to, in its sole discretion, waive, in whole or in part,
any Offer Condition or modify the terms of the Offer; _provided_ , _however_ ,
that, without the prior written consent of the Company, Merger Sub shall not
(i) reduce the number of shares of Company Common Stock subject to the Offer,
(ii) reduce the Offer Price or change the form of consideration payable in the
Offer, (iii) change, modify or waive the Minimum Tender Condition, (iv) add to
the conditions set forth in _Exhibit A_ or modify or change any Offer
Condition in a manner adverse to any holders of Company Common Stock or (v)
otherwise amend the Offer in any manner adverse to the holders of Company
Common Stock (other than in immaterial respects).

  

 

2  

  

(b) _Expiration of the Offer_. The Offer shall expire at midnight at the end
of the date that is twenty (20) business days after the commencement of the
Offer (determined using Rule 14d-1(g)(3) of the Exchange Act) (such time, or
such subsequent time to which the expiration of the Offer is extended in
accordance with the terms of this Agreement, the " _Expiration Time_ ");
_provided_ , _however_ , that, subject to the provisions of Article VIII, (i)
if at the Expiration Time, any Offer Condition shall not have been satisfied
or waived (to the extent permitted under applicable Law), Merger Sub may, in
its sole discretion, without the consent of the Company, extend the Offer for
one or more consecutive increments of not more than ten (10) Business Days
each (the length of such period to be determined by Parent or Merger Sub),
until the earlier of (A) the termination of this Agreement in accordance with
its terms and (B) the Outside Date and (ii) if at the Expiration Time, any
Offer Condition shall not have been satisfied or waived (to the extent
permitted under applicable Law), Merger Sub shall (and Parent shall cause
Merger Sub to), extend the Offer at the request of the Company for one or more
consecutive increments of not more than ten (10) Business Days each (the
length of such period to be determined by Parent or Merger Sub after
consultation with the Company), until the earlier of (A) the termination of
this Agreement in accordance with its terms and (B) the Outside Date. Merger
Sub shall extend the Offer for any period required by any rule, regulation,
interpretation or position of the United States Securities and Exchange
Commission (the " _SEC_ "), the staff thereof or the NASDAQ Stock Market ("
_NASDAQ_ ") applicable to the Offer or as may be required by any other
Governmental Entity; _provided_ , that Merger Sub shall not be required to
extend the Offer to a date later than the Outside Date. Nothing contained in
this _Section 1.1(b)_ shall affect any termination rights in _Article VIII_.

  


 

  

(c) _Offer Closing_. On the terms and subject to the conditions of this
Agreement (including the satisfaction or waiver of the conditions set forth in
_Exhibit A_ ), Merger Sub shall, and Parent shall cause Merger Sub to, (i)
accept for payment all shares of Company Common Stock validly tendered and not
validly withdrawn pursuant to the Offer prior to 9:00 a.m. New York City time,
on the business day (determined using Rule 14d-1(g)(3) of the Exchange Act)
immediately following the Expiration Time and (ii) pay for all such shares
(subject to any applicable Tax withholding pursuant to _Section 3.2(h)_ ) as
soon as practicable after the Expiration Time. The Offer Price payable in
respect of each share of Company Common Stock pursuant to the preceding
sentence shall be paid net to the holder thereof in cash, without interest, on
the terms and subject to the conditions of this Agreement. Acceptance for
payment of shares of Company Common Stock pursuant to and subject to the
conditions of the Offer upon the expiration of the Offer is referred to in
this Agreement as the " _Offer Closing_ ," and the date on which the Offer
Closing occurs is referred to in this Agreement as the " _Offer Closing
Date_."

  

 

3  

  

(d) _Schedule TO; Offer Documents_. On the date of commencement of the Offer,
Parent and Merger Sub shall file with the SEC a Tender Offer Statement on
Schedule TO with respect to the Offer (together with all amendments and
supplements thereto and including exhibits thereto, the " _Schedule TO_ "),
which shall contain an offer to purchase and a related letter of transmittal
and summary advertisement, a notice of appraisal rights as contemplated by
Section 262(d)(2) of the DGCL and other appropriate ancillary offer documents
(such Schedule TO and the documents included therein pursuant to which the
Offer will be made, together with any supplements or amendments thereto, the "
_Offer Documents_ "), and cause the Offer Documents to be disseminated to the
stockholders of the Company as and to the extent required by United States
federal securities Laws. Parent and Merger Sub shall cause the Schedule TO to
comply in all material respects with the Exchange Act, the DGCL and all other
applicable Law. The Company shall promptly furnish to Parent and Merger Sub
all information concerning the Company required by the Exchange Act to be set
forth in the Offer Documents. Each of Parent, Merger Sub and the Company shall
promptly correct any information supplied by it for inclusion or incorporation
by reference in the Offer Documents if and to the extent that such information
shall have become false or misleading in any material respect, and each of
Parent, Merger Sub and the Company shall take all steps necessary to amend or
supplement the Offer Documents and to cause the Offer Documents as so amended
or supplemented to be filed with the SEC and disseminated to the stockholders
of the Company, in each case as soon as reasonably practicable and as and to
the extent required by applicable United States federal securities Laws.
Parent and Merger Sub shall promptly notify the Company upon the receipt of
any comments from the SEC, or any request from the SEC for amendments or
supplements, to the Offer Documents, and shall promptly provide the Company
with copies of all correspondence between them and their Representatives, on
the one hand, and the SEC, on the other hand. Prior to the filing of the Offer
Documents (including any amendment or supplement thereto) with the SEC or
dissemination thereof to the stockholders of the Company, or responding to any
comments of the SEC with respect to the Offer Documents, Parent and Merger Sub
shall provide the Company and its counsel a reasonable opportunity to review
and comment on such Offer Documents or response, and Parent and Merger Sub
shall give reasonable, good faith consideration to any such comments.

  


 

  

(e) At or prior to the Offer Closing Date, Parent will authorize and duly
adopt, execute and deliver, and will ensure that a duly qualified Rights Agent
executes and delivers, the CVR Agreement, subject to any reasonable revisions
to the CVR Agreement that are requested by such Rights Agent ( _provided_ that
such revisions are not, individually or in the aggregate, detrimental to any
CVR holder, other than in immaterial respects).

  


 

  

(f) Parent shall provide or cause to be provided to Merger Sub on a timely
basis the consideration necessary to pay for any shares of Company Common
Stock that Merger Sub becomes obligated to accept for payment, and pay for,
pursuant to the Offer.

  

 

4  

  

Section 1.2 _Company Actions_

  


 

  

(a) The Company hereby approves and consents to the Transactions. The Company
represents that it has been advised that all of its directors and all of its
named executive officers (as defined in the Company's most recent proxy
statement) who own shares of Company Common Stock intend to tender such shares
pursuant to the Offer.

  


 

  

(b) To the extent reasonably practicable, on the date the Offer Documents are
filed with the SEC (and, in any event, within one (1) Business Day thereof),
the Company shall file with the SEC a Solicitation/Recommendation Statement on
Schedule 14D-9 with respect to the Offer (such Schedule 14D-9, together with
any supplements or amendments thereto, the " _Schedule 14D-9_ ") containing
the Company Recommendation and shall mail the Schedule 14D-9 to the
stockholders of the Company as and to the extent required by Rule 14d-9 under
the Exchange Act. The Company shall cause the Schedule 14D-9 to comply in all
material respects with the Exchange Act and all other applicable Law. Parent
and Merger Sub shall promptly furnish to the Company all information
concerning Parent and Merger Sub required by the Exchange Act to be set forth
in the Schedule 14D-9. Each of the Company, Parent and Merger Sub shall
promptly correct any information supplied by it for inclusion or incorporation
by reference in the Schedule 14D-9 if and to the extent that such information
shall have become false or misleading in any material respect, and the Company
shall take all steps necessary to amend or supplement the Schedule 14D-9 and
to cause the Schedule 14D-9 as so amended or supplemented to be filed with the
SEC and disseminated to the stockholders of the Company, in each case as soon
as reasonably practicable and as and to the extent required by applicable
United States federal securities Laws. The Company shall promptly notify
Parent upon the receipt of any comments from the SEC, or any request from the
SEC for amendments or supplements, to the Schedule 14D-9, and shall promptly
provide Parent with copies of all correspondence between the Company and its
Representatives, on the one hand, and the SEC, on the other hand. Prior to the
filing of the Schedule 14D-9 (including any amendment or supplement thereto)
with the SEC or mailing thereof to the stockholders of the Company, or
responding to any comments of the SEC with respect to the Schedule 14D-9, the
Company shall provide Parent and its counsel a reasonable opportunity to
review and comment on such Schedule 14D-9 or response, and the Company shall
give reasonable and good faith consideration to any such comments. The Company
hereby consents to the inclusion in the Offer Documents of the Company
Recommendation.

  


 

  

(c) In connection with the Offer and the Merger, the Company shall cause its
transfer agent to furnish Parent and Merger Sub promptly, and in any event
within five (5) Business Days of the date hereof, with mailing labels
containing the names and addresses of the record holders of Company Common
Stock as of the latest practicable date and of those persons becoming record
holders subsequent to such date, together with copies of all lists of
stockholders, security position listings and computer files and all other
information in the Company's possession or control regarding the beneficial
owners of shares of Company Common Stock, in each case as of the latest date
practicable, and shall furnish to Parent and Merger Sub such information and
assistance (including periodically updated lists of stockholders, security
position listings and computer files) as Parent may reasonably request in
communicating the Offer to holders of Company Common Stock. Subject to the
requirements of applicable Law, and except for such steps as are necessary to
disseminate the Offer Documents and any other documents necessary to
consummate the Offer and the Merger, Parent and Merger Sub and their agents
(x) shall hold in confidence the information contained in any such labels,
listings and files and will use such information only in connection with the
Offer and the Merger and (y) following the termination of this Agreement,
shall promptly, at the election of Parent, deliver to the Company or destroy,
and will use their reasonable best efforts to cause their agents to deliver to
the Company or destroy, all copies and any extract or summaries of such
information then in their possession or control and promptly certify to the
Company in writing that all such material has been so returned or destroyed.

  

 

5  

  

ARTICLE II

  


 

  

 _THE MERGER_

  


 

  

Section 2.1 _The Merger._ Subject to the terms and conditions of this
Agreement, and in accordance with the DGCL, at the Effective Time, the Company
and Merger Sub shall consummate the Merger pursuant to which (a) Merger Sub
shall be merged with and into the Company and the separate corporate existence
of Merger Sub shall thereupon cease, (b) the Company shall be the surviving
corporation in the Merger under the name "Synergetics USA, Inc." and shall
continue to be governed by the DGCL and (c) the separate corporate existence
of the Company with all its rights, privileges, immunities, powers and
franchises shall continue unaffected by the Merger. The corporation surviving
in the Merger is sometimes hereinafter referred to as the "Surviving
Corporation". The Merger shall be governed by Section 251(h) of the DGCL and
shall be effected as soon as practicable following the Offer Closing.

  


 

  

Section 2.2 _Closing; Effective Time_

  


 

  

(a) The closing of the Merger (the " _Closing_ ") shall take place at 10:00
a.m., New York City time, as soon as commercially practicable following the
Offer Closing, and in no event later than the fifth (5th) Business Day after
which, all of the conditions set forth in Article VII are satisfied or waived
(other than those conditions that by their nature are to be satisfied at the
Closing, it being understood that the occurrence of the Closing shall remain
subject to the satisfaction or waiver of such conditions at the Closing), at
the offices of Skadden, Arps, Slate, Meagher and Flom LLP, Four Times Square,
New York, New York 10036, unless another time, date or place is agreed to in
writing by the parties hereto. The date on which the Closing occurs is
referred to herein as the " _Closing Date_."

  


 

  

(b) Upon the terms and subject to the conditions set forth in this Agreement,
on the Closing Date, the parties hereto shall file a certificate of merger
(the " _Certificate of Merger_ ") with the office of the Secretary of State of
the State of Delaware and shall make all other filings or recordings required
under the DGCL. The Merger shall become effective on such date and at such
time as the Certificate of Merger is duly filed with the Secretary of State of
the State of Delaware, or at such subsequent date and time as may be agreed in
writing by Parent and the Company and specified in the Certificate of Merger.
The date and time at which the Merger becomes effective is referred to in this
Agreement as the " _Effective Time_."

  


 

  

Section 2.3 _Effect of the Merger._ The Merger shall have the effects
specified in the applicable provisions of the DGCL. Without limiting the
generality of the foregoing, and subject thereto, at the Effective Time, the
Surviving Corporation shall possess all the rights, privileges, powers and
franchises, and be subject to all of the restrictions, disabilities and duties
of the Company and Merger Sub, as provided under Section 259 of the DGCL.

  

 

6  

  

Section 2.4 _Organizational Documents of the Surviving Corporation_

  


 

  

(a) The certificate of incorporation of the Company, as heretofore amended,
shall be amended and restated in its entirety at the Effective Time to be
identical to the certificate of incorporation of Merger Sub in effect
immediately prior to the Effective Time, except that all references therein to
Merger Sub shall be automatically amended and shall become references to the
Surviving Corporation and the provisions of the certificate of incorporation
of Merger Sub relating to the incorporator of Merger Sub shall be omitted,
until thereafter changed or amended as provided therein or by applicable Law.

  


 

  

(b) The bylaws of Merger Sub as in effect immediately prior to the Effective
Time shall become the bylaws of the Surviving Corporation at the Effective
Time, except that all references to Merger Sub shall be automatically amended
and shall become references to the Surviving Corporation, until thereafter
changed or amended as provided therein or by applicable Law.

  


 

  

Section 2.5 _Directors of the Surviving Corporation._ The directors of Merger
Sub immediately prior to the Effective Time shall be the initial directors of
the Surviving Corporation until the earlier of their resignation or removal or
until their respective successors are duly elected and qualified, as the case
may be. At Parent's request, the Company shall obtain and deliver to Parent
the written resignations of each of the directors of the Company, to be
effective at the Effective Time.

  


 

  

Section 2.6 _Officers of the Surviving Corporation._ The officers of Merger
Sub immediately prior to the Effective Time shall be the initial officers of
the Surviving Corporation until the earlier of their resignation or removal or
until their respective successors are duly designated, as the case may be.

  


 

  

ARTICLE III

  


 

  

 _EFFECTS OF THE MERGER; EXCHANGE OF CERTIFICATES_

  


 

  

Section 3.1 _Effect on Capital Stock._ Upon the terms and subject to the
conditions of this Agreement, at the Effective Time, by virtue of the Merger
and without any action on the part of Parent, Merger Sub, the Company or the
holders of any shares of Company Common Stock:

  


 

  

(a) _Conversion of Company Common Stock_. Each share of Company Common Stock
issued and outstanding immediately prior to the Effective Time (other than (i)
shares owned by Parent, Merger Sub or any other direct or indirect wholly
owned subsidiary of Parent, (ii) shares to be canceled pursuant to _Section
3.1(c)_ and (iii) the Dissenting Shares) shall be converted into the right to
receive (A) an amount in cash, per share of Company Common Stock, equal to the
Cash Consideration and (B) one (1) CVR subject to and in accordance with the
terms and conditions of the CVR Agreement in each case, without any interest
and subject to any applicable Tax withholding in accordance with _Section
3.2(h)_ (collectively, the " _Merger Consideration_ "), upon surrender of such
shares of Company Common Stock pursuant to _Section 3.2(b)_ and in compliance
therewith. As of the Effective Time, each share of Company Common Stock shall
no longer be outstanding and shall automatically be canceled and shall cease
to exist, and each holder thereof shall cease to have any rights with respect
thereto, except the right to receive the Merger Consideration in accordance
with the terms of this Agreement.

  

 

7  

  

(b) _Conversion of Merger Sub Common Stock_. Each share of common stock, $0.01
par value, of Merger Sub (the " _Merger Sub Common Stock_ ") that is issued
and outstanding immediately prior to the Effective Time shall be converted
into one validly issued, fully paid and nonassessable share of common stock,
$0.01 par value, of the Surviving Corporation, and the shares of the Surviving
Corporation into which the shares of Merger Sub common stock are so converted
shall be the only shares of the Surviving Corporation that are issued and
outstanding immediately after the Effective Time.

  


 

  

(c) _Cancellation of Certain Shares_. Each share, if any, of Company Common
Stock that is held by the Company as a treasury share and each share of
Company Common Stock that is owned by the Company or Parent or by any direct
or indirect wholly owned Company Subsidiary or Parent shall be canceled
without any conversion, and no consideration shall be delivered or deliverable
in exchange therefor.

  


 

  

Section 3.2 _Exchange of Shares and Certificates_

  


 

  

(a) _Paying Agent_. At or prior to the Effective Time, Parent shall engage a
financial institution designated by Parent and reasonably satisfactory to the
Company to act as paying agent in connection with the Merger (the " _Paying
Agent_ "). At or prior to the Effective Time, Parent shall, or shall cause the
Surviving Corporation to, deposit with the Paying Agent, in trust for the
benefit of the holders of shares of Company Common Stock immediately prior to
the Effective Time, the aggregate Cash Consideration in respect of the Company
Common Stock, it being understood that any and all interest or other amounts
earned with respect to such funds shall be for the account of and turned over
to Parent in accordance with _Section 3.2(f)_ (it being understood and agreed,
for the avoidance of doubt, that Parent shall not be required to deposit any
funds related to any CVR with the Rights Agent unless and until such deposit
is required pursuant to the terms of the CVR Agreement). All cash deposited
with the Paying Agent shall hereinafter be referred to as the " _Exchange
Fund_."

  


 

  

(b) _Exchange Procedures_. Parent shall instruct the Paying Agent to mail,
promptly after the Effective Time (but in no event later than five (5)
Business Days following the Effective Time), to each holder of record of (i) a
certificate or certificates which immediately prior to the Effective Time
represented outstanding shares of Company Common Stock (the " _Certificates_
") or (ii) uncertificated shares of Company Common Stock represented by book-
entry (the " _Uncertificated Shares_ "), in each case, which at the Effective
Time were converted into the right to receive the Merger Consideration
pursuant to _Section 3.1_ , (A) a letter of transmittal in customary form
(which, in the case of Certificates, shall specify that delivery shall be
effected, and risk of loss and title to the Certificates shall pass, only upon
delivery of the Certificates to the Paying Agent and shall be in such form and
have such other provisions as Parent may reasonably specify) and (B)
instructions for use in effecting the surrender of the Certificates or
Uncertificated Shares in exchange for the Merger Consideration. Upon (1)
surrender of Certificates for cancellation to the Paying Agent or receipt of
an "agent's message" by the Paying Agent (or such other evidence, if any, of
transfer as the Paying Agent may reasonably request) in the case of a book-
entry transfer of Uncertificated Shares, together with such letter of
transmittal, duly completed and validly executed in accordance with the
instructions thereto and (2) such other documents as may reasonably be
required by the Paying Agent, the holder of such Certificates or
Uncertificated Shares shall be entitled to receive in exchange therefor the
amount of the Merger Consideration to which such holder is entitled pursuant
to _Section 3.1_ , and any Certificates so surrendered shall forthwith be
cancelled. If the Merger Consideration (including, for the avoidance of doubt,
payment in the form of or with respect to the CVRs) is to be paid to any
Person other than the Person in whose name the surrendered Certificate or the
transferred Uncertificated Share is registered, it shall be a condition to
such payment that (i) either such Certificate shall be properly endorsed or
shall otherwise be in proper form for transfer or such Uncertificated Share
shall be properly transferred and (ii) the Person requesting such payment
shall pay to the Paying Agent any transfer or other Taxes required as a result
of such payment to a Person other than the registered holder of such
Certificate or Uncertificated Share or establish to the satisfaction of Parent
that such Tax has been paid or is not payable. Until surrendered as
contemplated by this _Section 3.2(b)_ , each share of Company Common Stock
represented by a Certificate or Uncertificated Share shall be deemed at any
time after the Effective Time to represent only the right to receive the
Merger Consideration upon such surrender.

  

 

8  

  

(c) _No Further Ownership Rights in Company Common Stock_. The Merger
Consideration paid upon the surrender for exchange of Certificates or
Uncertificated Shares in accordance with the terms of this _Article III_ shall
be deemed to have been paid in full satisfaction of all rights pertaining to
the shares of Company Common Stock previously represented by such Certificates
or Uncertificated Shares. At the Effective Time, the stock transfer books of
the Company shall be closed, and there shall be no further registration of
transfers on the stock transfer books of the Surviving Corporation of the
shares of Company Common Stock which were outstanding immediately prior to the
Effective Time. If, after the Effective Time, Certificates or Uncertificated
Shares are presented to the Surviving Corporation or the Paying Agent for any
reason, they shall be cancelled and exchanged as provided in this _Article
III_.

  


 

  

(d) _Termination of Exchange Fund_. Any portion of the Exchange Fund which
remains undistributed to the holders of Company Common Stock six (6) months
after the Effective Time shall be delivered to Parent, upon demand, and any
holders of Company Common Stock who have not theretofore complied with this
_Article III_ shall thereafter look only to Parent for payment of their claim
for the Merger Consideration, subject to subsection (e) below.

  


 

  

(e) _No Liability_. None of Parent, Merger Sub, the Company and the Paying
Agent or any of their respective directors, officers, employees and agents
shall be liable to any Person in respect of Merger Consideration delivered to
a public official pursuant to any applicable abandoned property, escheat or
similar Law. If any Certificate or Uncertificated Share shall not have been
surrendered prior to six (6) years after the Effective Time, any cash
remaining in the Exchange Fund at that time shall, to the extent permitted by
applicable Law, become the property of the Surviving Corporation, free and
clear of all claims or interests of any Person previously entitled thereto.

  

 

9  

  

(f) _Investment of Exchange Fund_. If Parent determines to invest the Exchange
Fund, Parent shall cause the Paying Agent to invest the Exchange Fund in
direct short-term obligations of, or obligations fully guaranteed by the full
faith and credit of, the United States of America or in commercial paper
obligations rated A-1 or P-1 or better by Moody's Investors Service, Inc. or
Standard and Poor's Corporation, respectively, or a combination of the
foregoing, and, in each case, with maturities not exceeding three (3) months
or money market mutual funds comprised of any of the foregoing. To the extent
there are losses with respect to such investments or the Exchange Fund
diminishes for any other reasons below the level required to make prompt cash
payment of the aggregate funds required to be paid pursuant to this Agreement,
Parent shall, or shall cause Merger Sub to, promptly deposit additional funds
into the Exchange Fund such that the funds held in the Exchange Fund are
thereafter sufficient to satisfy the obligations of Parent and Merger Sub
hereunder. Any interest and other income resulting from such investment shall
become a part of the Exchange Fund, and any amounts in excess of the amounts
payable pursuant to this _Article III_ shall promptly be paid to Parent.

  


 

  

(g) _Certain Adjustments_. Without limiting the other provisions of this
Agreement, in the event that, during the period between the date hereof and
the Effective Time, the number of outstanding shares of Company Common Stock
or securities convertible or exchangeable into or exercisable for shares of
Company Common Stock shall be changed into a different number of shares or
securities or a different class, including as a result of a reclassification,
stock split (including a reverse stock split), stock dividend or distribution,
recapitalization, merger, issuer tender or exchange offer, or other similar
transaction, then the Offer Price, the Merger Consideration and any other
amounts payable pursuant to this Agreement shall be equitably adjusted,
without duplication, to reflect such change; _provided_ that, in any case,
nothing in this _Section 3.2(g)_ shall be construed to permit the Company to
take any action with respect to its securities that is prohibited by the terms
of this Agreement.

  


 

  

(h) _Withholding_. Parent, the Company, the Surviving Corporation, the Paying
Agent and the Rights Agent shall be entitled to deduct and withhold from the
consideration otherwise payable pursuant to this Agreement, the CVR Agreement
or otherwise such amounts as Parent, the Company, the Surviving Corporation or
the Paying Agent, as applicable, is required to deduct and withhold with
respect to the making of such payment under the Internal Revenue Code of 1986,
as amended (the " _Code_ ") and Treasury Regulations promulgated thereunder,
or any other provision of Tax Law. To the extent that amounts are so withheld
and paid over to the appropriate Governmental Entity by Parent, the Company,
the Surviving Corporation, the Paying Agent or the Rights Agent, as
applicable, such withheld amounts shall be treated for all purposes as having
been paid to the Person in respect of which such deduction and withholding was
made.

  


 

  

(i) _Lost, Stolen or Destroyed Certificates_. In the event any Certificates
shall have been lost, stolen or destroyed, the Paying Agent shall issue in
exchange for such lost, stolen or destroyed Certificates, upon the making and
delivery of an affidavit of that fact by the holder thereof and delivery of a
properly completed letter of transmittal to the Paying Agent, the Merger
Consideration as may be required pursuant to _Section 3.1(a)_ ; _provided_ ,
_however_ , that Parent may, in its discretion and as a condition precedent to
the issuance thereof, require the owner of such lost, stolen or destroyed
Certificates to deliver an agreement of indemnification in form reasonably
satisfactory to Parent, or a bond in such sum as Parent may reasonably direct
as indemnity, against any claim that may be made against Parent or the Paying
Agent in respect of the Certificates alleged to have been lost, stolen or
destroyed.

  

 

10  

  

Section 3.3 _Dissenting Shar_ _es._ Notwithstanding any provision of this
Agreement to the contrary, shares of Company Common Stock that are issued and
outstanding immediately prior to the Effective Time and which are held by
holders of such shares of Company Common Stock who properly exercise appraisal
rights with respect thereto in accordance with Section 262 of DGCL (the
"Dissenting Shares") shall not be exchangeable for the right to receive the
Merger Consideration, and holders of such Dissenting Shares will be entitled
only to receive payment of the appraised value of such shares of Company
Common Stock in accordance with the provisions of such Section 262 unless and
until such holders fail to perfect or effectively withdraw or lose their
rights to appraisal and payment under the DGCL. If, after the Effective Time,
any such holder fails to perfect or effectively withdraws or loses such right,
such shares of Company Common Stock will thereupon be treated as if they had
been converted into and to have become exchangeable for, at the Effective
Time, the right to receive the Merger Consideration without any interest
thereon. The Company shall give Parent (a) prompt notice of any demands
received by the Company for appraisals of shares of Company Common Stock and
(b) the opportunity to direct all negotiations and proceedings with respect to
demands for appraisal under the DGCL. The Company shall not, except with the
prior written consent of Parent, make any payment with respect to any demands
for appraisal or offer to settle or settle any such demands.

  


 

  

Section 3.4 _Treatment of Company Options and Company Restricted Stock
Awards_.

  


 

  

(a) _Company Options_. Effective as of the Effective Time, each option to
purchase shares of Company Common Stock granted under any Company Stock Plan
(each, a " _Company Option_ ") that is outstanding immediately prior to the
Effective Time and that is not then fully vested and exercisable shall become
fully vested and exercisable as of the Effective Time. Effective as of the
Effective Time, all Company Options outstanding immediately prior to the
Effective Time (after giving effect to the acceleration of vesting described
herein) shall be cancelled and, in consideration for such cancellation, the
holders thereof shall automatically (and without any further action being
required of such holders) receive from the Surviving Corporation, at, or as
soon as practicable following, the Effective Time, (i) a lump-sum cash payment
equal to (A) the total number of shares of Company Common Stock subject to
such Company Option, multiplied by (B) the excess, if any, of (x) the Cash
Consideration over (y) the per-share exercise price for such Company Option
and (ii) one (1) CVR for each share of Company Common Stock underlying such
Company Option outstanding immediately prior to the Effective Time, in each
case without interest and subject to any applicable Tax withholding in
accordance with _Section 3.2(h)_.

  


 

  

(b) _Other Awards Under the Company Stock Plans_. Each restricted share of
Company Common Stock granted under any Company Stock Plan (each, a " _Company
Restricted Stock Award_ ") that is outstanding immediately prior to the
Effective Time and that is not then fully vested shall become fully vested as
of the Effective Time. Effective as of the Effective Time, all Company
Restricted Stock Awards outstanding immediately prior to the Effective Time
(after giving effect to the acceleration of vesting described herein) shall be
cancelled and, in consideration for such cancellation, the holders thereof
shall automatically (and without further action being required of such
holders) receive, at, or as soon as practicable following, the Effective Time,
(i) an amount in cash from the Surviving Corporation equal to the Cash
Consideration and (ii) one (1) CVR for each share of Company Common Stock
underlying such Company Restricted Stock Award outstanding immediately prior
to the Effective Time, in each case without interest and subject to any
applicable Tax withholding in accordance with _Section 3.2(h)_ ).

  

 

11  

  

(c) _Company Actions_. Prior to the Effective Time, the Company shall take all
actions reasonably necessary (i) to effect the provisions of this _Section
3.4_ , (ii) to ensure that no Person has any rights to acquire Company Common
Stock or common stock of Parent or any of its Subsidiaries (including the
Surviving Corporation) pursuant to any Company Benefit Plan or Company Benefit
Agreement following the Effective Time and (iii) to terminate all of the
Company Stock Plans immediately prior to the Effective Time.

  


 

  

ARTICLE IV

  


 

  

 _REPRESENTATIONS AND WARRANTIES OF THE COMPANY_

  


 

  

Except (a) as set forth in the written disclosure letter delivered by the
Company to Parent and Merger Sub in connection with the execution and delivery
of this Agreement (the " _Company Disclosure Letter_ ") (with specific
reference to the particular section or subsection of this Agreement to which
the information set forth in such Company Disclosure Letter relates;
_provided_ , that any information set forth in one section or subsection of
the Company Disclosure Letter shall be deemed to apply to each other section
or subsection thereof to which its relevance is reasonably apparent on the
face of such disclosure contained in the Company Disclosure Letter) or (b) as
disclosed in the Company's Annual Report on Form 10-K for the fiscal year
ended July 31, 2014, and each Company SEC Report filed subsequent to such Form
10-K but prior to the date hereof, but excluding, in each case, any
disclosures set forth in any risk factor section or in any other section of
any such Company SEC Report to the extent they are forward-looking statements
or cautionary, predictive or forward-looking in nature; _provided,_ that the
exception provided for in this clause (b) shall be applied if, and only if,
the nature and content of the applicable disclosure in any such Company SEC
Report is reasonably specific as to matters and items such that the subject
matter of such disclosure is reasonably apparent on the face of the text of
such disclosure to be applicable to the representation or warranty set forth
herein, the Company represents and warrants to Parent and Merger Sub as
follows:

  


 

  

Section 4.1 _Organization, Standing and Corporate Power_

  


 

  

(a) The Company (i) is a corporation duly organized, validly existing and in
good standing under the Laws of the State of Delaware and (ii) has all
requisite corporate power and authority and all necessary governmental
approvals to own, lease and operate its properties and other assets and to
carry on its business as now being conducted, except where the failure to have
such power, authority or governmental approvals has not had, and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect. The Company is duly qualified or licensed to do
business and is in good standing in each jurisdiction in which the nature or
conduct of its business or the ownership, leasing or operation of its
properties and other assets requires it to be so qualified, licensed or in
good standing, except for such jurisdictions where the failure to be so
qualified, licensed or to be in good standing has not had, and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect.

  

 

12  

  

(b) Each Company Subsidiary is a corporation or other legal entity duly
organized, validly existing and in good standing under the Laws of the
jurisdiction of its incorporation or organization and has all requisite
corporate (or similar) power and authority and all necessary governmental
approvals to own, lease and operate its properties and other assets and to
carry on its business as now being conducted, except where the failure to be
in good standing or have such power, authority or governmental approvals has
not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect. Each Company Subsidiary is duly
qualified or licensed to do business and is in good standing in each
jurisdiction in which the nature or conduct of its business or the ownership,
leasing or operation of its properties and other assets requires it to be so
qualified, licensed or in good standing, except for such jurisdictions where
the failure to be so qualified, licensed or to be in good standing has not
had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

  


 

  

(c) The Company has delivered or made available to Parent true and correct
copies of the Amended and Restated Certificate of Incorporation of the
Company, as amended through the date hereof (as so amended, the " _Company
Certificate of Incorporation_ "); the Amended and Restated Bylaws of the
Company, as amended through the date hereof (as so amended, the " _Company
Bylaws_ " and together with the Company Certificate of Incorporation, the "
_Company Organizational Documents_ "); and the equivalent organizational
documents of each Company Subsidiary, in each case, as amended through the
date hereof. The Company Organizational Documents and the equivalent
organizational documents of the Company Subsidiaries are in full force and
effect and have not been amended or otherwise modified. The Company is not in
violation of any provision of the Company Organizational Documents. No Company
Subsidiary is in violation of any provision of its certificate of
incorporation, bylaws or equivalent organizational documents, except where
such violations have not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. The
Company has delivered or made available to Parent complete and correct copies
of the minutes (or, in the case of minutes that have not yet been finalized,
complete and correct drafts thereof) of (i) all meetings of the stockholders
or other equity-holders of the Company and each of the Company Subsidiaries,
(ii) the Company Board and the boards of directors (or equivalent governing
body) of each of the Company Subsidiaries and (iii) the committees of each
such board of directors (or comparable governing body), in each case held
since July 31, 2011 and prior to the date hereof.

  

 

13  

  

Section 4.2 _Capitalization_

  


 

  

(a) The authorized capital stock of the Company consists of 50,000,000 shares
of Company Common Stock. At the close of business on September 1, 2015, (i)
25,573,288 shares of Company Common Stock were issued and outstanding (which
includes 289,814 Company Restricted Stock Awards vesting in accordance with
their terms), (ii) no shares of Company Common Stock were held by the Company
in its treasury and (iii) 1,088,542 shares of Company Common Stock were
subject to outstanding and unexercised Company Options. _Section 4.2(a)_ of
the Company Disclosure Letter sets forth, as of the date hereof, the
authorized and outstanding capital stock (or other equity interests) of each
Company Subsidiary held directly or indirectly by the Company and the total of
such outstanding capital stock (or other equity interests).

  


 

  

(b) Except as set forth in _Section 4.2(a)_ , at the close of business on
September 1, 2015, no shares of capital stock or other voting securities of
the Company were issued, reserved for issuance or outstanding. Except as set
forth in _Section 4.2(a)_ of the Company Disclosure Letter, from September 1,
2015 until the date hereof, there have been no issuances by the Company of
shares of capital stock of, or other equity or voting interests in, the
Company, other than the issuance of shares of Company Common Stock pursuant to
the exercise of Company Options outstanding as of September 1, 2015, in
accordance with their terms. Except for the Tender Agreements and as set forth
in _Section 4.2(a), 4.2(b)_ and _4.2(c)_ of the Company Disclosure Letter, as
of the date hereof, there are no options, warrants, convertible or
exchangeable securities, subscriptions, stock appreciation rights, phantom
stock rights or stock equivalents or other rights, agreements, arrangements or
commitments (contingent or otherwise) of any character issued or authorized by
the Company or any Company Subsidiary (i) relating to any issued or unissued
capital stock or equity interest of the Company or any Company Subsidiary,
(ii) obligating the Company or any Company Subsidiary to issue, deliver or
sell, or cause to be issued, delivered or sold, any shares of capital stock
of, or options, warrants, convertible or exchangeable securities,
subscriptions or other equity interests in the Company or any Company
Subsidiary or (iii) that give any Person the right to receive any economic
benefit or right similar to or derived from the economic benefits and rights
accruing to holders of capital stock of the Company or any Company Subsidiary
(each of (i), (ii) and (iii), collectively, the " _Company Securities_ "). All
outstanding shares of Company Common Stock are, and all shares of Company
Common Stock that may be issued prior to the Effective Time will be when
issued, duly authorized, validly issued, fully paid and nonassessable. There
are no outstanding contractual obligations of the Company or any Company
Subsidiary to (x) repurchase, redeem or otherwise acquire any capital stock or
equity interest of the Company (including any shares of Company Common Stock)
or any Company Subsidiary or any Company Securities or (y) pay any dividend or
make any other distribution in respect thereof or to provide funds to, or make
any investment (in the form of a loan, capital contribution or otherwise) in,
any Person, other than pursuant to the Company Stock Plans. The Company is not
party to (1) any agreement granting registration rights to any Person, (2) any
stockholders agreements, voting trusts or other agreements or understandings
relating to voting or disposition of any shares of capital stock or other
securities of the Company or any Company Subsidiary or (3) any agreements
granting to any Person or group of Persons the right to elect, or to designate
or nominate for election, a member of the Company Board or the board of
directors of any Company Subsidiary.

  


 

  

(c) _Section 4.2(c)_ of the Company Disclosure Letter sets forth a true,
complete and correct list, as of September 1, 2015, of (i) all Company
Options, the expiration dates, the exercise or base prices and the names of
the holders thereof and (ii) all Company Restricted Stock Awards and the
holders thereof. Each outstanding Company Option and Company Restricted Stock
Award, including the Company Options set forth in _Section 4.2(b)_ of the
Company Disclosure Letter, shall be treated at the Effective Time as set forth
in _Section 3.4_.

  

 

14  

  

(d) _Section 4.2(d)_ of the Company Disclosure Letter lists all the
Subsidiaries of the Company (each a " _Company Subsidiary_ " and together, the
" _Company Subsidiaries_ ") in existence as of the date hereof. All of the
outstanding shares of capital stock of, or other equity interests in, each
Company Subsidiary have been duly authorized and validly issued and are fully
paid and nonassessable and are, except as set forth in _Section 4.2(d)_ of the
Company Disclosure Letter, owned directly or indirectly by the Company, and
with respect to those shares or other equity interests owned directly or
indirectly by the Company, are free and clear of all pledges, claims, liens,
charges, encumbrances and security interests of any kind or nature whatsoever
(collectively, " _Liens_ ") other than Permitted Liens and free of any other
restriction (including any restriction on the right to vote, sell or otherwise
dispose of such capital stock or other ownership interests), except for
restrictions imposed by applicable Laws.

  


 

  

(e) Neither the Company nor any Company Subsidiary directly or indirectly
owns, or has any right or obligation to subscribe for or otherwise acquire,
any equity or similar interest in, or any interest convertible into or
exchangeable or exercisable for, any corporation, partnership, joint venture
or other business association or entity (other than the Company Subsidiaries).

  


 

  

Section 4.3 _Authority_

  


 

  

(a) The Company has all necessary corporate power and authority to execute and
deliver this Agreement, to perform its obligations hereunder and to consummate
the Transactions. The execution, delivery and performance by the Company of
this Agreement and the consummation by the Company of the Transactions have
been duly authorized by all necessary corporate action on the part of the
Company, and no other corporate proceedings on the part of the Company are
necessary to authorize the Company to execute and deliver this Agreement or to
consummate the Transactions (other than the filing and recordation of
appropriate merger documents as required by the DGCL and as set forth in
_Section 4.6_ ). This Agreement has been duly executed and delivered by the
Company and, assuming the due authorization, execution and delivery by the
other parties hereto, constitutes the legal, valid and binding obligation of
the Company, enforceable against the Company in accordance with its terms
subject, as to enforcement of remedies, to bankruptcy, insolvency,
reorganization, moratorium or similar Laws affecting the rights and remedies
of creditors generally and to the effect of general principles of equity
(regardless of whether such enforceability is considered in a proceeding at
law or in equity).

  


 

  

(b) The Company Board, at a meeting duly called and held and at which a quorum
was present, duly adopted resolutions unanimously (a) approving and declaring
the advisability of this Agreement and the Transactions, (b) declaring that it
is in the best interests of the Company and the stockholders of the Company
(other than Parent and its Subsidiaries) that the Company enter into this
Agreement and consummate the Transactions and that the stockholders of the
Company tender their shares of Company Common Stock pursuant to the Offer, in
each case on the terms and subject to the conditions set forth herein, (c)
declaring that the terms of the Offer and the Merger are fair to the Company
and the Company's stockholders (other than Parent and its Subsidiaries) and
(d) recommending that the Company's stockholders accept the Offer and tender
their shares of Company Common Stock pursuant to the Offer (collectively, the
" _Company Recommendation_ "), which resolutions, except to the extent
permitted by _Section 6.5_ , have not been rescinded, modified or withdrawn in
any way.

  

 

15  

  

Section 4.4 _Opinion of Financial Advisor._ William Blair and Company, L.L.C.
has delivered to the Company Board its opinion to the effect that, as of the
date of such opinion and based on the assumptions, qualifications and
limitations contained therein, the consideration to be received by the holders
of Company Common Stock pursuant to the Offer and the Merger is fair, from a
financial point of view, to such holders. The Company has delivered or made
available to Parent a correct and complete copy of such opinion solely for
informational purposes.

  


 

  

Section 4.5 _No Conflict._ Neither the execution and delivery of this
Agreement by the Company nor the consummation by the Company of the
Transactions, nor performance of this Agreement by the Company will (a)
conflict with or violate the Company Organizational Documents or the
equivalent organizational documents of any Company Subsidiary, (b) assuming
receipt of the approvals referenced in Section 4.6, if required for
consummation of the Merger, conflict with or violate any United States
federal, state or local or any foreign statute, law, rule, regulation,
ordinance, code or any other requirement or rule of law including Regulatory
Laws (each, a "Law") or any charge, temporary restraining order or other
order, writ, injunction (whether preliminary, permanent or otherwise),
judgment, guideline, doctrine, guidance, decree, ruling, determination,
directive, corporate integrity agreement or similar agreement, award or
settlement, whether civil, criminal or administrative (each, an "Order"), or
any rule or regulation of any securities exchange on which the Company Common
Stock is listed for trading, in each case applicable to the Company or any
Company Subsidiary or by which any property or asset of the Company or any
Company Subsidiary is bound or affected, or (c) result in a breach of or
constitute a default (or an event which with notice or lapse of time or both
would become a default) under, give to others any right of termination,
amendment, acceleration or cancellation of, result in the triggering of any
payment or other obligation or any right of consent, or result in the creation
of a Lien (other than Permitted Liens) on any property or asset of the Company
or any Company Subsidiary pursuant to, any note, bond, mortgage, indenture,
Contract, agreement, lease, sublease, license, permit, franchise or other
instrument or obligation to which the Company or any Company Subsidiary is a
party or by which the Company or any Company Subsidiary or any property or
asset of any of them is bound or affected (including any Company Material
Contract and any permits), except, in the case of clauses (b) and (c), for any
such conflicts, violations, breaches, defaults or other occurrences which have
not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

  


 

  

Section 4.6 _Required Filings and Consents._ The execution and delivery by the
Company of this Agreement does not, and the performance by the Company of this
Agreement will not, require any consent, approval, order, authorization or
permit of, or declaration, registration, filing with, or notification to, any
United States federal, state or local or any foreign government or any court,
administrative or other governmental or government-authorized authority or
agency, domestic or foreign, including any Regulatory Authority (a
"Governmental Entity"), except for (a) applicable requirements, if any, of (i)
the Exchange Act, including the filing with the SEC of the Schedule 14D-9,
(ii) state securities or "blue sky" Laws, (iii) the DGCL to file the
Certificate of Merger or other appropriate documentation and (iv) NASDAQ, (b)
those required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended (the "HSR Act"), (c) such filings and approvals as are required or
advisable, in the discretion of Parent, to be made or obtained under any other
applicable federal, state or foreign statute, rule, regulation, order, decree,
administrative and judicial doctrine or other Law that is designed or intended
to prohibit, restrict or regulate actions having the purpose or effect of
monopolization, restraint of trade, lessening of competition or foreign
investment (together with the HSR Act, the Sherman Act, as amended, the
Clayton Act, as amended, the Federal Trade Commission Act, as amended, each a
"Competition Law" and, collectively, the "Competition Laws"), (d) such
filings, clearances, registrations, consents, waivers, orders, authorizations,
permits, declarations, amendments, supplements, notices and approvals as are
required to be made with or obtained from the United States Food and Drug
Administration (the "FDA"), the United States Federal Trade Commission (the
"FTC"), the United States Department of Health and Human Services, Centers for
Medicare and Medicaid Services or any other federal, state, local or foreign
Governmental Entity that is concerned with or regulates the development,
testing, packaging, labeling, storage, import, export, marketing, sale, use,
handling and control, purity, quality, safety, efficacy, reliability,
distribution or manufacturing of cosmetic products, pharmaceutical products,
medical devices and related products, federal or state health care programs or
the provision of health care or similar services (each, a "Regulatory
Authority") and (e) such consents, approvals, orders, authorizations, permits,
declarations, filings or notifications, the failure of which to obtain or make
would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect.

  

 

16  

  

Section 4.7 _Compliance with Laws_

  


 

  

(a) Since January 1, 2011, each of the Company and the Company Subsidiaries
(i) except as set forth in _Sections 4.7(a)(i)_ and _4.8(e)_ of the Company
Disclosure Letter, has been operated at all times in compliance with all Laws
and Orders applicable to the Company and the Company Subsidiaries and by which
any property, business or asset of the Company or any Company Subsidiary is
bound and (ii) is not in default or violation of any governmental licenses,
registrations, clearances, approvals, permits or franchises to which the
Company or any Company Subsidiary is a party or by which the Company or any
Company Subsidiary or any property or asset of the Company or any Company
Subsidiary is bound other than, in the case of clauses (i) and (ii), failures
to comply, defaults or violations which have not had, and would not reasonably
be expected to have, individually or in the aggregate, a Company Material
Adverse Effect. Except as otherwise set forth in _Section 4.8(e)_ of the
Company Disclosure Letter, since January 1, 2011, neither the Company nor any
Company Subsidiary has received any written communication from a Governmental
Entity that alleges that the Company or any Company Subsidiary is not in
compliance in any material respect with any applicable Law or Order.

  


 

  

(b) The Company and the Company Subsidiaries have established internal
controls and compliance programs that include policies and procedures
reasonably designed to cause the Company, any Company Subsidiaries and their
respective officers, employees, agents and contractors to be in compliance
with all applicable Laws in all material respects.

  

 

17  

  

Section 4.8 _Regulatory Compliance_.

  


 

  

(a) Except as set forth in _Sections 4.8(a)_ and _4.13_ of the Company
Disclosure Letter, all medical devices and supplies of the Company or any
Company Subsidiary (collectively, the " _Company Products_ ") are being or
have been developed, tested, manufactured, packaged, labeled, stored,
imported, exported, marketed, sold and distributed in compliance in all
material respects with all applicable Laws, including (i) the Federal Food,
Drug, and Cosmetic Act, as amended (" _FDCA_ "), (ii) the United States False
Claims Act (42 U.S.C.  1320a-7b(a)), as amended, (iii) the Physician Payments
Sunshine Act, (iv) the Patient Protection and Affordable Care Act, (v) the
United States federal Medicare and Medicaid statutes, (vi) the federal Anti-
Kickback Statute, 42 U.S.C.  1320a-7b, the federal Physician Self-Referral
(Stark) Law, 42 U.S.C.  1395nn, and the Federal Civil Monetary Penalties Law
(42 U.S.C.  1320a-7a), (vii) any other Laws governing research, development,
investigational use, marketing clearance, marketing approval, record keeping,
reporting, testing, specification development, manufacturing, processing,
packaging, labeling, storage, importation, transportation, handling,
advertising, promotion, sale, commercialization, distribution or export of
medical devices, (viii) all Laws similar to the foregoing within any other
federal, state, local or foreign jurisdiction, (ix) all binding rules and
regulations issued under such Laws, including those relating to good
laboratory practice, good clinical practice, record keeping, establishment
registration or licensing, device clearance or approval, medical device
reporting, correction and removal reporting, device labeling, filing of
reports, protection of human subjects, humane care and use of laboratory
animals, and good manufacturing practice and (x) all applicable guidance
documents of the FDA, FTC and any other Regulatory Authority (" _Regulatory
Laws_ ").

  


 

  

(b) All pre-clinical and clinical investigations and trials conducted or
sponsored by or on behalf of the Company or any Company Subsidiary are being
and have been conducted in compliance in all material respects with all
applicable Regulatory Laws, including FDA standards for conducting non-
clinical laboratory studies, FDA standards for the design, conduct,
performance, monitoring, auditing, recording, analysis and reporting of
clinical trials and all Laws restricting the use and disclosure of health
information. No pre-clinical or clinical testing conducted by or on behalf of
the Company or any Company Subsidiary has been terminated or suspended due to
safety or other non-business reasons, and, to the knowledge of the Company,
there are no facts that could give rise to such a determination. No
Governmental Entity, clinical investigator, institutional review board or
independent monitoring committee that has or had jurisdiction over or
participated in any such pre-clinical or clinical testing has provided notice
that it has initiated or, to the knowledge of the Company, threatened to
initiate any action to place a hold order on, or otherwise terminate, delay,
suspend or modify any such ongoing testing, and, to the knowledge of the
Company, there are no facts that would reasonably be expected to give rise to
such a determination.

  


 

  

(c) There are no Company Products being commercially distributed or tested by
the Company or the Company Subsidiaries which would require any approval or
clearance by the FDA or any other Regulatory Authority for the purpose for
which they currently are being manufactured or sold (i) which were not, and
are not, developed, manufactured, tested, distributed and marketed in
compliance with all applicable Regulatory Laws, (ii) for which such approval
or clearance has not been obtained or (iii) for which such approval or
clearance has been limited, suspended, non-renewed, withdrawn, revoked or
cancelled or is no longer in full force and effect except, with respect to
clauses (i) through (iii), as would not be material and adverse to the
Company. To the knowledge of the Company, there is no information that would
reasonably be expected to lead to the denial of any application for approval
or clearance currently pending before any Regulatory Authority.

  

 

18  

  

(d) Except as would not be material and adverse to the Company, the Company
and the Company Subsidiaries have and have had all Regulatory Authorizations
necessary for the lawful operation of their respective businesses, including
the registration, manufacturing, testing, packaging, handling, labeling,
storage, transport, import, export, marketing, sale, distribution and the use
of its products, properties and assets, including all Company Products, as
presently conducted and used, and each of such Regulatory Authorizations is
valid, subsisting and in full force and effect. There are currently no, and
since January 1, 2011, have been no, actions pending or, to the knowledge of
the Company, threatened that seek the revocation, cancellation or adverse
modification of any Regulatory Authorization (except as would not be material
and adverse to the Company). Since January 1, 2011, to the knowledge of the
Company, there has not occurred any violation of, default (with or without
notice or lapse of time or both) under, or event giving rise to any threat of
termination, amendment or cancellation of, with or without notice or lapse of
time or both, any Regulatory Authorization (except as would not be material
and adverse to the Company). All Company Products are, and have been,
manufactured, tested, packaged, labeled, stored, imported, exported, marketed,
sold and distributed in accordance with all requirements contained in all
applicable Regulatory Authorizations (except as would not be material and
adverse to the Company).

  


 

  

(e) Except as otherwise set forth in _Section 4.8(e)_ and _4.13(b)_ of the
Company Disclosure Letter, since January 1, 2011, neither the Company nor any
Company Subsidiary has (i) received or, to the knowledge of the Company, been
subject to any action, notice, citation, suspension, revocation, warning,
administrative proceeding, review or investigation by a Governmental Entity or
other Person that alleges or asserts that the Company or any Company
Subsidiary has violated any applicable Laws or which requires or seeks any
adjustment, modification or alteration in the Company's or any Company
Subsidiary's products, operations, activities, or services that has not been
resolved, including any qui tam lawsuits, FDA Form 483, FDA warning letter or
untitled letter or any similar notices or (ii) been subject to a corporate
integrity agreement, deferred prosecution agreement, consent decree,
settlement agreement or other similar agreements or orders mandating or
prohibiting future or past activities. The Company and the Company
Subsidiaries have not settled, or agreed to settle, any actions brought by any
Governmental Entity for a violation of any applicable Laws. As of the date
hereof, (i) there are no restrictions imposed by any Regulatory Authority upon
the business, activities or services of the Company or any Company Subsidiary
that restrict or prevent the Company or such Company Subsidiary from operating
as it currently operates and (ii) the Company Products and the Company are
not, and have not been, otherwise subject to any other enforcement actions
taken by FDA or any other Regulatory Authority, and (iii) to the knowledge of
the Company, there are no facts that could give rise to such an event as
described.

  


 

  

(f) The Company and the Company Subsidiaries (i) have, in all material
respects, cooperated fully with, and have prepared and submitted timely (A)
responses and (B) any corrective action plans required to be prepared and
submitted by the Company or any Company Subsidiary in response to all
inspections, investigations, audits, analyses and examinations performed by
the FDA, any other Regulatory Authority, any Person working with, for, or on
behalf of, the Company, any Company Subsidiary or any client, customer, or
other Person with contractual or other authority to audit Company operations
and (ii) have, in all material respects, fully implemented all corrective
actions described in such corrective action plans, to the knowledge of the
Company, to the satisfaction of the Person conducting the inspection,
investigation, audit, analysis or examination.

  

 

19  

  

(g) Since January 1, 2011, the Company and the Company Subsidiaries have
timely filed all material reports, statements, documents, registrations,
filings, amendments, supplements and submissions required to be filed by it
under applicable Regulatory Laws. Each such filing complied in all material
respects with applicable Regulatory Law as of the date of submission and was
true, complete and correct as of the date of submission. Any material and
legally necessary or required updates, changes, corrections, amendments,
supplements or modifications to such filings have been submitted to the
applicable Governmental Entity.

  


 

  

(h) Neither the Company nor any Company Subsidiary, nor, to the knowledge of
the Company, any officer, employee, agent or distributor of the Company or any
Company Subsidiary, has made an untrue statement of a material fact or a
fraudulent statement to the FDA or any other Regulatory Authority, failed to
disclose a material fact required to be disclosed to the FDA or any other
Regulatory Authority or committed an act, made a statement or failed to make a
statement that, at the time such disclosure was made, would reasonably be
expected to provide a basis for the FDA to invoke its policy respecting
"Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,"
set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for the FDA or any
other Regulatory Authority to invoke any similar policy.

  


 

  

(i) Neither the Company nor any Company Subsidiary, nor, to the knowledge of
the Company, any officer, employee or agent of the Company or any Company
Subsidiary, has been convicted of any crime or engaged in any conduct for
which debarment is mandated or authorized by 21 U.S.C.  335a or any similar
applicable Law, nor, to the knowledge of the Company, has any such Person been
so debarred. Neither the Company nor any Company Subsidiary, nor, to the
knowledge of the Company, any officer, employee or agent of the Company has
been convicted of any crime or, to the knowledge of the Company, engaged in
any conduct for which such Person would reasonably be expected to be excluded
from participating in federal health care programs under Section 1128 of the
Social Security Act of 1935, as amended, or any similar applicable Law or been
excluded from participation in such federal health care programs or similar
foreign programs. Neither the Company nor any Company Subsidiary nor, to the
knowledge of the Company, any officer, employee or agent of the Company or any
Company Subsidiary is subject to an investigation or proceeding by any
Regulatory Authority that could result in such suspension, exclusion or
debarment and there are no facts, to the knowledge of the Company, that would
reasonably be expected to give rise to such suspension, exclusion or
debarment.

  


 

  

(j) The Company and the Company Subsidiaries are, and since January 1, 2011
have been, in compliance in all material respects with all Laws and other
requirements governing participation in, and receipt of payment from,
Medicare, Medicaid and any other state or federal health care programs in
which they currently participate, including without limitation all
reimbursement and billing requirements. The Company and the Company
Subsidiaries, in all material respects, fully and accurately report their
prices to all Governmental Entities requiring such reports, including but not
limited to the Centers for Medicare and Medicaid Services and the Veterans'
Administration. The Company and the Company Subsidiaries have, in all material
respects, fully and accurately reported information to the Centers for
Medicare and Medicaid Services as required by the Physician Payments Sunshine
Act. The Company and the Company Subsidiaries have not received any written
notice regarding a negative change in reimbursement status of any Company
Product.

  

 

20  

  

(k) To the knowledge of the Company, no data generated by the Company or any
Company Subsidiary with respect to the Company Products that has been provided
to their customers or otherwise made public is the subject of any regulatory
or other action, either pending or, to the knowledge of the Company,
threatened, by any Regulatory Authority relating to the truthfulness or
scientific adequacy of such data.

  


 

  

(l) The Company and the Company Subsidiaries are, and since January 1, 2011
have been, in compliance, in all material respects, with all Regulatory Laws
and contractual requirements that regulate or limit the maintenance, use,
disclosure or transmission of medical records, patient information or other
personal information made available to or collected by the Company or any
Company Subsidiary, including the Health Insurance Portability and
Accountability Act of 1996 and the Health Information Technology for Economic
and Clinical Health Act, any implementing regulations, and any applicable
state and foreign privacy or medical information Laws (collectively, the "
_Privacy Laws_ "). The Company and the Company Subsidiaries have established
and implemented procedures, contracts and systems reasonably designed to cause
their respective employees and agents to comply with the Privacy Laws. The
Transactions will not violate, in any material respect, any Privacy Laws. The
Company and each Company Subsidiary employs reasonable and appropriate
administrative, physical and technical safeguards to ensure the
confidentiality, availability and integrity of health information to which it
has access.

  


 

  

Section 4.9 _SEC Filings; Financial Statements_

  


 

  

(a) Except as set forth in _Section 4.9(a)_ of the Company Disclosure Letter,
the Company has timely filed all reports, schedules, forms, statements and
other documents required to be filed or furnished by it with or to the SEC
since July 31, 2011 (together with all exhibits, financial statements and
schedules thereto, all information incorporated by reference and any documents
filed with or furnished to the SEC on a voluntary basis, the " _Company SEC
Reports_ "). As of its respective date, or, if amended, as of the date of the
last such amendment, each of the Company SEC Reports complied when filed or
furnished (or, if applicable, when amended) in all material respects with
applicable Law, including the requirements of the Securities Act of 1933, as
amended (together with the rules and regulations promulgated thereunder, the "
_Securities Act_ "), the Exchange Act and the Sarbanes-Oxley Act of 2002, as
amended (together with the rules and regulations promulgated thereunder, the "
_Sarbanes-Oxley Act_ ") applicable to such Company SEC Report. None of the
Company SEC Reports (including any financial statements or schedules included
or incorporated by reference therein) contained when filed or currently
contains, and any Company SEC Reports filed with the SEC subsequent to the
date hereof but prior to the Effective Time will not contain any untrue
statement of a material fact or omission to state a material fact required to
be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, except to the extent
updated, amended, restated or corrected by a subsequent Company SEC Report.

  

 

21  

  

(b) Except to the extent updated, amended, restated or corrected by a
subsequent Company SEC Report, all of the financial statements included in the
Company SEC Reports, in each case, including any related notes thereto, as
filed with the SEC (those financial statements filed with the SEC are
collectively referred to as the " _Company Financial Statements_ "), comply as
to form in all material respects with applicable accounting requirements and
the published rules of the SEC with respect thereto and have been prepared in
accordance with United States generally accepted accounting principles ("
_GAAP_ ") applied on a consistent basis throughout the periods involved
(except as may be indicated in the notes thereto or, in the case of the
unaudited statements, as may be permitted by Form 10-Q of the SEC and subject,
in the case of the unaudited statements, to normal, recurring year-end audit
adjustments). The consolidated balance sheets (including the related notes)
included in such Company Financial Statements (if applicable, as updated,
amended, restated or corrected in a subsequent Company SEC Report) fairly
present, in all material respects, the consolidated financial position of the
Company and the Company Subsidiaries, at the respective dates thereof, and the
consolidated statements of operations, stockholders' equity and cash flows (in
each case, including the related notes) included in such Company Financial
Statements (if applicable, as updated, amended, restated or corrected in a
subsequent Company SEC Report) fairly present, in all material respects, the
consolidated statements of operations, stockholders' equity and cash flows of
the Company and the Company Subsidiaries for the periods indicated, subject,
in the case of the unaudited statements, to normal, recurring year-end audit
adjustments.

  


 

  

(c) Neither the Company nor any Company Subsidiary has any Liability except
for (i) Liabilities that are reflected, or for which reserves were
established, on the audited consolidated balance sheet of the Company as of
July 31, 2014 in the Company SEC Reports, (ii) Liabilities incurred in the
ordinary course of business and consistent with past practice since July 31,
2014, (iii) Liabilities incurred in connection with this Agreement and the
Transactions, (iv) Liabilities that have not had, and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect, and (v) Liabilities that are disclosed in the Company SEC Reports.

  


 

  

(d) Each of the principal executive officer of the Company and principal
financial officer of the Company (or each former such officer) has made all
certifications required by Rule 13a-14 or 15d-14 under the Exchange Act and
Sections 302 and 906 of the Sarbanes-Oxley Act with respect to the Company SEC
Reports, and the statements contained in such certifications were true and
accurate in all material respects as of the date such certifications were
made. The Company maintains a system of "internal control over financial
reporting" (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act)
as required under Rules 13a-15(a) and 15d-15(a) under the Exchange Act and is
in compliance in all material respects with such system. The Company and the
Company Subsidiaries maintain and keep in all material respects books, records
and accounts, which, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the Company. The "disclosure
controls and procedures" (as defined in Rules 13a-15(e) and 15d-15(e) of the
Exchange Act) of the Company comply with Rules 13a-15(a) and 15d-15(a) under
the Exchange Act and are designed to ensure that all material information
relating to the Company and the Company Subsidiaries is communicated to the
Company's management, including the chief executive officer and chief
financial officer of the Company. Since July 31, 2011, the Company's principal
executive officer and its principal financial officer have disclosed to the
Company's auditors and the audit committee of the Company Board, (i) all known
significant deficiencies and material weaknesses in the design or operation of
internal controls over financial reporting that are reasonably likely to
adversely affect in any material respect the Company's ability to record,
process, summarize and report financial information and (ii) any fraud,
whether or not material, that involves management or other employees who have
a significant role in the Company's internal controls and the Company has
delivered or made available to Parent copies of any non-privileged written
materials in its possession relating to each of the foregoing. The Company has
delivered or made available to Parent all such written disclosures made by
management to the Company's auditors and audit committee since July 31, 2011.

  

 

22  

  

(e) There are no outstanding loans or other extensions of credit made by the
Company or any Company Subsidiary to any executive officer (as defined in Rule
3b-7 under the Exchange Act) or director of the Company or any Company
Subsidiary. The Company has not, since the enactment of the Sarbanes-Oxley
Act, taken any action prohibited by Section 402 of the Sarbanes-Oxley Act.

  


 

  

Section 4.10 _Absence of Certain Changes or Events._ Except as contemplated by
this Agreement, since July 31, 2014 and through the date hereof, (a) each of
the Company and the Company Subsidiaries has conducted its respective business
or businesses only in the ordinary course of business in all material respects
and in a manner consistent with prior practice in all material respects and
(b) there has not been any change, effect, event, occurrence, state of facts,
circumstances or development that has had or would reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect.
Except as contemplated by this Agreement or as set forth in Section 4.10 of
the Company Disclosure Letter, since July 31, 2014 and through the date
hereof, there has not been (x) any material change in accounting methods,
principles or practices employed by the Company or any Company Subsidiary,
other than as required by Law or GAAP or (y) any action of the types described
in Sections 6.1(b)(i)-(xii), (xv), (xviii), (xix), (xxi) which, had such
action been taken after the date hereof, would be in violation of Section
6.1(b).

  


 

  

Section 4.11 _Taxes_

  


 

  

(a) The Company and each of the Company Subsidiaries has duly and timely filed
(taking into account any extension of time within which to file) all Tax
Returns required to be filed by it, and all such Tax Returns are true,
complete and accurate in all material respects. The Company and each of the
Company Subsidiaries has paid (or there has been paid on its behalf) all Taxes
due and payable by it, except for those Taxes being contested in good faith by
appropriate proceedings and for which adequate reserves have been established
in the Company Financial Statements in accordance with GAAP.

  


 

  

(b) There are no Liens for any Taxes upon the assets of the Company or the
assets of any Company Subsidiary other than (i) statutory Liens for Taxes not
yet due and payable and (ii) Liens for Taxes contested in good faith by
appropriate proceedings and for which adequate reserves have been established
in the Company Financial Statements in accordance with GAAP.

  

 

23  

  

(c) Except as set forth in _Section 4.11(c)_ of the Company Disclosure Letter:
(i) to the knowledge of the Company, there is no audit, examination,
deficiency, refund litigation, proposed adjustment, or matter in controversy
or other administrative or court proceeding currently in existence, pending or
threatened in writing with respect to any Taxes or Tax Return of the Company
or any Company Subsidiary; (ii) neither the Company nor any Company Subsidiary
has received written notice of any claim made by a Governmental Entity in a
jurisdiction where the Company or the Company Subsidiaries, as applicable, do
not file a Tax Return, that the Company or such Company Subsidiary is or may
be subject to taxation by that jurisdiction and (iii) there are no outstanding
requests, agreements, consents or waivers to extend the statutory period of
limitations applicable to the assessment of any Taxes or deficiencies against
the Company or any Company Subsidiary and no power of attorney granted by the
Company or any Company Subsidiary with respect to any Taxes is currently in
force.

  


 

  

(d) Except as set forth on _Section 4.11(d)_ of the Company Disclosure Letter,
neither the Company nor any Company Subsidiary has applied for, received, or
has pending any request for a ruling or determination with respect to Taxes or
commenced negotiations or entered into a closing agreement or other similar
agreement relating to Taxes with any Governmental Entity.

  


 

  

(e) The Company and the Company Subsidiaries have withheld from amounts owing
to any employee, creditor or other Person all Taxes required by Law to be
withheld, and have paid over to the proper Governmental Entity in a timely
manner all such withheld amounts and have otherwise complied in all material
respects with all applicable withholding and related reporting requirements.

  


 

  

(f) Neither the Company nor any Company Subsidiary has distributed stock of
another Person, or has had its stock distributed by another Person, in a
transaction that was purported or intended to be governed in whole or in part
by Section 355 or 361 of the Code.

  


 

  

(g) Neither the Company nor any Company Subsidiary is a party to any Tax
indemnification, allocation or sharing agreement with any other Person for
which the Company or any Company Subsidiary will have obligations after the
Closing (other than pursuant to (i) any customary agreements with customers,
vendors, lenders, lessors or the like entered into in the ordinary course of
business or (ii) property Taxes payable with respect to any property lease).

  


 

  

(h) Neither the Company nor any Company Subsidiary has participated, within
the meaning of Treasury Regulation Section 1.6011-4(c), or has been a
"material advisor" or "promoter" (as those terms are defined in Section 6111
and 6112 of the Code) in (i) any "reportable transaction" within the meaning
of Sections 6011, 6662A and 6707A of the Code, (ii) any "confidential
corporate tax shelter" within the meaning of Section 6111 of the Code or (iii)
any "potentially abusive tax shelter" within the meaning of Section 6112 of
the Code.

  


 

  

(i) Except as set forth in _Section 4.11(i)_ of the Company Disclosure Letter,
neither the Company nor any Company Subsidiary (i) is or has ever been a
member of an affiliated group filing a consolidated federal income Tax Return
or any state, local or non-United States consolidated, combined, unitary or
similar group (other than a group of which the Company was the common parent)
or (ii) has any Liability for Taxes of any Person (other than the Company or a
Company Subsidiary) arising from the application of Treasury Regulation
Section 1.1502-6 or any similar provision of state, local or non-United States
Law, or as a transferee or successor, by Contract, or otherwise (other than
pursuant to (A) any customary agreements with customers, vendors, lenders,
lessors or the like entered into in the ordinary course of business or (B)
property Taxes payable with respect to any property lease).

  

 

24  

  

(j) Neither the Company nor any Company Subsidiary will be required, as a
result of (i) a change in accounting method for a Tax period (or a portion
thereof) ending on or before the Closing Date, to include any adjustment under
Section 481(c) of the Code (or any similar provision of state, local or non-
United States Law) in taxable income for any Tax period beginning on or after
the Closing Date or (ii) (A) any "closing agreement" described in Section 7121
of the Code (or any similar provision of state, local or non-United States
Law), (B) installment sale or intercompany transaction described in Treasury
Regulations under Section 1502 of the Code entered into prior to the Closing
or prepaid amount received outside the ordinary course of business or (C)
election pursuant to Section 108(i) of the Code (or any similar provision of
state, local or non-United States Law), to include any item of income or
exclude any item of deduction from Tax Liability in any Tax period (or portion
thereof), beginning after the Closing.

  


 

  

Section 4.12 _Litigation_

  


 

  

(a) Except as set forth in _Sections 4.8(e)_ , _4.12(a)_ and _4.20(d)_ of the
Company Disclosure Letter, there is no claim of which the Company has received
notice, suit, action, investigation, indictment, or administrative,
arbitration, alternative dispute resolution or other similar proceeding ("
_Litigation_ ") pending or, to the knowledge of the Company, threatened,
against the Company or any Company Subsidiary which has had or, if adversely
determined, would reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

  


 

  

(b) Except as set forth in _Section 4.12(b)_ of the Company Disclosure Letter,
there is no Order of any Governmental Entity or arbitrator outstanding
against, or, to the knowledge of the Company, investigation by, any
Governmental Entity involving the Company or any Company Subsidiary that is
material to the Company and the Company Subsidiaries, taken as a whole.

  


 

  

Section 4.13 _Product Liability and Recalls_

  


 

  

(a) The Company and any Company Subsidiary have not received written notice of
any product liability or regulatory Litigation against the Company or any
Company Subsidiary and, to the knowledge of the Company, no such Litigation
has been threatened against the Company or any Company Subsidiary. There is no
Order outstanding against the Company or any Company Subsidiary relating to
product liability Litigation.

  

 

25  

  

(b) Except as set forth in _Section 4.13(b)_ of the Company Disclosure Letter,
since January 1, 2011, there has been no voluntary or mandatory recall of
products manufactured or distributed by or on behalf of the Company or any
Company Subsidiary, or notice from any Governmental Entity or other Person
threatening to initiate or conduct such a recall, with respect to any Company
Product, including any field alert, field correction, market withdrawal or
replacement, safety alert, warning, "dear doctor" letter, safety alert or
other notice or action relating to an alleged lack of safety, efficacy or
regulatory compliance of any Company Product except as have not had, and would
not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect. To the knowledge of the Company, there are no
facts that are reasonably likely to cause (i) the voluntary or mandatory
recall, market withdrawal or replacement of any product sold or intended to be
sold by the Company or any Company Subsidiary, (ii) a change in the marketing
classification or a material change in the labeling of such products or (iii)
a termination or suspension of the marketing or distribution of such products.

  


 

  

Section 4.14 _Material Contracts_

  


 

  

(a) _Section 4.14_ of the Company Disclosure Letter contains a complete and
correct list, as of the date hereof, of each Contract described below in this
_Section 4.14(a)_ under which the Company or any Company Subsidiary has any
current or future rights, responsibilities, obligations or liabilities (in
each case, whether contingent or otherwise) or to which any of their
respective properties or assets is subject, in each case as of the date
hereof:

  


 

  

(i) any Contract (or group of related Contracts) (A) for the furnishing of
services or the sale of products which involves consideration in excess of
$150,000 in any twelve (12) month period or (B) for the receipt of services by
a third party or for the purchase of raw materials, commodities, supplies,
products, or other personal property, which involves payment by the Company or
any Company Subsidiary of consideration in excess of $150,000 in any twelve
(12) month period or which the Company reasonably expects will involve payment
by the Company or any Company Subsidiary of consideration in excess of
$150,000 in any future twelve (12) month period during the term of such
agreement;

  


 

  

(ii) any Contract (or group of related Contracts) under which the Company or
any Company Subsidiary is a lessor of any equipment, machinery, vehicle or
other tangible personal property to any other Person which requires future
annual payments in excess of $150,000;

  


 

  

(iii) any Contract (or group of related Contracts) under which the Company or
any Company Subsidiary is a lessee of, or holds or uses, any equipment,
machinery, vehicle or other tangible personal property owned by a third Person
which requires future annual payments in excess of $150,000;

  


 

  

(iv) any Contract under which the Company or any Company Subsidiary is a
lessee, sub-lessee, licensee, lessor, sub-lessor or licensor of real property;

  

 

26  

  

(v) any Contract pursuant to which the Company or any Company Subsidiary has
entered into a partnership, joint venture or other similar arrangement with
any Person other than the Company or a wholly owned Company Subsidiary;

  


 

  

(vi) any severance agreement and any employment or other Contract with an
employee or former employee, independent contractor or former independent
contractor, officer or director of the Company or any Company Subsidiary
providing for aggregate compensation in excess of $150,000 in any twelve (12)
month period;

  


 

  

(vii) any Collective Bargaining Agreement;

  


 

  

(viii) except as contemplated by the budget attached as _Section
4.14(a)(viii)_ of the Company Disclosure Letter, any Contract for capital
expenditures or the acquisition or construction of fixed assets which requires
aggregate future payments in excess of $150,000;

  


 

  

(ix) any Contract entered into other than in the ordinary course of business
containing covenants of the Company or any Company Subsidiary (A) to indemnify
or hold harmless another Person, unless such indemnification or hold harmless
obligation to such Person, or group of Persons, as the case may be, is less
than $150,000 or (B) containing covenants of the Company or any Company
Subsidiary not to (or otherwise restricting or limiting the ability of the
Company or any Company Subsidiary to) compete in any line of business or
geographic or therapeutic area, including any covenant not to compete with
respect to the provision of services or the development, testing, manufacture,
marketing, distribution, sale or maintenance of the Company Products or any
other product;

  


 

  

(x) any Contract requiring aggregate future payments or expenditures and
relating to cleanup, abatement, remediation or similar actions in connection
with environmental liabilities;

  


 

  

(xi) all Contracts pursuant to which the Company or any Company Subsidiary (A)
is granted or obtains or agrees to obtain any right to use any Intellectual
Property (other than standard form Contracts granting rights to use readily
available shrink wrap or click wrap Software having a replacement cost and
annual license fee of less than $50,000 in the aggregate for all such related
Contracts and other non-exclusive agreements with respect to non-material
Intellectual Property entered into in the ordinary course of business), (B) is
restricted in its right to use or register any Intellectual Property or (C)
permits or agrees to permit any other Person to use, enforce or register any
Intellectual Property owned by the Company or any Company Subsidiary,
including license agreements, coexistence agreements, covenants not to sue
other than Contracts for sales of Company Product and associated non-exclusive
licenses entered into in the ordinary course of business consistent with past
practice, and any Contract that would, as a result of the Transactions, (1)
require Parent or Merger Sub to license, assign or otherwise make available
rights in its or its Affiliates' Intellectual Property to any other Person or
(2) restrict the use by Parent or Merger Sub or its Affiliates of such rights
in Intellectual Property (the Contracts described in this _Section
4.14(a)(xi)_ collectively, " _IP Contracts_ ");

  

 

27  

  

(xii) any Indebtedness of the Company or any Company Subsidiary in a principal
amount in excess of $150,000;

  


 

  

(xiii) any Contract which requires future payments by the Company or any
Company Subsidiary in excess of $150,000 per annum containing "change of
control" or similar provisions;

  


 

  

(xiv) any Contract entered into since January 1, 2011 relating to the
acquisition or disposition of any business or any material assets for a
purchase price in excess of $150,000 other than in the ordinary course of
business (whether by merger, sale of stock or assets or otherwise);

  


 

  

(xv) any Contract entered into other than in the ordinary course of business
that involves aggregate future payments by or to the Company or any Company
Subsidiary in excess of $250,000 per annum, other than (A) a purchase or sales
order or other Contract entered into in the ordinary course of business
consistent with past practice or (B) Contracts with employees, consultants or
independent contractors relating to employment or the provision of services;

  


 

  

(xvi) any Contract the termination or breach of which, or in respect of which
the failure to obtain any consent required in connection with any of the
Transactions, is reasonably likely to have a Company Material Adverse Effect;

  


 

  

(xvii) any Contract that contains a "right of first refusal," "right of first
offer," "right of first negotiation" or similar provisions;

  


 

  

(xviii) any Contract pursuant to which the Company or any Company Subsidiary
has granted any exclusive marketing, sales representative relationship,
franchising, consignment or distribution right to any third party with a value
in excess of $150,000;

  


 

  

(xix) any Contract relating to the marketing, sale, advertising, distribution
or promotion of the Company and any Company Subsidiary's services or products
involving consideration in excess of $150,000 during the remaining term of
such Contract or per annum; and

  


 

  

(xx) any Contract that required during the last twelve (12) months or that is
reasonably expected to require, in the future, payments from the Company or
any Company Subsidiary in excess of $150,000 to any person or organization
who, to the knowledge of the Company, has made referrals to the Company or any
Company Subsidiary.

  


 

  

(b) Each Contract of the Company or any Company Subsidiary that is required to
be set forth on _Section 4.14_ of the Company Disclosure Letter or required to
be filed as an exhibit to the Company SEC Reports pursuant to Item 601(b)(10)
of Regulation S-K under the Securities Act (a " _Company Material Contract_ ")
is in full force and effect (except for those Contracts that have expired in
accordance with their terms) and is a legal, valid and binding agreement of
the Company or a Company Subsidiary, as the case may be, and, to the knowledge
of the Company, of each other party thereto, enforceable against the Company
or such Company Subsidiary, as the case may be, and, to the knowledge of the
Company, each other party thereto, in each case, in accordance with its terms,
except for such failures to be in full force and effect or to be legal, valid,
binding or enforceable that have not had, and would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect
and subject, as to enforcement of remedies, to bankruptcy, insolvency,
reorganization, moratorium or similar Laws affecting the rights and remedies
of creditors generally and subject to general principles of equity (regardless
of whether such enforceability is considered in a proceeding at law or in
equity). Each of the Company and Company Subsidiaries has performed or is
performing all obligations required to be performed by it under the Company
Material Contracts and is not in breach or default thereunder, and has not
waived or failed to enforce any rights or benefits thereunder, and, to the
knowledge of the Company, no other party to any of the Company Material
Contracts is in breach or default thereunder, and no event has occurred which,
with or without notice, lapse of time, or both, would constitute a default
under the provisions of such Company Material Contract or would give to others
any right of termination, amendment or cancellation of any Company Material
Contract or any license thereunder, except for, in each case, any such
failures to perform, breaches, defaults, waivers, failures to enforce or
events that have not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. The
Company has prior to the date hereof delivered or made available to Parent a
true and complete copy of each Company Material Contract (including all
amendments, modifications, extensions and renewals thereof and waivers
thereunder). The Company has no knowledge of any pending or threatened
bankruptcy, insolvency or similar proceeding with respect to any party to any
Company Material Contract which has had or would reasonably be expected to
have a Company Material Adverse Effect. Neither the Company nor any Company
Subsidiary (i) is a party to any voting agreement with respect to the voting
of any securities of the Company or (ii) has any contractual obligation to
file a registration statement under the Securities Act, in respect of any
securities of the Company or any Company Subsidiary.

  

 

28  

  

Section 4.15 _Employee Benefit Plans_

  


 

  

(a) _Section 4.15(a)(i)_ of the Company Disclosure Letter sets forth a true
and complete list of each Company Benefit Plan and each Company Benefit
Agreement.

  


 

  

(b) To the extent applicable with respect to each Company Benefit Plan and
Company Benefit Agreement, the Company has delivered or made available to
Parent true and correct copies of (i) each material Company Benefit Plan and
each material Company Benefit Agreement (or, in the case of any material
unwritten Company Benefit Plan or Company Benefit Agreement, a written summary
of the material provisions of such plan or agreement), including any
amendments thereto, (ii) the three most recent annual reports on Form 5500 and
accompanying schedules filed with the Internal Revenue Service (" _IRS_ "),
(iii) each summary plan description and summary of material modifications,
(iv) the most recent financial statements and actuarial or other valuation
reports, (v) the most recently received IRS determination or opinion letter,
(vi) each currently effective trust agreement or other document relating to
the funding or payment of benefits, (vii) non-discrimination testing results
for the last two completed plan years and (viii) any written correspondence
received from any Governmental Entity with respect to the registration,
qualification or compliance of any Company Benefit Plan or Company Benefit
Agreement.

  

 

29  

  

(c) Within the six-year period ending at the Effective Time, neither the
Company nor any Commonly Controlled Entity has sponsored, maintained,
contributed to or been obligated to sponsor, maintain or contribute to, or has
any actual or contingent Liability under, any benefit plan that is subject to
Title IV of ERISA or Section 412 of the Code or is otherwise a defined benefit
pension plan or is a plan described in Section 3(40) of ERISA or Section 413
of the Code. No Liability under Title IV of ERISA or Sections 412 or 430 of
the Code has been incurred by the Company or any Commonly Controlled Entity
that has not been satisfied in full.

  


 

  

(d) With respect to any Company Benefit Plan or Company Benefit Agreement that
is an employee welfare benefit plan, (i) no such Company Benefit Plan or
Company Benefit Agreement is funded through a "welfare benefits fund" (as such
term is defined in Section 419(e) of the Code), (ii) each such Company Benefit
Plan or Company Benefit Agreement that is a "group health plan" (as such term
is defined in Section 5000(b)(1) of the Code) materially complies with the
applicable requirements of Section 4980B(f) of the Code and any applicable
similar state or local Law except as has not had, and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect, (iii) to the knowledge of the Company, each such Company Benefit Plan
and Company Benefit Agreement may be amended or terminated without material
liability to the Company or any Company Subsidiary on or at any time after the
Effective Time and (iv) no such Company Benefit Plan or Company Benefit
Agreement provides benefits to, or on behalf of, any former employee after the
termination of employment except (A) where the full cost of such benefit is
borne entirely by the former employee (or such former employee's eligible
dependents or beneficiaries) or (B) where the benefit is required by Section
4980B of the Code.

  


 

  

(e) Except as set forth in _Section 4.15(e)_ of the Company Disclosure Letter,
each Company Benefit Plan and Company Benefit Agreement has been operated and
administered in all respects in accordance with its terms and with all
applicable Laws, including ERISA and the Code except as have not had, and
would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect. There are no pending, or to the knowledge of
the Company, threatened actions or suits by or on behalf of any Company
Benefit Plan or Company Benefit Agreement, by any employee or beneficiary
covered under any Company Benefit Plan or Company Benefit Agreement, as
applicable (other than routine claims for benefits). Except as set forth in
_Section 4.15(e)_ of the Company Disclosure Letter, all material
contributions, including participant contributions, and benefit payments
required under each Company Benefit Plan and Company Benefit Agreement have
been made in full and on a timely and proper basis pursuant to the terms of
such plan or agreement and applicable Law except as have not had, and would
not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect.

  


 

  

(f) Each Company Benefit Plan or Company Benefit Agreement that is intended to
be tax-qualified under Section 401(a) of the Code (i) has been the subject of
a determination or opinion letter from the IRS or an application therefor with
respect to all material and applicable Tax Law changes to the effect that such
Company Benefit Plan or Company Benefit Agreement currently is qualified and
exempt from income Taxes under Section 401(a) of the Code and the trust
relating to such plan is exempt from income Taxes under Section 501(a) of the
Code, (ii) to the knowledge of the Company, no such determination letter has
been revoked or threatened and (iii) to the knowledge of the Company, no event
has occurred since the date of the most recent determination or opinion letter
or application therefor relating to any such Company Benefit Plan or Company
Benefit Agreement that is reasonably expected to affect the qualification of
such plan or arrangement or adversely or materially increase the costs
relating thereto or require security under Section 307 of ERISA.

  

 

30  

  

(g) There are no understandings, agreements or undertakings, written or oral,
with any Person (other than pursuant to the express terms of the applicable
Company Benefit Plan or Company Benefit Agreement) that are (pursuant to any
such understandings, agreements or undertakings) reasonably expected to result
in any liabilities if such Company Benefit Plan or Company Benefit Agreement
were amended or terminated upon or at any time after the Effective Time or
that would prevent any unilateral action by the Company (or, after the
Effective Time, Parent) to effect such amendment or termination except as have
not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

  


 

  

(h) Each Company Benefit Plan and each Company Benefit Agreement that is a
"nonqualified deferred compensation plan" within the meaning of Section
409A(d)(1) of the Code subject to Section 409A of the Code is, and has been
operated in such manner as to be, in compliance with Section 409A of the Code
except as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect.

  


 

  

(i) Neither the execution and delivery of this Agreement nor the consummation
of the Transactions (either alone or in conjunction with any other event)
will, except as otherwise set forth in _Section 4.15(i)_ of the Company
Disclosure Letter or as provided in _Section 3.4_ of this Agreement, (i)
entitle any current or former employee, officer, director , consultant or
individual service provider of the Company or any Company Subsidiary (each, a
" _Company Participant_ ") to enhanced severance or termination pay or any
retention, bonus, change in control or similar payments or benefits, (ii)
result in, cause the accelerated vesting or delivery of, or increase the
amount or value of, any payment or benefit to any Company Participant, (iii)
trigger any payment or funding (through a grantor trust or otherwise) of any
compensation or benefits under, increase the amount payable or trigger any
other material obligation pursuant to, or increase the cost of, any Company
Benefit Plan or Company Benefit Agreement, (iv) limit or restrict the right of
the Company or any Company Subsidiary or, after the Offer Closing, Parent, to
merge, amend or terminate any Company Benefit Plan or Company Benefit
Agreement or (v) result in any breach or violation of, or a default under, any
Company Benefit Plan or Company Benefit Agreement.

  


 

  

(j) Neither the execution and delivery of this Agreement nor the consummation
of the Transactions (either alone or in conjunction with any other event) will
result in the payment of any amount that would, individually or in combination
with any other such payment, constitute an "excess parachute payment," as
defined in Section 280G(b)(1) of the Code. No Company Participant is entitled
to any gross-up, make-whole or other additional payment from the Company or
any Company Subsidiary in respect of any Tax (including federal, state, local
or foreign income, excise or other Taxes (including Taxes imposed under
Section 4999 of the Code or Section 409A of the Code) or interest or penalty
related thereto.

  

 

31  

  

(k) Except as has not had, and would not reasonably be expected to result in
material liability to the Company, each Company Benefit Plan or Company
Benefit Agreement which is subject to Law other than United States federal,
state or local law (i) has been maintained in accordance with all applicable
requirements (including registration and approval), (ii) if intended to
qualify for specific tax treatment, meets all the requirements for such
treatment and (iii) if intended to be funded and/or book-reserved, is fully
funded and/or book-reserved, as applicable, based on reasonable actuarial
assumptions.

  


 

  

Section 4.16 _Labor and Employment Matters_

  


 

  

(a) (i) The Company and the Company Subsidiaries are neither party to, nor
bound by, any labor agreement, collective bargaining agreement, work rules or
practices, or any other labor-related agreements or arrangements with any
labor union or labor organization (collectively, a " _Collective Bargaining
Agreement_ "), (ii) there are no Collective Bargaining Agreements that pertain
to any of the employees of the Company or any Company Subsidiary with respect
to their employment with the Company or any Company Subsidiary, (iii) no
employees of the Company or any Company Subsidiary are represented by any
labor union, works council or labor organization with respect to their
employment with the Company or any Company Subsidiary, (iv) no labor union,
labor organization, or group of employees of the Company or any Company
Subsidiary has made a pending demand for recognition or certification, and
there are no representation or certification proceedings or petitions seeking
a representation proceeding presently pending or, to the knowledge of the
Company, threatened in writing to be brought or filed with the National Labor
Relations Board or any other labor relations tribunal or authority, (v) to the
knowledge of the Company, since January 1, 2011, there have been no labor
union organizing activities with respect to any employees of the Company or
any Company Subsidiary and (vi) to the knowledge of the Company, since January
1, 2011, there have been no actual, or, to the knowledge of the Company,
threatened, labor arbitrations, grievances, labor disputes, strikes, lockouts,
walkouts, slowdowns, work stoppages or picketing by any employee of the
Company or any Company Subsidiary, against or affecting the Company or any
Company Subsidiary.

  


 

  

(b) Except as set forth in _Section 4.16(b)_ of the Company Disclosure Letter,
the Company and the Company Subsidiaries (i) are in compliance (except in
immaterial respects) with all Laws pertaining to labor, employment or
employment practices including all Laws regarding terms and conditions of
employment, health and safety, wages and hours, child labor,
employee/independent contractor classification, exempt/non-exempt
classification, labor relations, employment discrimination, disability rights
or benefits, equal opportunity, immigration, plant closures and layoffs,
affirmative action, employee leave issues, unemployment insurance and workers'
compensation and (ii) are not a party to any Litigation, audit, hearing,
complaint, charge, or governmental inquiry alleging a violation of any Law
pertaining to labor, employment or employment practices, nor, to the knowledge
of the Company, is any such Litigation, audit, hearing, complaint, charge, or
governmental inquiry threatened, except, with respect to clauses (i) and (ii)
as would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect.

  


 

  

(c) The Company and the Company Subsidiaries (i) have taken reasonable steps
to properly classify and treat all of their workers as independent contractors
or employees, (ii) have taken reasonable steps to properly classify and treat
all of their employees as "exempt" or "nonexempt" from overtime requirements
under applicable Law, (iii) are not delinquent in any payments to, or on
behalf of, any current or former independent contractors or employees for any
services or amounts required to be reimbursed or otherwise paid, (iv) have
withheld and reported all material amounts required by Law or by agreement to
be withheld and reported with respect to wages, salaries and other payments to
any current or former independent contractors or employees and (v) are not
liable for any payment to any trust or other fund governed by or maintained by
or on behalf of any Governmental Entity with respect to unemployment
compensation benefits, social security or other benefits or obligations for
any current or former independent contractors or employees (other than routine
payments to be made in the normal course of business and consistent with past
practice).

  

 

32  

  

(d) To the knowledge of the Company, no employee of the Company or any Company
Subsidiary is in any respect in violation of any term of any employment
agreement, nondisclosure agreement, common law nondisclosure obligation,
fiduciary duty, non-competition agreement, restrictive covenant or other
obligation (i) to the Company or any Company Subsidiary or (ii) to a former
employer of any such employee relating (A) to the right of any such employee
to be employed by the Company or any Company Subsidiary or (B) to the
knowledge or use of trade secrets or proprietary information.

  


 

  

(e) Except as set forth in _Section 4.16(b)_ of the Company Disclosure Letter,
to the knowledge of the Company, no current employee of the Company or any
Company Subsidiary at or above the level of vice-president has provided notice
to the Company of his or her intent to terminate his or her employment.

  


 

  

(f) The Company and the Company Subsidiaries are and have been in compliance
with all notice and other requirements under the Worker Adjustment and
Retraining Notification Act of 1988, as amended, or any similar foreign,
state, provincial or local Law relating to plant closings and layoffs.

  


 

  

(g) Neither the Company nor any Company Subsidiary, is or has been (i) a
"contractor" or "subcontractor" (as defined by Executive Order 11246), (ii)
required to comply with Executive Order 11246 or (iii) required to maintain an
affirmative action plan.

  


 

  

(h) The execution of this Agreement and the consummation of the transactions
contemplated by this Agreement will not result in any breach or other
violation of any collective bargaining agreement, employment agreement,
consulting agreement or any other labor-related agreement to which the Company
or any Company Subsidiary is a party.

  


 

  

Section 4.17 _Title to Personal Properties._ The machinery, equipment,
furniture, fixtures and other tangible personal property and assets owned,
leased or used by the Company or any Company Subsidiary (the "Assets") are, in
the aggregate, sufficient to carry on their respective businesses in all
material respects as presently conducted, and the Company and the Company
Subsidiaries are in possession of and have good title to, or valid leasehold
interests in or valid rights under contract to use, such Assets that are
material to the Company and the Company Subsidiaries, taken as a whole, free
and clear of all Liens other than Permitted Liens, except, in each case, as
have not had and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect.

  

 

33  

  

Section 4.18 _Real Property_

  


 

  

(a) _Section 4.18(a)_ of the Company Disclosure Letter sets forth, as of the
date of this Agreement, a list of all real property owned by the Company and
the Company Subsidiaries, including all of the buildings, structures and other
improvements thereon (the " _Owned Real Property_ "). The Company or one of
the Company Subsidiaries has good and valid fee simple title to all Owned Real
Property, free and clear of all Liens other than Permitted Liens. There are no
pending, or, to the knowledge of the Company, threatened in writing,
appropriation, condemnation, eminent domain or like proceedings relating to
the Owned Real Property. There are no outstanding options or rights of first
refusal in favor of any other party to purchase any Owned Real Property or any
portion thereof or interest therein that would reasonably be expected to
adversely affect the existing use of the Owned Real Property by the Company or
any Company Subsidiary in the operation of its business thereon in the
ordinary course of business.

  


 

  

(b) _Section 4.18(b)_ of the Company Disclosure Letter sets forth a true and
complete list, in all material respects, of all of the leases, subleases,
licenses, occupancy agreements or other instruments or permits pursuant to
which the Company or any Company Subsidiary holds a leasehold or subleasehold
estate or other right to use or occupy any interest in real property (the "
_Company Leases_ ") and each parcel of real property in which the Company or
any Company Subsidiary is a tenant, subtenant or occupant thereunder (the "
_Leased Real Property_ "). The Owned Real Property and the Leased Real
Property comprise all of the material real property used in the operation of
the business of the Company and the Company Subsidiaries. The Company has
delivered or made available to Parent copies of the Company Leases, including
all amendments, supplements, modifications, renewals, guaranties or other
agreements with respect thereto, which are true, correct and complete in all
material respects. Except as set forth in _Section 4.18(b)_ of the Company
Disclosure Letter, (i) each Company Lease (A) constitutes a valid and binding
obligation of the Company or the Company Subsidiary party thereto in all
material respects and (B) is enforceable against the Company or the Company
Subsidiary that is a party thereto, except as limited by bankruptcy,
insolvency, reorganization, moratorium or other similar Laws affecting the
enforcement of creditors' rights in general and subject to general principles
of equity (regardless of whether such enforceability is considered in a
proceeding at law or in equity) and is in full force and effect, (ii) none of
the Company or the Company Subsidiaries are in material breach or default
under any Company Lease, (iii) none of the Company or the Company Subsidiaries
have received or delivered a written notice of material default or objection
to or from any party to any Company Lease to pay and/or perform its
obligations, and, to the knowledge of the Company, no event has occurred or
circumstance exists which, with the delivery of notice, the passage of time or
both, would constitute a material breach or material default, or permit the
termination, modification, cancellation or acceleration of rent under such
Company Lease, (iv) the Company or one of the Company Subsidiaries, as
applicable, holds a good and valid leasehold interest in all Leased Real
Property free and clear of all Liens other than the Permitted Liens and none
of the Company Leases have been pledged or assigned by the Company or the
Company Subsidiaries, (v) no brokerage commissions, fees or similar costs or
expenses are owed by the Company or any Company Subsidiary with respect to any
Company Lease, other than in any immaterial amount, (vi) the Transactions do
not require the consent of any other party to any Company Lease and will not
result in a material breach of, or material default under, any Company Lease,
(vii) neither the Company nor any Company Subsidiary is a party to any lease,
sublease, concession agreement, use and occupancy agreement, assignment or
similar arrangement under which the Company or any Company Subsidiary is a
landlord, sublessor, sublicensor or assignor of any of the Leased Real
Property, (viii) neither the Company nor any Company Subsidiary has given any
written notice to any landlord under any of the Company Leases indicating that
it will not be exercising any extension or renewal options under the Company
Leases, (ix) no assessment for public improvement or otherwise which is due
and remains unpaid has been made against the Leased Real Property other than
the Permitted Liens and, to the knowledge of the Company, there is no
currently proposed or pending assessment for public improvements or otherwise
and (x) neither the Company nor any Company Subsidiary has received written
notice of any pending or, to the knowledge of the Company, threatened,
proceedings in eminent domain, condemnation or other similar proceedings
affecting any portion of the Leased Real Property.

  

 

34  

  

Section 4.19 _Environmental Matters_

  


 

  

(a) Each of the Company and the Company Subsidiaries is and has at all times
been in compliance with all applicable Environmental Laws, including
possessing and complying with the terms of all Environmental Permits required
for its operations under applicable Environmental Laws, except for such
noncompliance as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect.

  


 

  

(b) Except as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, there is
no pending or, to the knowledge of the Company, threatened Environmental Claim
against the Company or any Company Subsidiary, or, to the knowledge of the
Company, against any predecessor or other Person for whom the Company or any
Company Subsidiary is liable under contract or by operation of law.

  


 

  

(c) Neither the Company nor any Company Subsidiary is a party or subject to
any Order pursuant to Environmental Laws that has had, or would reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect.

  


 

  

(d) Except as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, there are
no actions, activities, circumstances, conditions, events or incidents,
including the presence, Release or threatened Release of Hazardous Substances,
that (i) would reasonably be expected to form the basis of any Environmental
Claim against the Company or any Company Subsidiary or (ii) would otherwise
reasonably be expected to result in any costs or liabilities to the Company or
any Company Subsidiary under Environmental Law.

  


 

  

(e) The Company has delivered or made available to Parent all material
assessments, reports, data, results of investigations or audits, and other
information that is in the possession of or reasonably available to the
Company or any Company Subsidiary pertaining to (i) any unresolved
Environmental Claims against the Company or any Company Subsidiary, or against
any predecessor or other Person for whom the Company or any Company Subsidiary
is liable under contract or by operation of law; (ii) any Hazardous Substances
in, on, beneath or adjacent to any property currently or formerly owned,
operated or leased by the Company or any Company Subsidiary; or (iii) the
Company's or any Company Subsidiary's compliance with applicable Environmental
Laws.

  

 

35  

  

Section 4.20 _Intellectual Property_

  


 

  

(a) _Section 4.20(a)_ of the Company Disclosure Letter sets forth a true and
correct list of all (i) issued Patents and Patent applications, (ii) Trademark
registrations and applications and material unregistered Trademarks, and (iii)
Copyright registrations and applications and material unregistered Copyrights
(including material Software), in each of the foregoing (i), (ii), and (iii),
that are owned or exclusively licensed by the Company or any Company
Subsidiary in any jurisdiction in the world (the " _Material Intellectual
Property_ "). The Company or one of the Company Subsidiaries is the sole,
exclusive, beneficial and, with respect to applications and registrations,
owner of all of the Material Intellectual Property owned or purported to be
owned by the Company or any Company Subsidiary (the " _Owned Intellectual
Property_ "), and all such Intellectual Property is subsisting, valid and
enforceable (or, with respect to applications, applied for).

  


 

  

(b) Except as set forth in _Section 4.20(b)_ of the Company Disclosure Letter,
the Company or a Company Subsidiary owns (free and clear of any Liens), or is
licensed or, to the knowledge of the Company, otherwise has a valid right to
use, all Intellectual Property used or held for use in the conduct of its
business as currently conducted, and to the knowledge of the Company as
currently planned to be conducted.

  


 

  

(c) To the knowledge of the Company, the material IP Contracts are valid and
legally enforceable, subject, as to enforcement of remedies, to bankruptcy,
insolvency, reorganization, moratorium or similar Laws affecting the rights
and remedies of creditors generally and subject to general principles of
equity (regardless of whether such enforceability is considered in a
proceeding at law or in equity). The Company has delivered or made available
to Parent copies of all material IP Contracts. Except as set forth in _Section
4.20(c)_ of the Company Disclosure Letter, (i) neither the Company nor any
Company Subsidiary has licensed or sublicensed its rights in any material
Intellectual Property, and (ii) no royalties, honoraria or other fees are
payable by the Company or any Company Subsidiary in excess of $100,000
annually for the use of, or right to use, any Intellectual Property rights.

  


 

  

(d) The conduct of the business of the Company and the Company Subsidiaries as
currently conducted, and the conduct of such business as conducted since
January 1, 2011, does not misappropriate, infringe, dilute or otherwise
violate and has not misappropriated, infringed, diluted or otherwise violated,
any Person's Intellectual Property rights (except that with respect to third-
party patents, patent applications, trademarks, trademark applications,
service marks or service mark applications, the foregoing representation is
made to the Company's knowledge only). Except as set forth in _Section
4.20(d)_ of the Company Disclosure Letter, there are currently no, and since
January 1, 2011, have been no Litigation asserted or, to the knowledge of the
Company, threatened (including in the forms of offers or invitations to obtain
a license) against the Company or any Company Subsidiary (i) alleging such
misappropriation, infringement, dilution or other violation of any Person's
Intellectual Property rights, (ii) challenging the Company's or any Company
Subsidiary's ownership or use of, or the registrability or maintenance of, any
Owned Intellectual Property, (iii) challenging the validity or enforceability
of any Owned Intellectual Property, (iv) alleging that the Company or any
Company Subsidiary is in breach of any applicable grant, license, agreement,
instrument or other arrangement pursuant to which the Company or any Company
Subsidiary or any of their respective Affiliates acquired the right to use
such Material Intellectual Property or (v) alleging misuse or antitrust
violations arising from the use or other exploitation by the Company or any
Company Subsidiary of any Intellectual Property. To the knowledge of the
Company, no Material Intellectual Property has been, or is being, used, or
enforced by the Company or any Company Subsidiary in a manner that,
individually or in the aggregate, is reasonably likely to result in the
cancellation, invalidity or unenforceability of such Material Intellectual
Property.

  

 

36  

  

(e) Except as set forth in _Section 4.20(e)_ of the Company Disclosure Letter,
to the knowledge of the Company, (i) no Person is misappropriating,
infringing, diluting or otherwise violating, either directly or indirectly,
any Owned Intellectual Property owned, used or held for use by the Company or
any Company Subsidiary in the conduct of their business and (ii) since January
1, 2011, no Person has misappropriated, infringed, diluted, or otherwise
violated, either directly or indirectly, any Owned Intellectual Property
owned, used or held for use by the Company or any Company Subsidiary in the
conduct of its business. Since January 1, 2011, no Litigation with respect to
any of the foregoing (e)(i) or (e)(ii) has been brought or threatened against
any Person by the Company or any Company Subsidiary.

  


 

  

(f) Neither the Company nor any Company Subsidiary has granted any Person any
right to control the prosecution or registration of any Owned Intellectual
Property or to bring, defend, or otherwise control any Litigation with respect
to any Owned Intellectual Property owned, used or held for use by the Company
or any Company Subsidiary.

  


 

  

(g) Except as set forth in _Section 4.20(g)_ of the Company Disclosure Letter,
neither the Company nor any Company Subsidiary has entered into, or is subject
to, any Orders, consents, indemnifications, forbearances to sue, licenses or
other arrangements in connection with the resolution of any disputes or
Litigation that (i) restrict the Company or any Company Subsidiary with
respect to the use, registration or maintenance of any Material Intellectual
Property, (ii) restrict the Company's or any Company Subsidiary's businesses
in any material manner in order to accommodate any Person's Intellectual
Property or (iii) permit any Person to use any Owned Intellectual Property
owned, used or held for use by the Company or any Company Subsidiary.

  


 

  

(h) The Company and each Company Subsidiary takes reasonable measures to
protect the confidentiality of the Company's and the Company Subsidiaries'
Trade Secrets. Except as set forth in _Section 4.20(h)_ of the Company
Disclosure Letter, each current or former employee, officer and contractor of
the Company or any Company Subsidiary who has created any Intellectual
Property that is material to the business of the Company and the Company
Subsidiaries, taken as a whole, as presently conducted, has executed a
proprietary information and inventions agreement, and no current or former
employee, officer or contractor of the Company or any Company Subsidiary has
excluded works or inventions from his or her assignment of inventions pursuant
to such employee's, officer's or contractor's proprietary information and
inventions agreement except to the extent that such invention is not material
to the business of the Company and the Company Subsidiaries, taken as a whole,
as presently conducted. To the knowledge of the Company, there has not been
any disclosure of any material Trade Secret of the Company or any Company
Subsidiary to any Person in a manner that has resulted, or would reasonably be
expected to result, in the Company's or such Company Subsidiary's loss of
trade secret rights in and to such information.

  

 

37  

  

(i) To the knowledge of the Company, all of the Company's and any Company
Subsidiary's products have been marked with Patent notice(s) in accordance
with applicable Law since the issuance of the relevant Patent(s).

  


 

  

(j) To the knowledge of the Company, the Company and each Company Subsidiary
has at all times complied in all material respects with all applicable Laws,
as well as its own written rules, policies and procedures, relating to
privacy, data protection and the collection and use of personal information
collected, used or held for use by the Company or any Company Subsidiary. No
Litigation has been asserted or, to the knowledge of the Company, threatened
against the Company or any Company Subsidiary alleging a violation of any
Person's privacy or personal information or data rights and the consummation
of the Transactions will not breach or otherwise cause any violation of any
such Law or written rule, policy or procedure relating to privacy, data
protection or the collection and use of personal information collected, used
or held for use by, or on behalf of, the Company or any Company Subsidiary in
the conduct of its business (except as would not be material and adverse to
the Company). The Company and each Company Subsidiary takes reasonable
measures to ensure that such information is protected against unauthorized
access, use, modification or other misuse.

  


 

  

(k) No funding, facilities or personnel of any Governmental Entity were used,
directly or indirectly, to develop or create, in whole or in part, any Owned
Intellectual Property.

  


 

  

(l) No current or former partner, director, stockholder, officer, contractor
or employee of the Company or any Company Subsidiary will, after giving effect
to the Transactions, own or retain any rights to use any of the Owned
Intellectual Property owned, used or held for use by the Company or any
Company Subsidiary.

  


 

  

(m) With respect to the use of the Software in the business of the Company or
the Company Subsidiaries, (i) no capital expenditures are necessary with
respect to such use other than capital expenditures in the ordinary course of
business that are consistent with the past practice of the Company or Company
Subsidiaries and (ii) to the knowledge of the Company, the Company or Company
Subsidiaries have not experienced any material defect in such Software,
including any material error or omission in the processing of any transactions
other than defects which have been corrected in all material respects. Since
January 1, 2011, to the knowledge of the Company, (x) there have been no
material security breaches in the Company's or any Company Subsidiary's
information technology systems, and (y) there have been no disruptions in any
of the Company's or any Company Subsidiary's information technology systems
that materially adversely affected the Company's or any Company Subsidiary's
business or operations.

  

 

38  

  

(n) The consummation of the Transactions will not result in a material breach
by the Company or any Company Subsidiary of, nor require the consent of any
other Person in respect of, any IP Contract.

  


 

  

Section 4.21 _Brokers._ No broker, investment banker, financial advisor or
other Person, other than William Blair and Company, L.L.C. and Raymond James and
Associates, Inc., the fees and expenses of which will be paid by the Company,
is entitled to any broker's, finder's, financial advisor's or other similar
fee or commission in connection with any of the Transactions based upon
arrangements made by or on behalf of the Company. Prior to the date hereof,
the Company has delivered or made available to Parent a true and correct copy
of all agreements between the Company and William Blair and Company, L.L.C. and
between the Company and Raymond James and Associates, Inc. relating to the
Transactions.

  


 

  

Section 4.22 _Insurance._ The Company has delivered or made available to
Parent prior to the date hereof a list that is true and correct in all
material respects of all material insurance policies in force naming the
Company, any Company Subsidiary or any employees thereof, as an insured or
beneficiary or as a loss payable payee or for which the Company or any Company
Subsidiary has paid or is obligated to pay all or part of the premiums. Except
as has not had, or is not reasonably expected to have, individually or in the
aggregate, a Company Material Adverse Effect, all such insurance policies are
in full force and effect, all premiums due and payable thereon have been paid,
and neither the Company nor any Company Subsidiary has received, as of the
date hereof, written notice of any pending or threatened cancellation or
premium increase (retroactive or otherwise) with respect thereto. The Company
and each Company Subsidiary is in compliance with all conditions contained in
such insurance policies, except where the failure to so comply has not had, or
is not reasonably expected to have, individually or in the aggregate, a
Company Material Adverse Effect.

  


 

  

Section 4.23 _Information Supplied._ None of the information included or
incorporated by reference in the Schedule 14D-9 (and none of the information
supplied by the Company in writing specifically for inclusion or incorporation
by reference in the Offer Documents) will, at the respective times the
Schedule 14D-9 and the Offer Documents are filed with the SEC or first
published, amended or supplemented or sent or given to the Company's
stockholders contain any statement that, in light of the circumstances under
which it is made, is false or misleading with respect to any material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under
which they are made, not false or misleading, except that no representation or
warranty is made by the Company with respect to statements made or
incorporated by reference in the Schedule 14D-9 based on information supplied
by Parent or Merger Sub specifically for inclusion or incorporation by
reference therein. The Schedule 14D-9 will comply as to form in all material
respects with the requirements of the Exchange Act.

  


 

  

Section 4.24 _Related Party Transactions._ Except for indemnification,
compensation, employment or other similar arrangements between the Company or
any Company Subsidiary, on the one hand, and any Affiliate (including any
director or officer), on the other hand, and except as set forth in Section
4.24 of the Company Disclosure Letter, there are no transactions, agreements,
arrangements or understandings between the Company or any Company Subsidiary,
on the one hand, and any Affiliate (including any director or officer)
thereof, but not including any wholly owned Company Subsidiary, on the other
hand, that would be required to be disclosed pursuant to Item 404 of
Regulation S-K under the Securities Act in the Company's Form 10-K or proxy
statement pertaining to an annual meeting of stockholders.

  

 

39  

  

Section 4.25 _Certain Business Practices_.

  


 

  

(a) Neither the Company nor any of the Company Subsidiaries, nor, to the
knowledge of the Company, any current or former directors, officers,
employees, agents, independent contractors or other parties acting on behalf
of the Company or any of the Company Subsidiaries, has directly or indirectly
(i) used, offered or promised anything of value for unlawful contributions,
payments, expenditures, gifts, meals, entertainment, trips or travel and
accommodations, or made, offered or promised any unlawful expenditures
relating to political activity to government officials, employees, candidates
for political office, members of political parties or organizations, or to any
official of a public international organization, in order to obtain or retain
business or secure an improper advantage, (ii) paid, offered, promised,
accepted or received any unlawful contributions, payments, expenditures,
gifts, meals, entertainment, trips, travel and accommodations, or anything
else of value, (iii) made, offered or promised any bribe, unlawful rebate,
payoff, influence payment, kickback or other unlawful payment of any nature,
or (iv) violated any provision of the United States Foreign Corrupt Practices
Act of 1977, as amended, including any provisions relating to the accurate and
fair reflection of all transactions in the books and records of such entity
and the maintenance of an adequate system of internal accounting controls, or
any other similar applicable anti-corruption or anti-bribery law, rule or
regulation (collectively, the " _Anti-Corruption Laws_ ").

  


 

  

(b) Neither the Company nor any Company Subsidiary, nor, to the knowledge of
the Company, any current or former directors, officers, employees, agents,
independent contractors or other parties acting on behalf of the Company or
any Company Subsidiary, has violated or operated in noncompliance with any
export restrictions, anti-boycott regulations, embargo regulations or other
applicable Laws of any Governmental Entity.

  


 

  

Section 4.26 _Takeover Statutes_ _._ The Company has taken all action
necessary to exempt the Offer, the Merger, the Tender Agreements, the CVR
Agreement and this Agreement and the transactions contemplated hereby and
thereby from (i) Section 203 of the DGCL and (ii) any other "fair price,"
"moratorium," "control share acquisition," "interested stockholder," "business
combination" or other similar Law (collectively, the "Takeover Statutes"). The
Company does not have in effect any "poison pill" or shareholder rights plan.

  

 

40  

  

ARTICLE V

  


 

  

 _REPRESENTATIONS AND WARRANTIES_

  

 _OF PARENT AND MERGER SUB_

  


 

  

Parent and Merger Sub jointly and severally represent and warrant to the
Company as follows:

  


 

  

Section 5.1 _Organization and Good Standing._ Each of Parent and Merger Sub is
a corporation duly organized, validly existing and in good standing under the
Laws of its jurisdiction of incorporation. Parent is the legal and beneficial
owner of all of the issued and outstanding capital stock of Merger Sub. Merger
Sub was formed at the direction of Parent solely for the purposes of effecting
the Transactions.

  


 

  

Section 5.2 _Authority_

  


 

  

(a) Each of Parent and Merger Sub has all necessary corporate power and
authority to execute and deliver this Agreement and, in the case of Parent,
the CVR Agreement, to perform its respective obligations hereunder and
thereunder and to consummate the Transactions. The execution, delivery and
performance by each of Parent and Merger Sub of this Agreement has been, and,
in the case of Parent, the CVR Agreement will be, at or prior to the Offer
Closing Date, and the consummation by each of Parent and Merger Sub of the
Transactions have been duly authorized by all necessary corporate action on
the part of each of Parent and Merger Sub and no other corporate proceedings
on the part of each of Parent or Merger Sub, respectively, are necessary to
authorize this Agreement and, in the case of Parent, the CVR Agreement, or to
consummate the Transactions (other than the filing and recordation of
appropriate merger documents as required by the DGCL). This Agreement has
been, and, in the case of Parent, the CVR Agreement will be, at or prior to
the Offer Closing Date, duly executed and delivered by each of Parent and
Merger Sub and, assuming the due authorization, execution and delivery by the
Company, each such agreement constitutes, or will constitute at the time of
such authorization, execution and delivery, a legal, valid and binding
obligation of each of Parent and Merger Sub, as applicable, enforceable
against each of Parent and Merger Sub, as applicable, in accordance with its
terms subject, as to enforcement of remedies, to bankruptcy, insolvency,
reorganization, moratorium or similar Laws affecting the rights and remedies
of creditors generally and to the effect of general principles of equity.

  


 

  

(b) The board of directors of Merger Sub, at a meeting duly called and held
(or acting by written consent) duly and unanimously adopted resolutions (i)
approving this Agreement and the Transactions and (ii) determining that the
terms of the Transactions are fair to and in the best interests of Merger Sub
and its stockholder.

  


 

  

(c) The board of directors of Parent, at a meeting duly called and held (or
acting by written consent) duly and unanimously adopted resolutions approving
this Agreement, the CVR Agreement and the Transactions.

  


 

  

Section 5.3 _No Conflict._ Neither the execution and delivery of this
Agreement or, in the case of Parent, the CVR Agreement by each of Parent and
Merger Sub nor the consummation of the Transactions by each of Parent and
Merger Sub, nor performance of this Agreement or, in the case of Parent, the
CVR Agreement by each of Parent and Merger Sub will (a) conflict with or
violate (i) the Amended and Restated Certificate of Incorporation or Amended
and Restated By-Laws of Parent or (ii) the certificate of incorporation or
bylaws of Merger Sub, (b) subject to Section 5.4, conflict with or violate any
Law or any Order or any rule or regulation of any securities exchange on which
Parent's common stock is listed for trading, in each case applicable to Parent
or Merger Sub or by which any property or asset of Parent or Merger Sub is
bound or affected, or (c) result in a breach of or constitute a default (or an
event which with notice or lapse of time or both would become a default)
under, give to others any right of termination, amendment, acceleration or
cancellation of, result in the triggering of any payment or other obligation
or any right of consent, or result in the creation of a Lien on any property
or asset of Parent or any Subsidiary of Parent (other than Permitted Liens)
pursuant to any note, bond, mortgage, indenture, Contract, agreement, lease,
license, permit, franchise or other instrument or obligation to which Parent
or any Subsidiary of Parent is a party or by which Parent or any Subsidiary of
Parent or any property or asset of any of them is bound or affected except, in
the case of clauses (b) and (c), for any such conflicts, violations, breaches,
defaults or other occurrences which would not reasonably be expected to
prevent or materially delay the consummation of the Transactions.

  

 

41  

  

Section 5.4 _Required Filings and Consents._ The execution and delivery by
Parent and Merger Sub of this Agreement does not, and the performance of this
Agreement by Parent and Merger Sub will not, require any consent, approval,
order, authorization or permit of, or declaration, registration, filing with,
or notification to, any Governmental Entity, except for (a) applicable
requirements, if any, of (i) the Exchange Act, including the filing with the
SEC of the Schedule TO, (ii) state securities or "blue sky" Laws, (iii) the
DGCL to file the Certificate of Merger or other appropriate documentation and
(iv) NASDAQ, (b) those required by any Competition Laws and (c) the filing of
customary applications and notices, as applicable with any Regulatory
Authority.

  


 

  

Section 5.5 _Ownership and Operations of Merger Sub._ All of the issued and
outstanding share capital of Merger Sub is, and immediately prior to the
Effective Time will be, owned, directly or indirectly, by Parent. Merger Sub
was formed solely for the purpose of engaging in the Transactions and has
engaged in no business other than in connection with the Transactions.

  


 

  

Section 5.6 _Sufficiency of Funds._ Parent has cash available or has existing
borrowing facilities that, together with the cash of the Company, are
sufficient to enable it to pay the aggregate Offer Price and Merger
Consideration and the consideration in respect of the Company Options and
Company Restricted Stock Awards and to pay all related fees and expenses as
required by this Agreement and to otherwise consummate the Transactions.

  


 

  

Section 5.7 _Litigation._ There is no Litigation pending or, to the knowledge
of Parent, threatened against Parent or Merger Sub which, individually or in
the aggregate, would reasonably be expected to prevent or materially delay the
consummation of the Transactions. There are no Orders of any Governmental
Entity or arbitrator outstanding against or, to the knowledge of Parent,
investigation by, any Governmental Entity involving Parent or Merger Sub or
any of their respective assets which, individually or in the aggregate, would
reasonably be expected to prevent or materially delay the consummation of the
Transactions.

  


 

  

Section 5.8 _Ownership of Company Common Stock_. __ Neither Parent nor Merger
Sub, nor any of their respective "affiliates" or "Associates" (as such terms
are defined in Rule 12b-2 under the Exchange Act) has beneficial ownership of
any Company Common Stock or other securities of the Company or any Company
Subsidiary, except as contemplated by this Agreement and except for any
securities that may be owned by any employee benefit plan or other benefit
plan administered by or on behalf of Parent or any of its Subsidiaries.
Neither Parent nor Merger Sub nor any of their respective Affiliates is or has
been since December 31, 2011, an "interested stockholder" (as defined in
Section 203 of the DGCL) of the Company.

  

 

42  

  

Section 5.9 _Brokers._ No broker, investment banker, financial advisor or
other Person is entitled to any broker's, finder's, financial advisor's or
other similar fee or commission in connection with any of the Transactions
based upon arrangements made by or on behalf of Parent.

  


 

  

Section 5.10 _Information Supplied._ None of the information included or
incorporated by reference in the Offer Documents (and none of the information
supplied by Parent or Merger Sub in writing specifically for inclusion or
incorporation by reference in the Schedule 14D-9) will, at the respective
times the Offer Documents and the Schedule 14D-9 are filed with the SEC or
first published, amended or supplemented or sent or given to the Company's
stockholders contain any statement that, in light of the circumstances under
which it is made, is false or misleading with respect to any material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under
which they are made, not false or misleading, except that no representation or
warranty is made by Parent or Merger Sub with respect to statements made or
incorporated by reference in the Offer Documents based on information supplied
by the Company specifically for inclusion or incorporation by reference
therein. The Offer Documents will comply as to form in all material respects
with the requirements of the Exchange Act.

  


 

  

ARTICLE VI

  


 

  

 _COVENANTS_

  


 

  

Section 6.1 _Conduct of Company 's Business Pending the Merger._

  


 

  

(a) From the date hereof until the Effective Time, except as otherwise
consented to by Parent in writing, and except as disclosed in _Section 6.1(a)_
of the Company Disclosure Letter or as otherwise explicitly required by this
Agreement, (A) the Company shall, and shall cause the Company Subsidiaries to,
use commercially reasonable efforts to conduct their respective businesses
only in, and the Company and the Company Subsidiaries shall not take any
action except in, the ordinary course of business consistent with past
practice and (B) the Company and the Company Subsidiaries shall use
commercially reasonable efforts to preserve intact their business
organizations, to preserve their assets and properties in good repair and
condition, to keep available the services of their current officers and
employees and to preserve, in all material respects, the current relationships
of the Company and the Company Subsidiaries with customers, suppliers,
licensors, licensees, distributors and other Persons with which the Company or
the Company Subsidiaries have business dealings.

  


 

  

(b) Without limiting the generality of the foregoing, except as set forth in
_Section 6.1(b)_ of the Company Disclosure Letter or as otherwise explicitly
required by this Agreement, to which actions the Parent hereby consents, from
the date hereof until the Effective Time, except as otherwise consented to by
Parent in writing, the Company shall not, nor shall the Company permit any
Company Subsidiary to:

  


 

  

(i) amend the Company Organizational Documents or the equivalent
organizational documents (including any partnership, limited liability company
or similar agreements) of any Company Subsidiary;

  

 

43  

  

(ii) declare or pay any dividends on or make other distributions (whether in
cash, stock or property) in respect of any of its capital stock or other
equity interests except for dividends and distributions by a direct or
indirect wholly owned Company Subsidiary to the Company or any other wholly
owned Company Subsidiary;

  


 

  

(iii) subdivide, reclassify, recapitalize, split, combine or exchange or enter
into any similar transaction with respect to any of its capital stock or other
equity interests or issue or authorize or propose the issuance of any other
securities in respect of, in lieu of, or in substitution for, shares of its
capital stock or other equity interests, except for any split, combination or
reclassification of capital stock of a wholly owned Company Subsidiary, or any
issuance or authorization or proposal to issue or authorize any securities of
a wholly owned Company Subsidiary to the Company or another wholly owned
Company Subsidiary;

  


 

  

(iv) repurchase, redeem or otherwise acquire any shares of its capital stock
or other equity interests or any Company Securities, other than in connection
with (A) the forfeiture or expiration of outstanding Company Options and (B)
the withholding of shares of Company Common Stock to pay the exercise price or
satisfy Tax obligations with respect to the exercise of Company Options or
vesting of Company Restricted Stock Awards pursuant to any obligations
contained in the Company Stock Plans;

  


 

  

(v) issue, deliver or sell, or authorize, propose or reserve for issuance,
delivery or sale, or otherwise encumber, any shares of its capital stock or
any Company Securities, other than the issuance of shares of Company Common
Stock upon the exercise of Company Options outstanding on the date hereof in
accordance with their present terms;

  


 

  

(vi) incur, assume, guarantee, prepay or otherwise become liable for any
Indebtedness (directly, contingently or otherwise), except for any
Indebtedness among the Company and wholly owned Company Subsidiaries or among
wholly owned Company Subsidiaries;

  


 

  

(vii) make any loans, advances or capital contributions to, or any investments
in, any other Person (other than loans or advances between any wholly owned
Company Subsidiaries or between the Company and any wholly owned Company
Subsidiaries);

  


 

  

(viii) (A) sell, assign, lease, sublease, license, sell and leaseback,
mortgage, pledge or otherwise encumber or dispose of any assets or properties
that are material, individually or in the aggregate, to the Company or any
Company Subsidiary, other than Permitted Liens or resulting from the sale of
Company Product in the ordinary course of business or (B) enter into, modify,
supplement or amend any lease or sublease of real property, except for: (x)
modifications or amendments that would not reasonably be expected to be
adverse to the Surviving Corporation or (y) Permitted Liens;

  


 

  

(ix) directly or indirectly acquire (A) by merging or consolidating with, or
by purchasing assets of, or by any other manner, any division, business or
equity interest of any Person (including in a transaction involving a tender
or exchange offer, business combination, recapitalization, liquidation,
dissolution, joint venture or similar transaction) or (B) any material assets;

  

 

44  

  

(x) adopt a plan or agreement of complete or partial liquidation, dissolution,
restructuring, recapitalization, merger, consolidation or other reorganization
of the Company or any Company Subsidiary (other than this Agreement);

  


 

  

(xi) implement or adopt any change in its accounting methods, principles or
policies other than as may be required by applicable Law or GAAP and as
concurred with by the Company's independent auditors;

  


 

  

(xii) except to the minimum extent required in order to comply with applicable
Law or except as required by any Company Benefit Plans or Company Benefit
Agreements (A) amend any of the terms or conditions of employment for any of
its directors or officers, (B) adopt, enter into, terminate or amend any
Company Benefit Plan, Company Benefit Agreement (or any plans, agreements or
arrangements that would constitute Company Benefit Plans or Company Benefit
Agreements if in effect on the date hereof) or Collective Bargaining Agreement
other than amendments that are immaterial or administrative in nature, (C)
increase in any manner (including by way of effecting employee promotions) the
compensation or benefits (including the severance, retention or change in
control pay) of, or pay any bonus to, any Company Participant, (D) grant any
awards under any Company Benefit Plan or Company Benefit Agreement (including
the grant of stock options, stock appreciation rights, performance units,
restricted stock, deferred stock awards, stock purchase rights or other stock-
based or stock-related awards) or remove or modify existing restrictions in
any Company Benefit Plan or Company Benefit Agreement on any awards made
thereunder (other than such removals that occur in accordance with the terms
of the awards), (E) take any action to accelerate the vesting or payment of
any compensation or benefits under any Contract, Company Benefit Plan or
Company Benefit Agreement, (F) make any material determination under any
Company Benefit Plan or Company Benefit Agreement that is inconsistent with
the ordinary course of business or past practice or (G) hire, terminate,
promote or demote any officer or employee of the Company, other than the
hiring, termination, promotion or demotion of employees whose base salary
exceeds $60,000;

  


 

  

(xiii) modify or amend in any material respect or terminate or cancel or
waive, release or assign any material rights or claims with respect to, any
Company Material Contract or enter into any agreement or Contract that would
qualify as a Company Material Contract;

  


 

  

(xiv) enter into any Company Material Contract relating to the development or
commercialization of any Company Product or other medical product, including
but not limited to licensing, development, manufacturing, distribution, co-
development, marketing or co-marketing agreements, or any Company Material
Contract containing exclusivity provisions or restrictive covenants;

  


 

  

(xv) pay, loan or advance (other than the payment of compensation, director's
fees or reimbursement of expenses in the ordinary course of business
consistent with past practice, including pursuant to existing indemnification
agreements with officers and directors) any amount to, or sell, transfer or
lease any properties or assets (real, personal or mixed, tangible or
intangible) to, or enter into any agreement with, any of its officers or
directors or any Affiliate or Associate of any of its officers or directors;

  

 

45  

  

(xvi) form or commence the operations of any business or any corporation,
partnership, joint venture, business association or other business
organization or division thereof;

  


 

  

(xvii) enter into any new line of business or increase the scope of any line
or business (other than continued development of pipeline products);

  


 

  

(xviii) (A) make, change or revoke any Tax election or method of Tax
accounting, (B) file any Tax Returns relating to the Company or any Company
Subsidiary that have been prepared in a manner that is inconsistent with the
past practices of the Company or any Company Subsidiary, (C) file any material
amended Tax Return, (D) settle or compromise any claim, investigation, audit,
liability or controversy for or relating to Taxes, (E) agree to an extension
or waiver of the statute of limitations with respect to the assessment or
determination of Taxes, (F) enter into any closing agreement with respect to
any Tax or (G) surrender any right to claim a material Tax refund;

  


 

  

(xix) (A) pay, discharge, settle or satisfy any claims, Litigation,
Liabilities or obligations (whether absolute, accrued, asserted or unasserted,
contingent or otherwise), other than the payment, discharge, settlement or
satisfaction, in the ordinary course of business consistent with past practice
or in accordance with their terms, of Liabilities or obligations: (1)
reflected or reserved against in, or contemplated by, the most recent
consolidated financial statements (or the notes thereto) included in the
Company SEC Reports or (2) incurred in the ordinary course of business
consistent with past practice or (B) cancel any material Indebtedness
(individually or in the aggregate) or waive any claims or rights of
substantial value;

  


 

  

(xx) make or agree to make any new capital expenditure or expenditures that
are not budgeted for in the budget attached as _Section 4.14(a)(viii)_ of the
Company Disclosure Letter and exceed $50,000 individually or $150,000 in the
aggregate;

  


 

  

(xxi) except as consistent with the ordinary conduct of its business and
consistent with past practice, (A) grant or acquire, agree to grant to or
acquire from any Person, or dispose of or permit to lapse any rights to any
Intellectual Property that is material to the conduct of the business of the
Company and the Company Subsidiaries, taken as a whole, or disclose or agree
to disclose to any Person, other than representatives of the Parent, any Trade
Secrets, (B) compromise, settle or agree to settle any Litigation or institute
any Litigation concerning any Intellectual Property that is material to the
conduct of the business of the Company or any Company Subsidiary, or (C) fail
to take any action necessary or advisable to protect or maintain the
Intellectual Property owned, used or held for use by the Company or any
Company Subsidiary that is material to the conduct of the business of the
Company and the Company Subsidiaries as currently conducted and planned by the
Company or the Company Subsidiaries to be conducted, provided that nothing in
this clause (C) shall be interpreted as requiring the Company or any Company
Subsidiary to commence any Litigation; or

  

 

46  

  

(xxii) authorize, or commit or agree to take, any of the foregoing actions.

  


 

  

(c) Prior to the Closing Date, the Company shall, at the Company's expense,
file the necessary corrective change of ownership and records with all patent,
trademark, and copyright offices and domain name registrars and other similar
authorities in any jurisdiction throughout the world where Intellectual
Property owned by the Company or any Company Subsidiary is recorded in the
name of one or more legal predecessors of the Company or any Company
Subsidiary or any Person other than the Company or any Company Subsidiary.

  


 

  

Section 6.2 _Access to Information; Confidentiality._

  


 

  

Subject to the confidentiality agreement between the parent of Parent and the
Company, dated January 6, 2015 (the " _Confidentiality Agreement_ ") and
applicable Law, the Company shall, and shall cause each Company Subsidiary to,
afford to Parent and its officers, employees, accountants, counsel, financial
advisors and other Representatives, full access at all reasonable times on
reasonable notice during the period between the date hereof and the earlier of
the Effective Time and the termination of this Agreement in accordance with
_Section 8.1_ to all their properties, books, contracts, commitments,
personnel and records, including for the purpose of conducting Phase I
environmental site assessments ( _provided_ , that such access shall not
unreasonably interfere with the business or operations of the Company) and,
during such period, the Company shall, and shall cause each Company Subsidiary
to, furnish promptly to Parent (a) a copy of each report, schedule,
registration statement and other document filed by it during such period
pursuant to the requirements of federal or state securities Laws and (b) all
other information concerning its business, properties, Litigation matters,
personnel and environmental compliance and property condition as Parent may
reasonably request, including bi-weekly sales reports, bi-weekly headcount
reports, bi-weekly cash reports, bi-weekly accounts receivable reports and bi-
weekly reports on the average selling price of all services and products of
the Company and the Company Subsidiaries; _provided_ , that nothing in this
_Section 6.2_ shall require the Company to provide any access, or to disclose
any information, if permitting such access or disclosing such information
would (i) violate applicable Law, (ii) violate any of its obligations with
respect to confidentiality ( _provided_ , that the Company shall, upon the
request of Parent, use its commercially reasonable efforts to obtain the
required consent of any third party to such access or disclosure) or (iii)
result in the loss of attorney-client privilege ( _provided_ , that the
Company shall use its commercially reasonable efforts to allow for such access
or disclosure in a manner that does not result in a loss of attorney-client
privilege). No review pursuant to this _Section 6.2_ shall affect or be deemed
to modify any representation or warranty contained herein, the covenants or
agreements of the parties hereto or the conditions to the obligations of the
parties hereto under this Agreement. All information provided pursuant to this
_Section 6.2_ shall be subject to the terms of the Confidentiality Agreement.
If Parent wishes to conduct a Phase I environmental site assessment or similar
environmental assessment, (w) Parent and the Company shall coordinate the
scope of the assessment (which, in any event, shall conform to applicable
industry and statutory standards), (x) Parent shall give to the Company copies
of any non-privileged report generated in the course of the assessment, (y) a
representative of Company shall, at its option, be present at all site visits
and inspections, and (z) the Parent's Representatives shall, at all times
while on the premises of the Company or any Company Subsidiary, comply with
all reasonable directions and requests relating to safety, security and
confidentiality.

  


 

  

Section 6.3 _Notification of Certain Matters._ Parent shall give prompt notice
to the Company and the Company shall give prompt notice to Parent, as the case
may be, of the occurrence, or failure to occur, of any event, which occurrence
or failure to occur is reasonably likely to cause (a)(i) any representation or
warranty of such party contained in this Agreement that is qualified as to
"materiality," or "Company Material Adverse Effect" to be untrue or inaccurate
in any respect or (ii) any other representation or warranty of such party
contained in this Agreement to be untrue or inaccurate in any material
respect, in each case at any time from and after the date hereof until the
Offer Closing or (b) any material failure of Parent or Merger Sub or the
Company, as the case may be, to comply with or satisfy any covenant, condition
or agreement to be complied with or satisfied by it under this Agreement. In
addition, (A) the Company shall give prompt notice to Parent of any change or
event having, or which would be reasonably likely to have, a Company Material
Adverse Effect, (B) Parent shall give prompt notice to the Company, and the
Company shall give prompt notice to Parent, as the case may be, of any change
or event which would be reasonably likely to result in the failure of any of
the conditions set forth in Exhibit A to be satisfied and (C) each of Parent
and the Company shall give prompt notice to the other after receiving or
becoming aware of any notice or other communication from any Person alleging
that the consent of such Person is or may be required in connection with the
Transactions. Notwithstanding the above, the delivery of any notice pursuant
to this Section 6.3 shall not (i) cure any breach of, or non-compliance with,
any other provision of this Agreement, (ii) limit or otherwise affect the
representations, warranties, covenants or agreements of the parties, or (iii)
limit the remedies available hereunder to the party receiving such notice.

  

 

47  

  

Section 6.4 _Antitrust Filings; Reasonable Best Efforts._

  


 

  

(a) Each party shall make or cause to be made, in cooperation with the other
parties and to the extent applicable and as promptly as practicable, (i) no
later than fifteen (15) Business Days following the execution and delivery of
this Agreement, an appropriate filing of a Notification and Report Form
pursuant to the HSR Act with respect to the Transactions and (ii) all other
necessary filings, forms, declarations, notifications, registrations and
notices with other Governmental Entities under Competition Laws relating to
the Transactions. Each party shall use its commercially reasonable efforts to
respond at the earliest practicable date to any requests for additional
information made by the FTC or any other Governmental Entities, and act in
good faith and reasonably cooperate with the other party in connection with
any investigation of any Governmental Entity. Each party shall use its
commercially reasonable efforts to furnish to each other party all information
required for any filing, form, declaration, notification, registration and
notice with respect to Competition Laws and the Transactions. Each party shall
give the other parties reasonable prior notice of any communication with, and
any proposed understanding or agreement with, any Governmental Entity
regarding any filings, forms, declarations, notifications, registrations or
notices with respect to Competition Laws and the Transactions, and permit the
other parties to review and discuss in advance, and consider in good faith the
views of the other parties in connection with, any proposed communication,
understanding or agreement with any Governmental Entity with respect to the
Transactions; provided however, that materials may be redacted or withheld (i)
as necessary to comply with contractual agreements, (ii) as necessary to
address reasonable privilege or confidentiality concerns and (iii) to remove
references concerning the valuation of the Company and the Company
Subsidiaries. None of the parties shall independently participate in any
meeting, or engage in any substantive conversation, with any Governmental
Entity in respect of any filings or inquiry with respect to Competition Laws
and the Transactions without giving the other parties prior notice of the
meeting and, unless prohibited by such Governmental Entity, the opportunity to
attend and/or participate. The parties will consult and cooperate with one
another in connection with any information or proposals submitted in
connection with proceedings under or relating to any Competition Law. Without
limiting the foregoing, the Company and Parent shall each use its commercially
reasonable efforts (A) to avoid the entry of any judgment that would restrain,
prevent or delay the Closing, (B) to eliminate every impediment under any
Competition Law that may be asserted by any Governmental Entity so as to
enable the Closing to occur as soon as reasonably possible (and in any event
no later than the Outside Date) and (C) vigorously to contest and resist any
such action or proceeding, including any administrative or judicial action.
Parent shall control and lead all communications and strategy relating to the
Competition Laws (provided that the Company is not constrained from complying
with applicable Law), provided, further, that the Parties shall consult and
cooperate with one another, and consider in good faith the views of one
another, regarding the form and content of any analyses, appearances,
presentations, memoranda, briefs, arguments, opinions and proposals made or
submitted by or on behalf of either Party in connection with proceedings under
or relating to any Competition Law.

  

 

48  

  

(b) Subject to _Section 6.4(c)_ , each of the parties to this Agreement agrees
to use its reasonable best efforts to take, or cause to be taken, all actions,
and to do, or cause to be done, and to assist and cooperate with the other
parties to this Agreement in doing, all things necessary, proper or advisable
to consummate and make effective, in the most expeditious manner practicable,
the Transactions, including (i) the obtaining of all other necessary actions
or nonactions, waivers, consents, licenses, permits, authorizations, orders
and approvals from Governmental Entities and the making of all other necessary
registrations and filings (including filings with Governmental Entities, if
any), (ii) the obtaining of all consents, approvals or waivers from third
parties necessary to consummate the Transactions, (iii) the preparation of any
documents that may be required to be filed with the SEC, (iv) the execution
and delivery of any additional instruments reasonably necessary to consummate
any of the Transactions, and to fully carry out the purposes of, this
Agreement and (v) the providing of all such information concerning such party,
its Subsidiaries and its Affiliates as well as the officers, directors,
employees and partners of its Subsidiaries and Affiliates, in each case, as
may be reasonably requested in connection with any of the matters set forth in
_Section 6.4(a)_ or this _Section 6.4(b)_.

  


 

  

(c) Notwithstanding anything to the contrary in this _Section 6.4_ or any
other provision of this Agreement, Parent or its Affiliates shall not be
required, and the Company and its Affiliates shall not agree with a Government
Entity without prior consent of Parent, to divest any of its businesses,
product lines or assets, hold separate or take or agree to take any other
action or agree to any limitation or restriction in order to resolve any
objections asserted under Competition Laws by any Governmental Entity with
respect to any of the Transactions if such action (i) would, or would
reasonably be expected to, materially and adversely affect the Company and the
Company Subsidiaries, taken as a whole, (ii) would, or would reasonably be
expected to, materially impair the benefits sought to be derived by Parent
from the Transactions (taking into account, among other things, effects on the
assets, business and operations and relationships of both Parent and its
Subsidiaries and of the Company and the Company Subsidiaries) or (iii) causes
Parent to sell, divest, hold separate, license, cause a third party to
acquire, or otherwise dispose of any material operations, divisions,
businesses, product lines, customers or assets of Parent or its Subsidiaries,
or any other actions that may materially limit Parent's freedom of action with
respect to, or its ability to retain, any of its Subsidiaries, material
operations, divisions, businesses, product lines, customers or assets (with
materiality being measured based on the size of the Company and the Company
Subsidiaries, taken as a whole) (any such action being referred to herein as
an " _Adverse Regulatory Requirement_ ").

  

 

49  

  

Section 6.5 _No Solicitation; Company Recommendation._

  


 

  

(a) The Company shall, and shall cause the Company Subsidiaries and the
Company's and Company Subsidiaries' respective Representatives to, immediately
cease and cause to be terminated any discussions or negotiations with any
Person conducted heretofore with respect to a Company Takeover Proposal, and
concurrently therewith shall request the return from, or destruction by, all
such Persons of all copies of confidential information previously furnished to
such Persons by the Company, the Company Subsidiaries or the Company's and
Company Subsidiaries' respective Representatives, in connection with exploring
any Company Takeover Proposal prior to the date hereof and shall terminate
access to any data room (electronic or otherwise) by any Person other than
Parent and its Representatives. The Company shall not, and shall cause the
Company Subsidiaries and the Company's and Company Subsidiaries' respective
Representatives not to, directly or indirectly (i) solicit, initiate,
facilitate or encourage (including by way of furnishing or providing access to
non-public information with the intent of encouraging the making, submission
or announcement of any Company Takeover Proposal), any inquiries or proposals
that constitute, or which would reasonably be expected to lead to, a Company
Takeover Proposal, (ii) participate in any discussions (other than to refer to
this Agreement) or negotiations with any third party regarding any Company
Takeover Proposal, (iii) approve any transaction under, or any Person (other
than Parent or Merger Sub) becoming an "interested stockholder" under, Section
203 of the DGCL (except in connection with the Transactions) or (iv) enter
into any merger or other agreement, agreement in principle, letter of intent,
term sheet, joint venture agreement, partnership agreement or other similar
instrument constituting or related to any Company Takeover Proposal;
_provided_ , _however_ , that if after the date hereof but prior to the Offer
Closing Date the Company Board receives an unsolicited, bona fide written
Company Takeover Proposal made after the date hereof but prior to the Offer
Closing Date, that did not result from or arise in connection with a breach of
this _Section 6.5(a) (other than an immaterial breach)_ , and the Company
Board determines in its good faith judgment (after consultation with outside
counsel and a financial advisor of nationally recognized reputation) that such
Company Takeover Proposal constitutes, or would reasonably be expected to lead
to, a Superior Proposal, then the Company may, if the Company Board determines
(after consultation with outside counsel) that failure to take such actions
would be inconsistent with the Company Board's fiduciary duties to the
Company's stockholders under applicable Law, and subject to compliance with
this _Section 6.5(a)_ and _Section 6.5(b)_ , at any time prior to the Offer
Closing Date (but in no event after the Offer Closing Date) and after
providing Parent not less than forty-eight (48) hours prior written notice of
such determination by the Company Board (A) furnish information with respect
to the Company and the Company Subsidiaries to the Person making such Company
Takeover Proposal, but only after such Person enters into a customary
confidentiality agreement with terms substantially similar to, and with a
standstill not less restrictive, and other provisions not less restrictive
(other than in an immaterial respect) than, those contained in the
Confidentiality Agreement (including the "standstill" covenant); _provided_ ,
that (1) such confidentiality agreement may not include any provision calling
for an exclusive right to negotiate with the Company and (2) the Company
provides Parent, in accordance with the terms of the Confidentiality
Agreement, any non-public information with respect to the Company furnished to
such other Person which was not previously furnished to Parent prior to the
time it is provided to such other Person, which information shall be treated
in accordance with the terms of the Confidentiality Agreement, and (B)
participate in discussions and negotiations with such Person regarding such
Company Takeover Proposal. Without limiting the foregoing, it is understood
that any violation of the foregoing restrictions by any Company Subsidiaries
or the Company's or the Company Subsidiaries' respective Representatives shall
be deemed to be a breach of this _Section 6.5_ by the Company.

  

 

50  

  

(b) In addition to the other obligations of the Company set forth in this
_Section 6.5_ , the Company shall promptly advise Parent, orally and in
writing (and in any case within twenty-four (24) hours of knowledge of
receipt) of the receipt by the Company of any Company Takeover Proposal, or
any inquiry that would reasonably be expected to lead to any Company Takeover
Proposal, or any request for information relating to the Company or any
Company Subsidiaries or for access to the business, properties, assets, books
or records of the Company or any Company Subsidiary by any third party with
respect to a Company Takeover Proposal. The Company shall, in any such notice
to Parent, indicate the identity of the Person making such Company Takeover
Proposal, indication or request, and the terms and conditions of such Company
Takeover Proposal, indication or request (and shall include with such notice
copies of any written materials received from or on behalf of such Person
relating to such Company Takeover Proposal, indication or request), and
thereafter shall promptly keep Parent reasonably informed, in a prompt manner,
of all material developments affecting the status and terms of any such
Company Takeover Proposal, indication or request or any changes to the terms
thereof (and the Company shall provide Parent promptly after receipt or
delivery thereof with copies of any additional written materials received that
relate to such Company Takeover Proposal, indication or request or any changes
to the terms thereof) and of the status of any such discussions or
negotiations. In addition, during the period from the date hereof through the
Effective Time, the Company shall enforce, and not terminate, amend, modify or
waive (except for waiver of any standstill provisions to allow such
counterparty to make a proposal to the Company Board) any provision of any
confidentiality agreement to which the Company or any Company Subsidiary is a
party.

  


 

  

(c) Except as expressly permitted by this _Section 6.5_ , neither the Company
Board nor any committee thereof shall (i)(A) withdraw or modify, or propose
publicly to withdraw or modify, in a manner adverse to Parent or Merger Sub,
the Company Recommendation, (B) approve, recommend or declare advisable, or
propose publicly to approve, recommend or declare advisable, any Company
Takeover Proposal or take any action or make any public statement that is
inconsistent with the Company Recommendation, (C) take any formal action or
make any recommendation or public statement in connection with a tender offer
or any exchange offer from any third party, other than (1) a recommendation
against such offer, (2) a position contemplated by Rule 14e-2(a) under the
Exchange Act or making a statement contemplated by Item 1012(a) of Regulation
M-A or Rule 14d-9 under the Exchange Act or (3) a customary "stop, look and
listen" communication of the type contemplated by Rule 14d-9(f) under the
Exchange Act, or (D) fail to include the Company Recommendation in the
Schedule 14D-9 (any action described in this clause (i) a " _Company Adverse
Recommendation Change_ ") or (ii) approve or recommend, or propose publicly to
approve or recommend, or cause or authorize the Company or any Company
Subsidiary to enter into, any letter of intent, agreement in principle,
memorandum of understanding, merger, acquisition, purchase or joint venture
agreement or other agreement constituting or related to, or that is intended
to or reasonably expected to lead to, any Company Takeover Proposal (other
than a confidentiality agreement in accordance with _Section 6.5(a)_ ) (each,
a " _Company Acquisition Agreement_ "). It is agreed that any violation of the
restrictions on the Company set forth in this _Section 6.5_ by any officer,
director or any other Representative of the Company shall be deemed a breach
of this _Section 6.5_ by the Company.

  

 

51  

  

(d) Notwithstanding anything to the contrary contained herein, but subject to
_Section 6.5(f)_ , prior to the Offer Closing Date, the Company Board may (i)
make a Company Adverse Recommendation Change, if (A) the Company Board
determines in its good faith judgment (after consultation with outside
counsel) that failure to take such actions would be inconsistent with the
Company Board's fiduciary duties to the Company's stockholders under
applicable Law and (B) the Company Board (1) receives after the date hereof
but before the Offer Closing Date an unsolicited, bona fide written Company
Takeover Proposal that did not result from or arise in connection with a
breach of this _Section 6.5_ (other than in any immaterial respect) and (2)
determines in its good faith judgment (after consultation with outside counsel
and a financial advisor of nationally recognized reputation) that such Company
Takeover Proposal constitutes a Superior Proposal and authorizes the Company
to enter into a Company Acquisition Agreement with respect to such Superior
Proposal and/or (ii) following or concurrently with making a Company Adverse
Recommendation Change in accordance with clause (i) and _Section 6.5(f)_ ,
authorizes the Company to terminate this Agreement and enter into a Company
Acquisition Agreement if, concurrently with entering into such Company
Acquisition Agreement the Company terminates this Agreement pursuant to
_Section 8.1(d)(ii)_ and pays the Termination Fee required pursuant to
_Section 8.3_.

  


 

  

(e) Notwithstanding anything to the contrary contained herein, but subject to
_Section 6.5(f)_ , the Company Board may make a Company Adverse Recommendation
Change for a reason unrelated to a Company Takeover Proposal if the Company
Board determines (based on a written opinion of outside counsel) that, in
light of material facts, events or circumstances in each case related to the
Company that have developed since the date of this Agreement that did not
exist to the knowledge of the Company prior to the date hereto, failure to
take such actions would be inconsistent with the Company Board's fiduciary
duties to the Company's stockholders under applicable Law.

  


 

  

(f) The Company Board shall not make a Company Adverse Recommendation Change
pursuant to _Section 6.5(d)_ unless (i) the Company promptly provides written
notice to Parent at least five (5) Business Days before taking such action
(the " _Notice Period_ ") advising Parent that the Company Board is
considering making a Company Adverse Recommendation Change, which notice shall
(A) specify the material terms of the applicable Company Takeover Proposal,
identify the Person making such Superior Proposal and include copies of any
written materials relating to such Company Takeover Proposal or (B) in the
case of any action intended to be taken pursuant to Section 6.5(e), contain a
reasonably detailed description of the underlying facts giving rise to, and
the reasons for taking, such action (the " _Company Notice of Adverse
Recommendation_ ") and (ii) during the Notice Period, the Company and its
Representatives shall have, if requested by Parent, negotiated in good faith
with Parent and Parent's Representatives to make such adjustments in the terms
of this Agreement as would enable Parent to proceed with the Transactions on
such adjusted terms and, at the end of such Notice Period, after taking into
account any such adjusted terms as may have been proposed by Parent since its
receipt of such written notice, the Company Board shall have again in good
faith made the determination referred to in clause (i)(B)(2) of _Section
6.5(d)_ or _Section 6.5(e)_ , as applicable. To the extent the Notice Period
described in the preceding sentence would expire after the Offer Closing Date,
the Offer Closing Date shall be automatically extended such that it will occur
on the first Business Day after the expiration of the Notice Period. In the
event of any material change (including, for the avoidance of doubt, any
change in price) to the terms of a Superior Proposal, the Company shall, in
each case, make the determination referred to in clause (i)(B)(2) of _Section
6.5(d)_ , deliver a new Company Notice of Adverse Recommendation and commence
a new Notice Period except that the duration of the Notice Period shall be
reduced to 48 hours (rather than three (3) Business Days).

  

 

52  

  

(g) For purposes of this Agreement:

  


 

  

" _Company Takeover Proposal_ " means any inquiry, proposal or offer (whether
in writing or otherwise) from any Person or "group" (as defined in Section
13(d) of the Exchange Act), other than Parent and its Subsidiaries, relating
to any (A) direct or indirect acquisition (whether in a single transaction or
a series of related transactions) of assets of the Company or any of the
Company Subsidiaries (including securities of the Company Subsidiaries) equal
to more than 15% of the Company's consolidated assets or to which more than
15% of the Company's revenues or earnings on a consolidated basis are
attributable, (B) direct or indirect acquisition (whether in a single
transaction or a series of related transactions or by merger, consolidation or
otherwise) of more than 15% of any class of equity securities of the Company
or any Company Subsidiaries or (C) tender offer or exchange offer that if
consummated would result in any Person or "group" (as defined in Section 13(d)
of the Exchange Act) beneficially owning more than 15% of any class of equity
securities of the Company or any Company Subsidiaries or of any resulting
parent company of the Company, other than the Transactions.

  


 

  

" _Superior Proposal_ " means a bona fide written Company Takeover Proposal
(substituting references to "15%" therein with "50%") that did not arise from
a breach of this _Section 6.5_ (other than an immaterial breach), is obtained
after the date hereof but prior to the Offer Closing Date, with no financing
contingency and that the Company Board determines in its good faith judgment
(after consultation with outside counsel and a financial advisor of nationally
recognized reputation) to be (a) more favorable to the stockholders of the
Company from a financial point of view than the Offer and the Merger, taking
into account all relevant factors (including all the terms and conditions of
such proposal and the Offer and this Agreement (including any changes to the
terms of the Offer and this Agreement proposed by Parent in accordance with
_Section 6.5(e)_ )) and (b) reasonably capable of being completed in
accordance with its terms, taking into account all financial, regulatory,
legal and other aspects and terms of such proposal and the third party.

  


 

  

(h) For purposes of this _Section 6.5_ , the term " _Representatives_ " shall
mean directors, officers, consultants, legal counsel, financial advisors,
authorized agents, employees at or above the level of vice-president or
director and accountants.

  


 

  

(i) Nothing in this Agreement shall prohibit the Company Board from taking and
disclosing to the Company's stockholders a position contemplated by Rule
14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A under the Exchange Act
or making any disclosure to its stockholders required pursuant to the rules
and regulations of the SEC if the Company Board determines (after consultation
with outside legal counsel) that failure to take such actions would be
inconsistent with the Company Board's fiduciary duties to the Company's
stockholders under applicable Law. Nothing in this Agreement shall prohibit
the accurate disclosure of factual information (and such disclosure shall not
be deemed to be a Company Adverse Recommendation Change) regarding (x) the
business, financial condition or results of operations of the Company or (y)
the fact that a Company Takeover Proposal has been made, the identity of the
party making such proposal or the material terms of such proposal to the
extent, in the case of each of clauses (x) and (y), (1) the Company in good
faith determines that such information, facts, identity and/or terms is
required to be disclosed under applicable Law and (2) any such disclosure
includes the Company Recommendation without disclosing or effecting a Company
Adverse Recommendation Change.

  

 

53  

  

Section 6.6 _Stockholder Litigation._ The Company shall give Parent the
opportunity to participate (at Parent's expense) in the defense or settlement
of any stockholder Litigation against the Company and its directors relating
to the any of the Transactions; provided, however, that no such settlement
shall be agreed to without Parent's prior written consent, which consent shall
not be unreasonably withheld, conditioned or delayed, except that Parent shall
not be obligated to consent to any settlement which does not include a full
release of the Company, Parent and its Affiliates or which imposes an
injunction or other equitable relief upon the Company, Parent or any of its
Affiliates (including, after the Effective Time, the Surviving Corporation).

  


 

  

Section 6.7 _Indemnification; Director and Officer Insurance._ For not less
than six (6) years from and after the Effective Time, Parent agrees to, and to
cause the Surviving Corporation to, (a) indemnify and hold harmless all past
and present directors, officers and employees of the Company to the same
extent such Persons are indemnified as of the date hereof by the Company
pursuant to the Company Certificate of Incorporation and Company Bylaws and
indemnification agreements, if any, in existence on the date hereof with any
directors, officers or employees of the Company for acts or omissions
occurring at or prior to the Effective Time and (b) advance expenses as
incurred to the extent provided for under such indemnification agreements;
provided, however, that Parent agrees to, and to cause the Surviving
Corporation to, indemnify and hold harmless such Persons to the fullest extent
permitted by Law for acts or omissions occurring in connection with the
approval of this Agreement and the consummation of any of the Transactions.
Parent shall cause the Surviving Corporation to provide, for an aggregate
period of not less than six (6) years from and after the Effective Time, the
Company's current directors and officers an insurance and indemnification
policy that provides coverage for events occurring at or prior to the
Effective Time (the "DandO Insurance") that is no less favorable than the
Company's existing policy or, if substantially equivalent insurance coverage
is unavailable, the best available coverage; provided, however, that the
Surviving Corporation shall not be required to pay an annual premium for the
DandO Insurance in excess of 300% of the last annual premium paid prior to the
date hereof; provided, that (a) Parent may substitute therefor a single
premium tail coverage with respect to DandO Insurance at a level at least as
favorable as in the DandO Insurance, or (b) if Parent does not make the
substitution provided for in clause (a), then the Surviving Corporation may
substitute therefor a single premium tail coverage with respect to DandO
Insurance at a level at least as favorable as in the DandO Insurance for a
premium not to exceed 300% of the last annual premium paid prior to the date
hereof. If the Surviving Corporation or Parent, or any of their successors or
assigns, shall (i) be liquidated and dissolved, (ii) consolidate with or merge
into any other Person and shall not be the continuing or surviving entity of
such consolidation or merger or (iii) sell or otherwise transfer all or a
majority of its assets to any other Person, proper provisions shall be made so
that the continuing or surviving entity or Parent, as applicable, and its
successors and assigns shall assume the obligations set forth in this Section
6.7. The provisions of this Section 6.7 shall survive the Effective Time,
shall thereafter not be terminated or amended in any manner so as to adversely
affect (in any material respect) any indemnified party described in this
Section 6.7, are intended to be for the benefit of, and shall be enforceable
by, each indemnified party described in this Section 6.7 and his or her heirs
and Representatives and are in addition to, and not in substitute for, any
other rights that any such person may have by Contract or otherwise.

  

 

54  

  

Section 6.8 _Public Announcements._ The parties agree that the initial press
release(s) to be issued with respect to the Transactions shall be in the
form(s) agreed to by the parties. Except with respect to any Company Adverse
Recommendation Change made in accordance with the terms of this Agreement,
Parent and Merger Sub, on the one hand, and the Company, on the other hand,
shall, to the extent reasonably practicable, consult with each other before
making, and give each other a reasonable opportunity to review and comment
upon, any press release or other public statements (including broad-based
employee communications) with respect to this Agreement and the Transactions,
and shall not issue any such press release or make any such public statement
prior to such reasonably practicable consultation, except as may be required
by applicable Law, NASDAQ, the New York Stock Exchange or court process, in
which case the party required to make the release or announcement shall use
its commercially reasonable efforts to allow each other party reasonable time
to comment on such release or announcement in advance of such issuance.

  


 

  

Section 6.9 _Employees_ _._

  


 

  

(a) For a period of one (1) year following the Offer Closing, Parent shall or
shall cause the Surviving Corporation to either (i) provide the employees of
the Company and the Company Subsidiaries who are employed immediately prior to
the Effective Time (the " _Covered Employees_ ") who remain employed during
such period by Parent, the Surviving Corporation or any of their respective
Subsidiaries with compensation and benefits which, taken as a whole, have a
value substantially comparable, in the aggregate, to the compensation and
benefits provided by the Company and the Company Subsidiaries as of the date
hereof or (ii) provide or cause the Surviving Corporation (or, in such case,
its successors or assigns) to provide Covered Employees who remain employed
during such period by Parent, the Surviving Corporation or their respective
Subsidiaries with compensation and benefits which, taken as a whole, have a
value substantially comparable, in the aggregate, to those provided to
similarly situated employees of Parent and its Subsidiaries; provided,
however, in either case, neither Parent nor Surviving Corporation shall be
required to provide any equity based compensation. Parent shall have no
obligation and the Company shall take no action that would have the effect of
requiring Parent or the Surviving Corporation to continue any specific plans
or to continue the employment of any specific Person.

  


 

  

(b) For purposes of determining eligibility to participate in, and non-
forfeitable rights under any employee benefit plan or arrangement of Parent or
the Surviving Corporation or any of their respective Subsidiaries (including
for purposes of vacation eligibility), but not for purposes of benefit accrual
under any defined benefit pension plan of Parent or any of its Subsidiaries,
Covered Employees shall receive service credit for service with the Company
(and with any predecessor or acquired entities or any other entities for which
the Company granted service credit) as if such service had been completed with
Parent; _provided_ , _however_ , that such service need not be recognized to
the extent that such recognition would result in any duplication of benefits
for the same period of service.

  

 

55  

  

(c) To the extent applicable, Parent shall or shall cause the Surviving
Corporation and any of their respective Subsidiaries to waive, or use
commercially reasonable efforts to cause its insurance carriers to waive, any
pre-existing condition limitation on participation and coverage applicable to
any Covered Employee or any of his or her covered dependents under any health
or welfare plan of Parent or the Surviving Corporation or any of their
respective Subsidiaries (a " _New Plan_ ") in which such Covered Employee or
covered dependent shall become eligible to participate after the Effective
Time to the extent such Covered Employee or covered dependent was no longer
subject to such pre-existing condition limitation under the corresponding
Company Benefit Plan in which such Covered Employee or such covered dependent
was participating immediately before he or she became eligible to participate
in the New Plan. Parent shall or shall cause the Surviving Corporation or the
relevant Subsidiary of either to provide each Covered Employee with credit for
any co-payments and deductibles paid prior to the Effective Time and during
the calendar year in which the Effective Time occurs under any Company Benefit
Plan in satisfying any applicable co-payment and deductible requirements for
such calendar year under any New Plan in which such Covered Employee
participates after the Effective Time.

  


 

  

(d) If requested by Parent prior to the Closing Date, the Company shall
terminate, or cause to the have terminated, the Company's 401(k) and Profit
Sharing Plan as of the date immediately preceding the Closing Date. All
resolutions and other documents issued, adopted or executed in connection with
such termination shall be subject to Parent's reasonable prior review and
comment.

  


 

  

(e) No provision of this Agreement shall (i) confer any rights or remedies of
any kind or description upon any Covered Employee or any other Person other
than the Company and Parent and their respective successors and assigns, (ii)
be construed as an amendment, waiver or creation of or limitation on the
ability to terminate any Company Benefit Plan or Company Benefit Agreement or
benefit plan or agreement of Parent (including any New Plan) or (iii) limit
the ability of the Parent, the Company, the Surviving Corporation or any of
their respective Subsidiaries to terminate the employment of any Covered
Employee at any time.

  


 

  

(f) _Rule 14d-10 Matters_. Notwithstanding anything in this Agreement to the
contrary, the Company will not, on or after the date hereof and prior to the
Offer Closing, enter into, establish, amend or modify any plan, program,
agreement or arrangement pursuant to which compensation is paid or payable, or
pursuant to which benefits are provided, in each case to any former, current
or future director, officer, employee, consultant, advisor or independent
contractor of the Company or any Company Subsidiary (or any Person who would
have assumed such role or performed such duties but for a requirement to
refrain from assuming such role or performing such duties in such plan,
program, agreement or arrangement) unless, prior to such entry into,
establishment, amendment or modification, the compensation committee of the
Company Board (each member of which shall be an "independent director" in
accordance with the requirements of Rule 14d-10(d)(2) under the Exchange Act
at the time of any such action) shall have taken all such steps as may be
necessary to (i) approve as an employment compensation, severance or other
employee benefit arrangement each such plan, program, agreement or arrangement
and (ii) satisfy the requirements of the non-exclusive safe harbor under Rule
14d-10(d)(2) under the Exchange Act with respect to such plan, program,
agreement or arrangement. The Company shall, prior to the Offer Closing, take
such actions necessary and appropriate to ratify, confirm and approve, in
accordance with and for the purpose of Rule 14d-10 under the Exchange Act,
compensation paid or payable to Covered Employees under any Company Benefit
Plan or Company Benefit Agreement or otherwise in connection with the
Transactions.

  

 

56  

  

Section 6.10 _Rule 16b-3._ Prior to the Offer Closing, the Company shall use
commercially reasonable efforts to cause any dispositions of Company Common
Stock (including derivative securities with respect to Company Common Stock)
resulting from the Transactions by each individual who is subject to the
reporting requirements of Section 16(a) of the Exchange Act with respect to
the Company to be exempt under Rule 16b-3 promulgated under the Exchange Act.

  


 

  

Section 6.11 _Takeover Statutes._ The Company and the Company Board shall take
all actions necessary so that the restrictions of the Takeover Statutes shall
remain inapplicable to any and all of the Transactions. If any Takeover
Statute becomes applicable to any of the Transactions, the Company and the
Company Board shall grant such approvals and take such actions as are
necessary so that any such Transactions may be consummated as promptly as
practicable on the terms contemplated by this Agreement and otherwise act to
eliminate or minimize the effects of such Takeover Statute on such
Transactions.

  


 

  

Section 6.12 _Termination of Credit Agreements_.

  


 

  

(a) Prior to or at the Offer Closing Date, the Company shall have delivered
executed payoff letters (the " _Debt Payoff Letters_ " _and each, a_ " _Debt
Payoff Letter_ " _)_ in form and substance reasonably satisfactory to Parent
for _(i)_ the Amended and Restated Loan and Security Agreement (the " _Credit
Agreement_ "), dated as of December 16, 2014, by and among the Company and
certain of its subsidiaries, as borrowers, and Regions Bank, as lender, __ and
(ii) other outstanding Indebtedness of the Company or any Company Subsidiary,
if any. Each Debt Payoff Letter shall (A) confirm the aggregate principal
amount then outstanding, along with accrued and per diem accruable interest
thereon and all fees and other obligations of the Company accrued under the
Credit Agreement or such other Indebtedness, as applicable (the " _Payoff
Amount_ " _)_ , (B) contain payment instructions for the Payoff Amount, (C)
evidence the satisfaction, release and discharge of the debt and liabilities
under such Credit Agreement or such other Indebtedness and the agreement by
such lenders to release all Liens and terminate, as and if appropriate, all
related documents upon the payment of such amount in accordance with the
payment instructions, (D) provide authorizations to file any Uniform
Commercial Code termination statements, terminations and releases of
outstanding mortgages, and security interests as are reasonably necessary to
release such Liens, and (E) evidence that upon the receipt of payment of the
Payoff Amount, all tangible collateral (including, without limitation, all
equity certificates and related transfers or assignments in blank) securing
the obligations under the Credit Agreement held in Regions Bank's possession
shall be promptly delivered to the Company or its designee. Prior to or at the
Offer Closing Date, the Company shall have obtained documents, including
executed terminations and releases of outstanding mortgages and security
interests, including intellectual property security agreements as are
reasonably necessary to release such Liens.

  

 

57  

  

(b) The Company acknowledges that as of the Closing Date, the Company and the
Company Subsidiaries shall have no Indebtedness.

  


 

  

Section 6.13 _Deregistration; Stock Exchange Delisting._ After the Offer
Closing, the Company shall use its commercially reasonable efforts to take, or
cause to be taken, all actions, and do or cause to be done all things,
reasonably necessary, proper or advisable on its part under applicable Law and
the rules and policies of NASDAQ to enable the delisting by the Surviving
Corporation of the Company Common Stock from NASDAQ and the deregistration of
the Company Common Stock under the Exchange Act as promptly as practicable
after the Effective Time, and in any event no more than ten (10) days
thereafter.

  


 

  

Section 6.14 _Merger._ Following the consummation of the Offer, each of
Parent, Merger Sub and the Company shall take all necessary and appropriate
actions to cause the Merger to become effective as soon as practicable after
the Offer Closing, without a meeting of the stockholders of the Company, in
accordance with Section 251(h) of the DGCL and upon the terms and subject to
the conditions of this Agreement. In furtherance, and without limiting the
generality, of the foregoing, neither Parent nor Merger Sub shall, and shall
not permit and shall cause their respective Affiliates or Representatives not
to, take any action that could render Section 251(h) of the DGCL inapplicable
to the Merger.

  


 

  

Section 6.15 _Nonregistrable CVRs._ Parent and the Company shall cooperate,
including by making changes to the form of CVR Agreement attached hereto as
Exhibit B, as necessary to ensure that the CVRs are not subject to
registration under the Securities Act, the Exchange Act or any applicable
state securities or "blue sky" laws.

  


 

  

ARTICLE VII

  


 

  

 _CONDITIONS_

  


 

  

Section 7.1 _Conditions to the Obligation of Each Party._ The respective
obligations of the Company, Parent and Merger Sub to effect the Merger are
subject to the satisfaction or waiver (to the extent permitted by Law) of the
following conditions:

  


 

  

(a) No Law shall have been enacted or promulgated after the date hereof which
prohibits the consummation of the Merger and there shall be no Order issued by
a Governmental Entity of competent jurisdiction in effect prohibiting
consummation of the Merger;

  


 

  

(b) The approvals, consents, and consultations that are required or advisable,
as determined by Parent, by the applicable Competition Laws shall have been
obtained, or any applicable waiting period thereunder shall have expired or
shall have been terminated;

  

 

58  

  

(c) No action or proceeding by any Governmental Entity of competent
jurisdiction shall have been commenced and be continuing that seeks to make
illegal, enjoin or prevent in any respect the transactions contemplated by
this Agreement;

  


 

  

(d) Merger Sub shall have accepted for payment all shares of Company Common
Stock validly tendered and not withdrawn pursuant to the Offer; and

  


 

  

(e) The CVR Agreement shall have been executed by Parent and the Rights Agent
and be in full force and effect.

  


 

  

ARTICLE VIII

  


 

  

 _TERMINATION_

  


 

  

Section 8.1 _Termination._ This Agreement may be terminated and the
Transactions may be abandoned at any time prior to the Effective Time:

  


 

  

(a) by mutual written consent of Parent and the Company;

  


 

  

(b) by either the Parent or the Company (by written notice to the other
specifying the applicable provision or provisions hereof pursuant to which
such termination is effected):

  


 

  

(i) if the Offer Closing shall not have occurred by March 1, 2016 (the "
_Outside Date_ "); _provided_ , _however_ , that if all conditions set forth
on _Exhibit A_ hereto have theretofore been satisfied or waived or shall then
be capable of being satisfied, other than the condition set forth in paragraph
(ii) of _Exhibit A_ as a result of and to the extent that such failure is due
to the failure of the applicable waiting period (and any extension thereof)
applicable to the consummation of the Offer or the Merger under the HSR Act to
have expired or been terminated on or prior to the Expiration Time, such
Outside Date shall be automatically extended to June 1, 2016 and such date
shall be deemed the Outside Date; and _provided_ , _further_ , that the right
to terminate this Agreement pursuant to this _Section 8.1(b)(i)_ shall not be
available to any party whose failure to perform any of its obligations under
this Agreement has been the cause of, or resulted in, the failure of the Offer
Closing to have occurred on or by such date; or

  


 

  

(ii) if any Law or Order having any of the effects set forth in _Section
7.1(a)_ shall be in effect and shall have become final and nonappealable;
_provided_ , _however_ , that the right to terminate this Agreement pursuant
to this _Section 8.1(b)(i)_ shall not be available to any party if the Order
was primarily due to the failure of such party to perform any of its
obligations under this Agreement.

  


 

  

(c) by Parent (by written notice to the Company specifying the applicable
provision or provisions hereof pursuant to which such termination is
effected):

  


 

  

(i) at any time prior to the Offer Closing, upon a Company Adverse
Recommendation Change (whether or not in compliance with _Section 6.5_ );

  

 

59  

  

(ii) if, prior to the Offer Closing, the Company shall have breached or failed
to perform any of its representations, warranties, covenants or other
agreements contained in this Agreement, which breach or failure to perform (A)
has resulted in or would reasonably be expected to result in to the failure of
a condition set forth in clauses (v) or (vi) of _Exhibit A_ and (B) is not
curable or has not been cured before the earlier of the Outside Date or twenty
(20) Business Days following the date the Company receives written notice of
such breach or failure to perform;

  


 

  

(iii) if the Company Board fails to reaffirm publicly the Company
Recommendation within five (5) Business Days of Parent's written request for
such reaffirmation (or if the Outside Date is less than five (5) Business Days
from the receipt of such request from Parent, by the close of business on the
penultimate Business Day preceding the Outside Date);

  


 

  

(iv) if, prior to the Offer Closing, the Company shall have materially
breached any of the provisions of _Section 6.5_ ; or

  


 

  

(v) if, at the Expiration Time, Parent is not required to extend the Offer
pursuant to this Agreement and any of the conditions set forth in _Exhibit A_
shall not have been satisfied.

  


 

  

(d) by the Company (by written notice to Parent specifying the applicable
provision or provisions hereof pursuant to which such termination is
effected):

  


 

  

(i) if, prior to the Offer Closing, Parent or Merger Sub shall have breached
in any material respect any of its representations or warranties or failed to
perform in any material respect any of its covenants contained in this
Agreement, which breach or failure to perform (A) has prevented or materially
delayed, or would reasonably be expected to prevent or materially delay, the
consummation by Parent or Merger Sub of the Transactions and (B) is not
curable or has not been cured before the earlier of the Outside Date or twenty
(20) Business Days following the date Parent receives written notice of such
breach or failure to perform;

  


 

  

(ii) at any time prior to the Offer Closing, to accept and enter into a
binding agreement with respect to a Superior Proposal; _provided,_ that no
termination of this Agreement pursuant to this subsection (d)(ii) shall be
effective, unless the Company shall have complied in all material respects
with the provisions of _Section 6.5_ and the Company shall have paid the
Termination Fee and otherwise complied with its obligations under _Section
8.3(b)_ ); or

  


 

  

(iii) if Merger Sub fails to commence (within the meaning of Rule 14d-2
promulgated under the Exchange Act) the Offer within ten (10) Business Days
following the date hereof or if Merger Sub fails to consummate the Offer in
accordance with the terms of the Offer and this Agreement; provided, however,
that the reason for Merger Sub's failure to consummate the Offer is not
proximately caused by the Company's breach of this Agreement.

  


 

  

Section 8.2 _Effect of Termination._ In the event of the termination of this
Agreement by either Parent or the Company pursuant to Section 8.1, this
Agreement shall forthwith be terminated and have no further effect, the
obligations of the parties hereunder shall terminate, and there shall be no
liability on the part of any party hereto with respect thereto, except that
(i) the last sentence of Section 6.2, the second sentence of Section 6.8, this
Section 8.2, Section 8.3 and Article IX shall survive the termination of this
Agreement and (ii) nothing herein shall relieve any party from liability or
damages for fraud, any willful breach or any willful misrepresentation.

  

 

60  

  

Section 8.3 _Fees and Expenses_

  


 

  

(a) Except as provided in this _Section 8.3_ , all fees and expenses incurred
in connection with this Agreement and the Transactions shall be paid by the
party incurring such fees or expenses, whether or not any of the Transactions
are consummated.

  


 

  

(b) i) In the event that:

  


 

  

(A) (1) prior to the Offer Closing, a Company Takeover Proposal shall have
been made to the Company and such Company Takeover Proposal becomes publicly
known prior to the Offer Closing or shall have been made directly to the
stockholders of the Company generally prior to the Offer Closing or any Person
shall have publicly announced an intention (whether or not conditional) to
make a Company Takeover Proposal, (2) thereafter this Agreement is terminated
by Parent pursuant to _Section 8.1(c)(ii)_ or _Section 8.1(c)(v)_ and (3)
within twelve (12) months after such termination, the Company enters into a
definitive agreement to consummate a Company Takeover Proposal or consummates
a Company Takeover Proposal (regardless of whether such Company Takeover
Proposal is the same Company Takeover Proposal referred to in clause (1));
provided, that for purposes of this _Section 8.3(b)(i)_ (A), the term "Company
Takeover Proposal" shall have the meaning assigned to such term in _Section
6.5(g)_ , except that the references to "15%" shall be deemed to be references
to "50%"; or

  


 

  

(B) (1) prior to the Offer Closing, a Company Takeover Proposal shall have
been made to the Company or shall have been made directly to the stockholders
of the Company generally or shall have otherwise become publicly known or any
Person shall have publicly announced an intention (whether or not conditional)
to make a Company Takeover Proposal, (2) thereafter this Agreement is
terminated by Parent or the Company pursuant to _Section 8.1(b)(i)_ and (3)
within twelve (12) months after such termination, the Company enters into a
definitive agreement to consummate a Company Takeover Proposal or consummates
a Company Takeover Proposal (regardless of whether such Company Takeover
Proposal is the same Company Takeover Proposal referred to in clause (1));
provided, that for purposes of this _Section 8.3(b)(i)_ (A), the term "Company
Takeover Proposal" shall have the meaning assigned to such term in _Section
6.5(g)_ , except that the references to "15%" shall be deemed to be references
to "50%"; or

  


 

  

(C) this Agreement is terminated by Parent pursuant to _Section 8.1(c)(i)_ ,
_Section 8.1(c)(iii)_ or _Section 8.1(c)(iv_ ); or

  


 

  

(D) this Agreement is terminated by the Company pursuant to _Section
8.1(d)(ii)_ ;

  

 

61  

  

then the Company shall pay Parent a fee equal to $6,200,000 (six million two
hundred thousand dollars) (the " _Termination Fee_ ") by wire transfer of
same-day funds (x) on the date of termination of this Agreement in the case of
a termination described in clause (D), (y) within five (5) Business Days after
termination in the case of a termination described in clause (C), and (z) upon
the earlier of the entry into a definitive agreement with respect to a Company
Takeover Proposal or the consummation of a Company Takeover Proposal in the
case of a termination in connection with a termination described in clause (A)
or (B); _provided_ , that in no event shall the Company be required to pay the
Termination Fee on more than one occasion.

  


 

  

(ii) Notwithstanding anything to the contrary in this Agreement, absent fraud
or willful breach, the parties agree that the payment of the Termination Fee
shall be the sole and exclusive remedy available to Parent and Merger Sub
against the Company and its Affiliates with respect to this Agreement in the
event the Termination Fee becomes due and payable under the terms of this
Agreement, and, upon payment of the Termination Fee, neither the Company, nor
any Company Subsidiary, shall have any further liability to Parent and Merger
Sub relating to or arising out of this Agreement or the Transactions.

  


 

  

(iii) The Company acknowledges that the agreements contained in this _Section
8.3(b)_ are an integral part of the Transactions, and that, without these
agreements, Parent would not enter into this Agreement; accordingly, if the
Company fails promptly to pay the amount(s) due pursuant to this _Section
8.3(b)_ , and, to obtain such payment, Parent commences a suit which results
in a judgment against the Company for the amount(s) due pursuant to this
_Section 8.3(b)_ , the Company shall pay to Parent its out-of-pocket costs and
expenses (including attorneys' fees and expenses) in connection with such
suit, together with interest on such amount(s) at the prime rate of Citibank,
N.A. in effect on the date such payment was required to be made.

  


 

  

ARTICLE IX

  


 

  

 _GENERAL PROVISIONS_

  


 

  

Section 9.1 _Nonsurvival of Representations and Warranties._ None of the
representations and warranties in this Agreement or in any instrument
delivered pursuant to this Agreement shall survive the Effective Time. This
Section 9.1 shall not limit the survival of any covenant or agreement of the
parties in the Agreement which by its terms contemplates performance after the
Effective Time.

  


 

  

Section 9.2 _Notices._ All notices, requests, claims, demands and other
communications under this Agreement shall be in writing and shall be deemed
given if delivered personally, sent via electronic mail (receipt confirmed),
facsimile (with automated confirmation of receipt) or sent by a nationally
recognized overnight courier (providing proof of delivery) to the parties at
the following addresses (or at such other address for a party as shall be
specified by like notice):

  

 

62  

  

(a) if to the Company to:

  


 

  

Synergetics USA, Inc.

  

3845 Corporate Centre Drive

  

O'Fallon, MO 63368

  

Fax No: (636) 329-8125

  

Attention: Peter Rasche, General Counsel

  


 

  

E-mail address: prasche@synergeticsusa.com

  


 

  

with a copy to:

  


 

  

Armstrong Teasdale LLP

  

7700 Forsyth Blvd., Suite 1800

  

St. Louis, MO 63105

  

Fax No: (314) 612-2229

  

Attention: David W. Braswell, Esq.

  


 

  

E-mail address: dbraswell@armstrongteasdale.com

  


 

  

(b) if to Parent or Merger Sub, to it at:

  


 

  

Valeant Pharmaceuticals International

  

400 Somerset Corporate Boulevard

  

Bridgewater, NJ 08807

  

Fax No: (949) 315-3590

  

Attention: General Counsel

  


 

  

E-mail address: Robert.Chaionn@valeant.com

  


 

  

with a copy to:

  


 

  

Skadden, Arps, Slate, Meagher and Flom LLP

  

Four Times Square

  

New York, NY 10036

  

Fax No: (212) 735-2000

  

Attention: Stephen F. Arcano, Esq.

  

Marie L. Gibson, Esq.

  


 

  

E-mail address: Stephen.Arcano@skadden.com

  

Marie.Gibson@skadden.com

  


 

  

Section 9.3 _Interpretation._ When a reference is made in this Agreement to an
Article, Section or Exhibit, such reference shall be to an Article or Section
of, or an Exhibit to, this Agreement unless otherwise indicated. Whenever the
words "include," "includes" or "including" are used in this Agreement, they
shall be deemed to be followed by the words "without limitation." The words
"hereof," "herein" and "hereunder" and words of similar import when used in
this Agreement shall refer to this Agreement as a whole and not to any
particular provision of this Agreement. All terms defined in this Agreement
shall have the defined meanings when used in any certificate or other document
made or delivered pursuant hereto unless otherwise defined therein. The
definitions contained in this Agreement are applicable to the singular as well
as the plural forms of such terms and to the masculine as well as to the
feminine and neuter genders of such term. Any agreement, instrument or statute
defined or referred to herein or in any agreement or instrument that is
referred to herein means such agreement, instrument or statute as from time to
time amended, modified or supplemented, including (in the case of agreements
or instruments) by waiver or consent and (in the case of statutes) by
succession of comparable successor statutes and references to all attachments
thereto and instruments incorporated therein. References to a Person are also
to its permitted successors and assigns. References to clauses without a
cross-reference to a Section or subsection are references to clauses within
the same Section or, if more specific, subsection. References from or through
any date shall mean, unless otherwise specified, from and including or through
and including, respectively. The symbol "$" refers to United States Dollars.

  

 

63  

  

Section 9.4 _Entire Agreement; No Third-Party Beneficiaries._ This Agreement
together with the Tender Agreements, the CVR Agreement, the Confidentiality
Agreement, the exhibits hereto or thereto, the Company Disclosure Letter and
the other documents and certificates delivered pursuant hereto, (a) constitute
the entire agreement, and supersede all prior agreements and understandings,
both written and oral, among the parties with respect to the subject matter of
this Agreement and (b) except for the provisions of Section 6.7, is not
intended to confer, nor shall it confer, upon any Person other than the
parties hereto any rights or remedies or benefits of any nature whatsoever.

  


 

  

Section 9.5 _Assignment._ Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned, in whole or in part, by
operation of Law or otherwise, by any of the parties without the prior written
consent of the other parties, except that Merger Sub may assign, in its sole
discretion, any or all of its rights, interests and obligations under this
Agreement to any wholly owned Subsidiary of Valeant Pharmaceuticals
International, Inc., provided, that no such assignment shall relieve Merger
Sub of any of its obligations hereunder; provided, further, that no such
assignment shall be permitted if it would materially impede or delay the
consummation of the Offer, the Merger or the other transactions contemplated
hereby. Any assignment in violation of the preceding sentence shall be void.
Subject to the preceding two sentences, this Agreement will be binding upon,
inure to the benefit of, and be enforceable by, the parties and their
respective successors and assigns.

  


 

  

Section 9.6 _Amendments._ Subject to compliance with applicable Law, this
Agreement may be amended by the parties, by action taken or authorized by
their respective boards of directors, at any time; provided, that after the
Offer Closing there shall be no amendment that decreases the Merger
Consideration or that would cause the Merger not to be consummated as soon as
practicable following the Offer Closing. No amendment shall be made to this
Agreement after the Effective Time. This Agreement may not be amended except
by an instrument in writing signed on behalf of each of the parties.

  


 

  

Section 9.7 _Waiver; Remedies Cumulative._ At any time prior to the Effective
Time, any party hereto may (a) extend the time for the performance of any of
the covenants, obligations or other acts of any other party hereto or (b)
waive any inaccuracy of any representations or warranties or compliance with
any of the agreements, covenants or conditions of any other party or with any
conditions to its own obligations. Any agreement on the part of a party hereto
to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such party by its duly authorized
officer. The failure of any party to this Agreement to assert any of its
rights under this Agreement or otherwise shall not constitute a waiver of such
rights. The waiver of any such right with respect to particular facts and
other circumstances shall not be deemed a waiver with respect to any other
facts and circumstances and each such right shall be deemed an ongoing right
that may be asserted at any time and from time to time. All rights and
remedies existing under this Agreement are cumulative to, and not exclusive
of, any rights or remedies otherwise available.

  

 

64  

  

Section 9.8 _Governing Law._ THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS,
INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF
DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND TO BE PERFORMED WHOLLY WITHIN
SUCH STATE WITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE
THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.

  


 

  

Section 9.9 _Consent to Jurisdiction; Service of Process; Venue._ Each of the
parties hereto (a) consents to submit itself to the personal jurisdiction of
any federal court located in the State of Delaware or any Delaware state court
for the purpose of any action or proceeding arising out of this Agreement or
any of the Transactions, (b) agrees that it will not attempt to deny or defeat
such personal jurisdiction by motion or other request for leave from any such
court, (c) consents to the service of process by first class certified mail,
return receipt requested, postage prepaid, to the address at which such party
is to receive notice in accordance with Section 9.2 and (d) agrees that it
will not bring any action relating to this Agreement or any of the
Transactions in any court other than a federal court located in the State of
Delaware or a Delaware state court, and irrevocably and unconditionally waives
(and agrees not to plead or claim) any objection to the laying of venue of any
action, suit or proceeding arising out of this Agreement or the Transactions
in a federal court located in the State of Delaware or a Delaware state court
or that any such action, suit or proceeding brought in any such court has been
brought in an inconvenient forum.

  


 

  

Section 9.10 _Waiver of Jury Trial._ EACH OF PARENT, MERGER SUB AND THE
COMPANY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE)
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY OR THE ACTIONS OF PARENT, MERGER SUB OR THE COMPANY IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT.

  


 

  

Section 9.11 _Specific Performance._ The parties agree that irreparable damage
would occur and that the parties would not have any adequate remedy at law in
the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached. It is
accordingly agreed that the parties shall be entitled to an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically
the terms and provisions of this Agreement in any federal court located in the
State of Delaware or in Delaware state court, this being in addition to any
other remedy to which they are entitled at law or in equity.

  

 

65  

  

Section 9.12 _Further Assurances._ Subject to the provisions of this
Agreement, the parties hereto will, from time to time, do all acts and things
and execute and deliver all such further documents and instruments, as the
other parties hereto may, either before or after the Closing Date, reasonably
require to effectively carry out or better evidence or perfect the full intent
and meaning of this Agreement.

  


 

  

Section 9.13 _Severability._ If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule of Law or
public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect, insofar as the foregoing can be
accomplished without materially affecting the economic benefits anticipated by
the parties to this Agreement. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible to the fullest
extent permitted by applicable Law in an acceptable manner to the end that the
Transactions are fulfilled to the extent possible.

  


 

  

Section 9.14 _Headings._ The headings and table of contents contained in this
Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement.

  


 

  

Section 9.15 _Counterparts._ This Agreement may be executed in two or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other parties.

  


 

  

Section 9.16 _Certain Definitions._

  


 

  

(a) " _Associate_ " and " _Affiliate_ " shall have the same meaning as set
forth in Rule 12b-2 promulgated under the Exchange Act.

  


 

  

(b) " _Business Day_ " means a day other than Saturday, Sunday or any other
day on which commercial banks located in the State of Missouri or New York are
authorized or required by Law to remain closed.

  


 

  

(c) " _Commonly Controlled Entity_ " means any Person that, together with the
Company, is treated as a single employer under Section 414(b), (c), (m) or (o)
of the Code or any other applicable Law.

  


 

  

(d) " _Company Benefit Agreements_ " mean, collectively, (i) each employment,
deferred compensation, change in control, severance, termination, employee
benefit, loan or indemnification agreement between the Company or any Company
Subsidiary, on the one hand, and any Company Participant, on the other hand,
and (ii) each Contract between the Company or any Company Subsidiary, on the
one hand, and any Company Participant, on the other hand, including any
agreement or Contract which is entered into on or after the date hereof.

  

 

66  

  

(e) " _Company Benefit Plans_ " mean, collectively (i) each "employee benefit
plan" (as such term is defined in Section 3(3) of ERISA) and (ii) each
vacation or paid time off, severance, termination, retention, change in
control, employment, consulting, independent contractor, incentive
compensation, performance, profit sharing, stock-based, stock-related, stock
option, fringe benefit, perquisite, stock purchase, stock ownership, phantom
stock and deferred compensation plan, arrangement, agreement and understanding
and other compensation, benefit and fringe benefit plans, arrangements,
agreements and understandings, sponsored, maintained, contributed to or
required to be sponsored, maintained or contributed to, by the Company, any
Company Subsidiary or any Commonly Controlled Entity, in each case, providing
benefits to any Company Participant, but not including the Company Benefit
Agreements (all such plans, arrangements, agreements and understandings,
including any such plan, arrangement, agreement or understanding entered into
or adopted on or after the date hereof).

  


 

  

(f) " _Company Material Adverse Effect_ " means any change, effect, event,
occurrence, state of facts, circumstance or development that, individually or
in the aggregate with all other changes, effects, events, occurrences, state
of facts, circumstances or developments, (i) results in any change or effect
that is or would reasonably be expected to be materially adverse to the
business, properties, assets, liabilities (contingent or otherwise), financial
condition or results of operations of the Company and the Company
Subsidiaries, taken as a whole or (ii) prevents or materially impedes, hinders
or delays the consummation by the Company of the Transactions; _provided_ ,
_however_ , that none of the following shall constitute or be taken into
account in determining the existence of a Company Material Adverse Effect: (A)
any change relating to the United States or global economy or securities
markets in the United States in general, (B) any change to conditions
affecting the medical device industry in which the Company participates in
general, (C) any failure, in and of itself, by the Company to meet any
internal or published projections, forecasts or revenue or earnings
predictions for any period ending on or after the date hereof ( _provided_ ,
that the underlying causes of such failure may be considered in determining
whether a Company Material Adverse Effect has occurred), (D) the effect of any
change after the date hereof in any applicable Law or GAAP or the
interpretation or enforcement thereof, (E) any natural disasters or changes in
global or national economic or political conditions or acts of war (whether or
not declared), armed hostilities, sabotage, military actions or the escalation
thereof (whether underway on the date hereof or hereafter commenced), and
terrorism, (F) a change in the market price or trading volume of the Company
Common Stock ( _provided_ , that the underlying causes of such decline or
change may be considered in determining whether a Company Material Adverse
Effect has occurred), (G) the execution or announcement of this Agreement or
the pendency or consummation of the Transactions or (H) any effects directly
resulting from or arising out of (1) the failure by the Company or any of the
Company Subsidiaries to take any action specifically prohibited by this
Agreement or (2) any actions taken by the Company or any of the Company
Subsidiaries as specifically required by this Agreement or with the explicit
consent of Parent or Merger Sub; except, in the cases of clauses (A), (B), (D)
and (E), if such change, effect, event, occurrence, state of facts,
circumstance or development disproportionately affects the Company as compared
to other participants in the industry or industries in which the Company and
the Company Subsidiaries participate.

  

 

67  

  

(g) " _Company Stock Plans_ " collectively, (i) the Second Amended and
Restated Synergetics 2001 Stock and Performance Incentive Plan and (ii) the
Amended and Restated Synergetics 2005 Non-Employee Directors' Stock Option
Plan, as amended.

  


 

  

(h) " _Contract_ " means any written or oral agreement, contract, subcontract,
settlement agreement, lease, sublease, binding understanding, instrument,
note, option, bond, mortgage, indenture, trust document, loan or credit
agreement, license, sublicense, insurance policy, benefit plan or legally
binding commitment or undertaking of any nature, as in effect as of the date
hereof or as may hereinafter be in effect.

  


 

  

(i) " _Environmental Claim_ " means any claim, action, cause of action, suit,
proceeding, investigation, order, demand or notice by any Person alleging
actual or potential liability (including actual or potential liability for
investigatory costs, cleanup, cleanup costs, governmental response costs,
natural resources damages, property damages, personal injuries, attorneys'
fees or penalties) arising out of, based on, resulting from or relating to (i)
the presence, Release of, or exposure to any Hazardous Substances or (ii)
circumstances forming the basis of any violation, or alleged violation, of, or
liability with respect to, any Environmental Law.

  


 

  

(j) " _Environmental Law_ " means all federal, state, local, foreign and
common laws, statutes, codes, regulations, ordinances, and other enforceable
requirements of Governmental Entities relating to (i) pollution or protection
of human health and safety (including workplace health and safety), (ii) the
protection, restoration or cleanup of or prevention of harm to the environment
(including ambient air, surface water, groundwater, land surface or subsurface
strata, and natural resources), (iii) the exposure to, or Releases or
threatened Releases of, Hazardous Substances, (iv) the manufacture,
processing, distribution, use, treatment, generation, storage, containment,
disposal, transport or handling of Hazardous Substances, or (v) recordkeeping,
notification, disclosure and reporting requirements regarding Hazardous
Substances.

  


 

  

(k) " _Environmental Permits_ " means permits, licenses, approvals,
exemptions, registrations, certificates, identification numbers or other
authorizations issued pursuant to Environmental Law.

  


 

  

(l) " _ERISA_ " means the Employee Retirement Income Security Act of 1974, as
amended.

  


 

  

(m) " _Hazardous Substances_ " means any material, substance, chemical, or
waste (or combination thereof) that (i) is listed, defined, designated,
regulated or classified as hazardous, toxic, radioactive, dangerous, a
pollutant, a contaminant, petroleum, oil, or words of similar meaning or
effect under any Environmental Law, or (ii) can form the basis of any
liability under any Environmental Law.

  


 

  

(n) " _Indebtedness_ " means, with respect to any Person, without duplication,
as of the date of determination, (A) all obligations of such Person for
borrowed money, including accrued and unpaid interest, and any prepayment fees
or penalties, (B) all obligations of such Person evidenced by bonds,
debentures, notes or similar instruments, (C) all obligations of such Person
issued or assumed as the deferred purchase price of property (including any
potential future earn-out, purchase price adjustment, release of "holdback" or
similar payment, but excluding obligations of such Person for inventory and
other obligations incurred in the ordinary course of business consistent with
past practice), (D) all Indebtedness of others secured by a Lien on property
or assets owned or acquired by such Person, whether or not the Indebtedness
secured thereby has been assumed, (E) all obligations of such Person under
interest rate, currency or commodity derivatives or hedging transactions or
similar arrangement (valued at the termination value thereof), (F) all letters
of credit or performance bonds issued for the account of such Person, and (G)
all guarantees and keepwell arrangements of such Person of any Indebtedness of
any other Person other than a wholly owned Subsidiary of such Person.

  

 

68  

  

(o) " _Intellectual Property_ " means all intellectual property rights and
industrial property rights and rights in confidential information of any type
or nature throughout the world, including all United States and foreign (i)
trademarks, service marks, names, corporate names, trade names, brand names,
certification marks, designs, logos, slogans, commercial symbols, business
name registrations, Internet domain names, trade dress and other similar
indications of source or origin and general intangibles of like nature,
together with the goodwill associated with the foregoing and registrations and
applications relating to the foregoing in any jurisdiction, including any
extension, modification or renewal of any such registration or application ("
_Trademarks_ "), (ii) industrial designs, invention disclosures, patents and
patent applications (including divisions, continuations, continuations-in-
part, reexaminations, and renewals), and any renewals, extensions,
supplementary protection certificates or reissues thereof, in any jurisdiction
(" _Patents_ "), (iii) copyrights, writings and other works and other
copyrightable subject matter, (including rights in computer programs (whether
in source code, object code or other forms), algorithms, databases,
compilations and data, technology supporting the foregoing, and all
documentations including user manuals and training materials, related to any
of the foregoing (" _Software_ ")), in any jurisdiction, whether registered or
not, and all applications and registrations for the foregoing, and any
renewals or extensions thereof (" _Copyrights_ "), (iv) trade secrets, non-
public information, and all other confidential or proprietary information and
materials, including, discoveries, research and development, ideas, know-how,
inventions, proprietary processes, designs, procedures, laboratory notes,
technical information, formulae, biological materials, models and
methodologies, in each case whether patentable or not, and rights in any
jurisdiction to limit the use or disclosure thereof by any Person (" _Trade
Secrets_ ") and (v) any other intellectual property or proprietary rights and
all rights and remedies against past infringement, misappropriation, or other
violation of any of the foregoing.

  


 

  

(p) " _Liability_ " means any and all debts, liabilities and obligations,
whether accrued or fixed, absolute or contingent, known or unknown or matured
or unmatured, including those arising under any Law and those arising under
any Contract.

  


 

  

(q) " _Permitted Liens_ " shall mean (i) mechanics', carriers',
warehousemens', workmens' and other similar Liens arising in the ordinary
course of business which are not yet due and payable or are being contested in
good faith by appropriate proceedings, (ii) Liens for Taxes, assessments and
other governmental charges not yet due and payable or that may subsequently be
paid without penalty or that are being contested in good faith by appropriate
proceedings, (iii) with respect to the Owned Real Property, (A) easements,
covenants, rights-of-way, claims, restrictions and other encumbrances of
record, (B) any state of facts a current survey of the Owned Real Property
would show and (C) zoning, building and other similar restrictions imposed by
Law, (iv) with respect to the Company Leases, any Lien affecting solely the
interest of the landlord thereunder and not the interest of the tenant
thereunder, which does not materially impair the value or use of such Company
Lease, (v) Liens in favor of customs and revenue authorities arising as a
matter of applicable Law to secure payments of customs duties in connection
with the importation of goods, (vi) Liens arising in connection with worker's
compensation, unemployment insurance, old age pensions and social security
benefits which are not overdue or are being contested in good faith by
appropriate proceedings and (vii) Liens arising by operation of law on
insurance policies and proceeds thereof to secure premiums thereunder.

  

 

69  

  

(r) " _Person_ " means any individual, corporation, partnership (general or
limited), limited liability company, limited liability partnership, trust,
joint venture, joint-stock company, syndicate, association, entity,
unincorporated organization or government or any political subdivision, agency
or instrumentality thereof.

  


 

  

(s) " _Regulatory Authorizations_ " means all approvals, clearances,
authorizations, registrations, certifications, licenses and permits granted by
any Regulatory Authority.

  


 

  

(t) " _Release_ " means any release, spill, emission, discharge, leaking,
pumping, injection, deposit, disposal, dispersal, leaching or migration into
the indoor or outdoor environment (including ambient air, surface water,
groundwater and surface or subsurface strata) or into or out of any property,
including the movement of Hazardous Substances through or in the air, soil,
surface water, groundwater or property.

  


 

  

(u) " _Representatives_ " mean, with respect to any Person, the officers,
directors, employees, auditors, attorneys, financial advisors, lenders and
other agents of such Person.

  


 

  

(v) " _Required Regulatory Authorizations_ " means those Regulatory
Authorizations set forth in _Section 9.16(v)_ of the Company Disclosure
Letter.

  


 

  

(w) " _Subsidiary_ " of any Person means another Person, (i) an amount of the
voting securities, other voting rights or voting partnership interests of
which that is sufficient to elect at least a majority of its board of
directors or other governing body is directly or indirectly owned or
controlled by such first Person or by any one or more of its Subsidiaries, or
by such first Person and one or more of its Subsidiaries (or, if there are no
such voting interests, 50% or more of the equity interests of which is owned
directly or indirectly by such first Person), (ii) of which such first Person
or any other Subsidiary of such first Person is a general partner (excluding
partnerships, the general partnership interests of which held by such first
Person and any Subsidiary of such first Person do not have a majority of the
voting interests in such partnership) or (iii) based on the extent of control
by the first Person, is required to be consolidated in the consolidated
financial statements of the first Person in accordance with GAAP.

  

 

70  

  

(x) " _Taxes_ " means any and all federal, state, local, foreign or other
taxes of any kind (together with any and all interest, penalties, additions to
tax and additional amounts imposed with respect thereto) imposed by any
Governmental Entity, including, without limitation, taxes or other similar
charges on or with respect to income, franchises, windfall or other profits,
gross receipts, property, capital, sales, use, transfer, inventory, license,
capital stock, payroll, employment, unemployment, social security, workers'
compensation, severance, stamp, occupation, premium or net worth, and taxes or
other similar charges in the nature of excise, withholding, ad valorem, value
added, estimated taxes, or custom duties.

  


 

  

(y) " _Tax Return_ " means any report, return, document, declaration,
amendment or other information or filing required to be filed with respect to
taxes (whether or not a payment is required to be made with respect to such
filing), including information returns, any documents with respect to or
accompanying payments of estimated taxes, or with respect to or accompanying
requests for the extension of time in which to file any such report, return,
document, declaration or other information.

  


 

  

(z) " _to the knowledge of the Company_ ," " _known to Company_ ," and similar
formulations shall mean the actual current knowledge, after reasonable
investigation, of the people set forth in _Section 9.16(z)_ of the Company
Disclosure Letter.

  


 

  

(aa) " _United States_ " means the United States of America.

  


 

  

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

  

 

71  

  

IN WITNESS WHEREOF, Parent, Merger Sub and the Company have each caused this
Agreement to be executed as of the date first written above by their
respective officers thereunto duly authorized.

  


 

      |  |  

VALEANT PHARMACEUTICALS INTERNATIONAL

   
---|---|--- 
     |  |   
     |  

By:

  |  

/s/ Robert L. Rosiello

   
     |  |  

Name: Robert L. Rosiello

   
     |  |  

Title: Executive Vice President and Chief Financial Officer

   
     |  |   
     |  |  

BLUE SUBSIDIARY CORP.

   
     |  |   
     |  

By:

  |  

/s/ Ari S. Kellen

   
     |  |  

Name: Ari S. Kellen

   
     |  |  

Title: Executive Vice President

   
     |  |   
     |  |  

SYNERGETICS USA, INC.

   
     |  |   
     |  

By:

  |  

/s/ David M. Hable

   
     |  |  

Name: David M. Hable

   
     |  |  

Title: President and Chief Executive Officer

   
   


 

  

   

  

 _EXHIBIT A_

  


 

  

CONDITIONS OF THE OFFER

  


 

  

Notwithstanding any other provisions of the Offer or the Agreement, Merger Sub
shall not be required to, and Parent shall not be required to cause Merger Sub
to, accept for payment or, subject to any applicable rules and regulations of
the SEC, including Rule 14e-1(c) under the Exchange Act, pay for any tendered
shares of Company Common Stock unless:

  


 

  

    | (i) | prior to the Expiration Time there shall have been validly
tendered (not including shares tendered pursuant to procedures for guaranteed
delivery and not actually delivered prior to the Expiration Time) and not
validly withdrawn that number of shares of Company Common Stock which, when
added to the shares of Company Common Stock, if any, already owned by Parent,
Merger Sub or any of their respective Subsidiaries, represents at least a
majority of the total number of outstanding shares of Company Common Stock on
a fully diluted basis (which assumes conversion or exercise of all derivative
securities regardless of the conversion or exercise price, the vesting
schedule or other terms and conditions thereof) (the " _Minimum Tender
Condition_ ");  
---|---|--- 
  

  


 

  

    | (ii) | the applicable waiting period (and any extension thereof)
applicable to the consummation of the Offer or the Merger under any
Competition Law shall have expired or been terminated on or prior to the
Expiration Time and all other Required Regulatory Authorizations shall have
been obtained on or prior to the Expiration Time;  
---|---|--- 
  

  


 

  

    | (iii) | there shall not be existing any temporary restraining
order, preliminary injunction, pending or threatened, nor any Litigation by
any Governmental Entity pending or threatened, which challenges or seeks to
enjoin or materially delay the Offer Closing or the consummation of the other
Transactions, or which seeks to prohibit or impose any material limitations on
Parent's ownership of the Company and the Company Subsidiaries (taken as a
whole), or the operation of all or a material portion of Parent's, on the one
hand, or the Company's and the Company Subsidiaries' (taken as a whole), on
the other hand, businesses or assets (whether held directly or through
Subsidiaries or Company Subsidiaries), or to compel Parent or any of its
Subsidiaries or the Company or any Company Subsidiary to dispose of, or hold
separate, any material portion of its respective business or assets;  
---|---|--- 
  

  


 

  

    | (iv) | no applicable Law and no permanent injunction or other
judgment, order or decree entered, promulgated, enforced or issued by any
court or other Governmental Entity of competent jurisdiction in the United
States or any foreign jurisdiction shall be and remain in effect which has the
effect of (a) making illegal or otherwise prohibiting or materially delaying
the Offer Closing or the consummation of the other Transactions (including the
Tender Agreements), (b) imposing any material limitations on Parent's
ownership of the Company and the Company Subsidiaries (taken as a whole), or
operation of all or a material portion of Parent's, on the one hand, or the
Company's and the Company Subsidiaries' (taken as a whole), on the other hand,
businesses or assets (whether held directly or through Subsidiaries or Company
Subsidiaries), or (c) compelling Parent or any of its Subsidiaries or the
Company or any Company Subsidiary to dispose of, or hold separate, any
material portion of its respective business or assets;  
---|---|--- 
  

  

 

A - 1  

  

    | (v) | (A) the representations and warranties of the Company set
forth in _Section 4.1(a)_ , _Section 4.2_ , _Section 4.3_ , _Section 4.21_ and
_Section 4.26_ of the Agreement shall be true and correct in all respects both
as of the date of the Agreement and as of the Offer Closing Date as though
made on and as of the Offer Closing Date (except to the extent such
representations and warranties relate to an earlier date, in which case such
representations and warranties shall be true and correct in all respects on
and as of such earlier date), (B) the representations and warranties of the
Company set forth in the first sentence of _Section 4.10_ shall be true and
correct in all respects, both as of the date of the Agreement and at all times
prior to the Offer Closing Date as though made at and as of such time (except
to the extent such representations and warranties relate to an earlier date,
in which case such representations and warranties shall be true and correct in
all respects on and as of such earlier date) and (C) the representations and
warranties of the Company contained in the Agreement and in the certificate
delivered by the Company pursuant to subparagraph (viii) below (other than
those referred to in clauses (A) and (B)) (disregarding for purposes of this
subparagraph (v), any materiality or Company Material Adverse Effect
qualifications contained in such representations and warranties) shall be true
and correct in all respects both as of the date of the Agreement and as of the
Offer Closing Date as though made on and as of the Offer Closing Date (except
to the extent such representations and warranties expressly relate to an
earlier date, in which case such representations and warranties shall be true
and correct in all respects on and as of such earlier date), except where the
failure of any such representations or warranties to be so true and correct
has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect;  
---|---|--- 
  

  


 

  

    | (vi) | the Company shall have performed in all material respects
all obligations, agreements and covenants required to be performed by it under
the Agreement (or any failure to perform as such shall have been cured) at or
prior to the Offer Closing Date;  
---|---|--- 
  

  


 

  

    | (vii) | since the date of the Agreement there shall not have been
any occurrence, event, change, effect or development that has had or would
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect;  
---|---|--- 
  

  


 

  

    | (viii) | the Company shall have delivered to Parent a certificate,
signed by the chief executive officer and chief financial officer of the
Company, to the effect that each of the conditions specified in subparagraphs
(v), (vi) and (vii) above is satisfied;  
---|---|--- 
  

  

 

A \- 2  

  

    | (ix) | the Tender Agreements shall be valid, binding and
enforceable on the parties thereto;  
---|---|--- 
  

  


 

  

    | (x) | the Company shall not have entered into a definitive
agreement or agreement in principle with any Person with respect to a Company
Takeover Proposal;  
---|---|--- 
  

  


 

  

    | (xi) | the Company Board shall not have made a Company Adverse
Recommendation Change; and  
---|---|--- 
  

  


 

  

    | (xii) | the Agreement shall not have been terminated in accordance
with its terms and the Offer shall not have been terminated in accordance with
the terms of the Agreement.  
---|---|--- 
  

  


 

  

The foregoing conditions shall be in addition to, and not a limitation of, the
rights of Parent and Merger Sub to extend, terminate and/or modify the Offer
pursuant to the terms of the Agreement.

  


 

  

The foregoing conditions are for the sole benefit of Parent and Merger Sub,
may be asserted by Parent or Merger Sub regardless of the circumstances
(including any action or inaction by Parent or Merger Sub, _provided_ , that
nothing herein shall relieve any party hereto from any obligation or liability
such party has under the Agreement) giving rise to any such conditions and may
be waived by Parent or Merger Sub in whole or in part at any time and from
time to time in their sole discretion (except for the Minimum Tender
Condition), in each case, subject to the terms of the Agreement and the
applicable rules and regulations of the SEC. The failure by Parent or Merger
Sub at any time to exercise any of the foregoing rights shall not be deemed a
waiver of any such right and each such right shall be deemed an ongoing right
which may be asserted at any time and from time to time. Capitalized terms
used but not defined in this _Exhibit A_ shall have the meaning ascribed to
them elsewhere in the Agreement to which this _Exhibit A_ is attached. 
 

 

  

 

A - 3  

  

 

 _EXHIBIT B_

  


 

  

FORM OF CONTINGENT VALUE RIGHTS AGREEMENT

  

    

  

Table of Contents

  


 

     

ARTICLE I DEFINITIONS

  |  

1

   
---|--- 
     |  |   
    

SECTION 1.1

  |  

Definitions

  |  

1

   
     |  |   
    

ARTICLE II CONTINGENT VALUE RIGHTS

  |  

5

   
     |  |   
    

SECTION 2.1

  |  

Holders of CVRs; Appointment of Rights Agent

  |  

5

   
     |  |   
    

SECTION 2.2

  |  

Nontransferable

  |  

5

   
     |  |   
    

SECTION 2.3

  |  

No Certificate; Registration; Registration of Transfer; Change of Address

  |  

5

   
     |  |   
    

SECTION 2.4

  |  

Payment Procedures

  |  

6

   
     |  |   
    

SECTION 2.5

  |  

No Voting, Dividends or Interest; No Equity or Ownership Interest

  |  

9

   
     |  |   
    

SECTION 2.6

  |  

Ability to Abandon CVRs

  |  

9

   
     |  |   
    

ARTICLE III THE RIGHTS AGENT

  |  

10

   
     |  |   
    

SECTION 3.1

  |  

Certain Duties and Responsibilities of the Rights Agent

  |  

10

   
     |  |   
    

SECTION 3.2

  |  

Certain Rights of the Rights Agent

  |  

10

   
     |  |   
    

SECTION 3.3

  |  

Resignation and Removal; Appointment of Successor

  |  

11

   
     |  |   
    

SECTION 3.4

  |  

Acceptance of Appointment by Successor

  |  

11

   
     |  |   
    

ARTICLE IV COVENANTS

  |  

12

   
     |  |   
    

SECTION 4.1

  |  

List of Holders

  |  

12

   
     |  |   
    

SECTION 4.2

  |  

Efforts

  |  

12

   
     |  |   
    

ARTICLE V AMENDMENTS

  |  

13

   
     |  |   
    

SECTION 5.1

  |  

Amendments Without Consent of Holders or Rights Agent

  |  

13

   
     |  |   
    

SECTION 5.2

  |  

Amendments with Consent of Holders

  |  

13

   
     |  |   
    

SECTION 5.3

  |  

Amendments Affecting Rights Agent

  |  

14

   
     |  |   
    

SECTION 5.4

  |  

Effect of Amendments

  |  

14

   
     |  |   
    

ARTICLE VI MISCELLANEOUS

  |  

14

   
     |  |   
    

SECTION 6.1

  |  

Notices to Rights Agent and Parent

  |  

14

   
   

  

 

i  

  


 

     

SECTION 6.2

  |  

Notice to Holders

  |  

15

   
---|---|--- 
     |  |   
    

SECTION 6.3

  |  

Entire Agreement

  |  

15

   
     |  |   
    

SECTION 6.4

  |  

Successors and Assigns

  |  

15

   
     |  |   
    

SECTION 6.5

  |  

Benefits of Agreement

  |  

16

   
     |  |   
    

SECTION 6.6

  |  

Governing Law

  |  

16

   
     |  |   
    

SECTION 6.7

  |  

Consent to Jurisdiction; Service of Process; Venue

  |  

16

   
     |  |   
    

SECTION 6.8

  |  

WAIVER OF JURY TRIAL

  |  

16

   
     |  |   
    

SECTION 6.9

  |  

Further Assurances

  |  

16

   
     |  |   
    

SECTION 6.10

  |  

Severability

  |  

17

   
     |  |   
    

SECTION 6.11

  |  

Headings

  |  

17

   
     |  |   
    

SECTION 6.12

  |  

Counterparts

  |  

17

   
     |  |   
    

SECTION 6.13

  |  

Termination

  |  

17

   
     |  |   
    

SECTION 6.14

  |  

Legal Holidays

  |  

17

   
     |  |   
    

SECTION 6.15

  |  

Interpretation

  |  

17

   
   

  

 

ii  

  

THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [], 2015 (this
"Agreement"), is entered into by and between Valeant Pharmaceuticals
International, a Delaware corporation ("Parent"), and [], a [] (the "Rights
Agent").

  


 

  

W I T N E S S E T H:

  


 

  

WHEREAS, Synergetics USA, Inc., a Delaware corporation (the "Company"), Parent
and Blue Subsidiary Corp., a Delaware corporation ("Merger Sub"), have entered
into an Agreement and Plan of Merger, dated as of September 1, 2015 (as it may
be amended from time to time, the "Merger Agreement"), pursuant to which
Merger Sub (a) has made a tender offer (the "Offer") to acquire all of the
outstanding shares of common stock, par value $0.001 per share, of the Company
(the "Shares") and (b) will, following consummation of the Offer, merge with
and into the Company (the "Merger"), with the Company surviving the Merger as
a wholly owned subsidiary of Parent;

  


 

  

WHEREAS, pursuant to the Merger Agreement, and in accordance with the terms
and conditions thereof, in each of the Offer and the Merger, Parent has agreed
to provide Holders (as defined below) the right to receive up to two
contingent cash payments upon the achievement of certain milestones as
hereinafter described in accordance with the terms hereof and of the Merger
Agreement; and

  


 

  

WHEREAS, pursuant to this Agreement, the maximum potential amount payable per
CVR (as defined below) is $1.00 in cash, without interest and subject to
reduction for any applicable withholding taxes in respect thereof.

  


 

  

NOW, THEREFORE, in consideration of the premises and the consummation of the
transactions referred to above, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, it is mutually
covenanted and agreed, for the proportionate benefit of all Holders (as
defined below), as follows:

  


 

  

ARTICLE I

  


 

  

 _DEFINITIONS_

  


 

  

SECTION 1.1 _Definitions_.

  


 

  

Capitalized terms used but not otherwise defined herein shall have the
meanings ascribed thereto in the Merger Agreement. The following terms shall
have the meanings ascribed to them as follows:

  


 

  

"Acting Holder(s)" means any Holder or Holders of at least thirty-five percent
(35%) of the outstanding CVRs as set forth on the CVR Register.

  


 

  

"Business Day" means a day other than Saturday, Sunday or any other day on
which commercial banks located in the State of Delaware or New York, New York
are authorized or required by Law to remain closed.

  

    

  

"CVRs" means the rights of Holders to receive contingent cash payments
pursuant to the Merger Agreement and this Agreement.

  


 

  

"Full Milestone 2 Payment" means an amount equal to $0.50 per CVR, payable in
cash, without interest thereon and subject to reduction for any applicable
withholding taxes in respect thereof.

  


 

  

"Holder" means, at the relevant time, a Person in whose name a CVR is
registered in the CVR Register.

  


 

  

"Independent Accountant" means a nationally recognized independent accounting
firm mutually satisfactory to Parent and the Holder Representative.

  


 

  

"Milestone Achievement Period" means the period commencing on the first day of
the first calendar quarter following the Effective Time through and ending on
June 30, 2018; _provided_ that if the Effective Time occurs on the first day
of a calendar quarter, the period shall commence on the Effective Date.

  


 

  

"Milestone 1 Payment" shall mean an amount equal to $0.50 per CVR, payable in
cash, without interest thereon and subject to reduction for any applicable
withholding taxes in respect thereof.

  


 

  

"Milestone 1 Target" means the first achievement of Net Sales of Fifty Five
Million Dollars ($55,000,000) during any four (4) consecutive calendar
quarters during the Milestone Achievement Period.

  


 

  

"Milestone 2 Target" means the first achievement of Net Sales of Sixty Five
Million Dollars ($65,000,000) during any four (4) consecutive calendar
quarters during the Milestone Achievement Period.

  


 

  

"Milestone Payments" means the Milestone 1 Payment and either (a) the Full
Milestone 2 Payment or (b) the Partial Milestone 2 Payment.

  


 

  

"Net Sales" means (a) total revenue after the Effective Time with respect to
all Ophthalmology Products of the Company and its Affiliates set forth on the
income statement of the Company as calculated in accordance with Parent's
policies in effect from time to time as applied to Parent's business regarding
revenue recognition which conform with U.S. generally accepted accounting
principles minus, if any, (b) rebates, returns, charge-backs, discounts or
reductions in connection therewith. Notwithstanding the foregoing, any gross
amounts actually collected, earned and accrued with respect to any of the
Ophthalmology Products, and resulting from a transaction between or among the
Company, Parent and their respective Affiliates shall be excluded from the
computation of Net Sales; _provided_ , _however_ , that the subsequent and
final sales of Ophthalmology Products, that result in such gross amounts, to
third parties by such Affiliates, shall be included in the computation of Net
Sales.

  


 

  

"Net Sales Statement" means a written statement of Parent setting forth the
calculation of Net Sales for the four most recently concluded calendar
quarters in the Milestone Achievement Period.

  

  

 

2  

  

"Ophthalmology Products" means all non-neurosurgical products and services
licensed or sold by the Company and its Affiliates, including by their
respective direct sales representatives and distribution partners, _provided_
that Ophthalmology Products shall not include any products or services
licensed or sold to original equipment manufacturer customers of the Company
or its Affiliates, including without limitation to Johnson and Johnson
(including Codman and Shurtleff, Inc.), Stryker Corporation, Abbott Laboratories
Inc. (including Abbott Medical Optics Inc.), Novartis Corporation (including
Alcon, Inc.) and Mobius Therapeutics, LLC, or their respective Affiliates, and
further _provided_ , _however_ , notwithstanding anything herein to the
contrary, all products and services licensed or sold by Sterimedix Ltd. (a
Company Affiliate) shall be included in Ophthalmology Products.

  


 

  

"Partial Milestone 2 Payment" means an amount per CVR, payable in cash,
without interest thereon and subject to reduction for any applicable
withholding taxes in respect thereof, equal to (a) (i) Net Sales during the
final four (4) consecutive calendar quarters during the Milestone Achievement
Period, minus Fifty Five Million Dollars ($55,000,000), divided by (ii) Ten
Million Dollars ($10,000,000), multiplied by (b) $0.50. For example, if
aggregate Net Sales for the final calendar year of the Milestone Achievement
Period is Sixty Million Dollars ($60,000,000), the Partial Milestone 2 Payment
shall be ($60,000,000-$55,000,000) / ($10,000,000) x ($0.50), or $0.25.

  


 

  

"Permitted Transfer" means a transfer of one or more CVRs (a) upon death by
will or intestacy; (b) by instrument to an inter vivos or testamentary trust
in which the CVRs are to be passed to beneficiaries upon the death of the
trustee; (c) made pursuant to a court order; (d) made by operation of law
(including a consolidation or merger) or without consideration in connection
with the dissolution, liquidation or termination of any corporation, limited
liability company, partnership or other entity; (e) in the case of CVRs
payable to a nominee, from a nominee to a beneficial owner (and, if
applicable, through an intermediary) or from such nominee to another nominee
for the same beneficial owner, in each case as allowable by the Depository
Trust Company; or (f) as provided in _Section 2.6_.

  


 

  

"Rights Agent" means the Rights Agent named in the first paragraph of this
Agreement, until a successor Rights Agent shall have become such pursuant to
the applicable provisions of this Agreement, and thereafter "Rights Agent"
shall mean such successor Rights Agent.

  


 

  

"Selling Entity" means Parent, its Affiliates (including the Company) and
their respective direct and indirect transferees, licensees, grantees and
acquirers with respect to rights to develop or commercialize the Ophthalmology
Products (but not a distributor of the Ophthalmology Products acting solely in
the capacity of a distributor and not otherwise a direct or indirect
transferee, licensee, grantee or acquirer with respect to development or
commercialization rights as to the Ophthalmology Products).

  

  

 

3  

  

 _Index of Defined Terms_

  


 

     

Acting Holder(s

  |  

Section 1.1

   
---|--- 
    

Agreement

  |  

Preamble

   
    

Assignee

  |  

Section 6.4

   
    

Business Day

  |  

Section 1.1

   
    

Code

  |  

Section 2.4(h)

   
    

Company

  |  

Recitals

   
    

CVR Register

  |  

Section 2.3(b)

   
    

CVRs

  |  

Section 1.1

   
    

Final Statement

  |  

Section 2.4(f)

   
    

Full Milestone 2 Payment

  |  

Section 1.1

   
    

Holder

  |  

Section 1.1

   
    

Holder Representative

  |  

Section 2.4(f)

   
    

Independent Accountant

  |  

Section 1.1

   
    

Loss

  |  

Section 3.2(f)

   
    

Merger

  |  

Recitals

   
    

Merger Agreement

  |  

Recitals

   
    

Merger Sub

  |  

Recitals

   
    

Milestone 1 Compliance Certificate

  |  

Section 2.4(a)

   
    

Milestone 1 Payment

  |  

Section 1.1

   
    

Milestone 1 Target

  |  

Section 1.1

   
    

Milestone 2 Compliance Certificate

  |  

Section 2.4(b)

   
    

Milestone 2 Target

  |  

Section 1.1

   
    

Milestone Achievement Period

  |  

Section 1.1

   
    

Milestone Payments

  |  

Section 1.1

   
    

Net Sales

  |  

Section 1.1

   
    

Net Sales Statement

  |  

Section 1.1

   
    

Non-Compliance Certificate

  |  

Section 2.4(e)

   
    

Non-Compliance Certificate Review Period

  |  

Section 2.4(f)

   
    

Objection Notice

  |  

Section 2.4(f)

   
    

Offer

  |  

Recitals

   
    

Ophthalmology Products

  |  

Section 1.1

   
    

Parent

  |  

Preamble

   
    

Partial Milestone 2 Compliance Certificate

  |  

Section 2.4(c)

   
    

Partial Milestone 2 Payment

  |  

Section 1.1

   
    

Permitted Transfer

  |  

Section 1.1

   
    

Preliminary Statement

  |  

Section 2.4(f)

   
    

Preliminary Statement Review Period

  |  

Section 2.4(f)

   
    

Rights Agent

  |  

Section 1.1

   
    

SEC

  |  

Section 2.4(a)

   
    

SEC Report

  |  

Section 2.4(a)

   
    

Selling Entity

  |  

Section 1.1

   
    

Shares

  |  

Recitals

   
   

  

 

4  

  

ARTICLE II

  


 

  

 _CONTINGENT VALUE RIGHTS_

  


 

  

SECTION 2.1 _Holders of CVRs; Appointment of Rights Agent_.

  


 

  

(a) Pursuant to the terms of the Merger Agreement, (i) each holder of any
Shares or Company Restricted Stock Awards that are converted into the right to
receive the Merger Consideration shall be entitled to one CVR for each such
Share or Company Restricted Stock Award and (ii) each holder of any Company
Option that is outstanding immediately prior to the Effective Time shall be
entitled to one CVR for each Share underlying such Company Option.

  


 

  

(b) Parent hereby appoints the Rights Agent to act as rights agent for Parent
in accordance with the express terms and conditions set forth in this
Agreement, and the Rights Agent hereby accepts such appointment.

  


 

  

SECTION 2.2 _Nontransferable_. CVRs may not be sold, assigned, transferred,
pledged, encumbered or disposed of in any other manner, in whole or in part,
other than pursuant to a Permitted Transfer. Any attempted sale, assignment,
transfer, pledge, encumbrance or disposition of CVRs, in whole or in part, in
violation of this _Section 2.2_ shall be void ab initio and of no effect.

  


 

  

SECTION 2.3 _No Certificate; Registration; Registration of Transfer; Change of
Address_.

  


 

  

(a) CVRs shall not be evidenced by a certificate or other instrument.

  


 

  

(b) The Rights Agent shall keep a register (the "CVR Register") for the
purposes of (i) identifying the Holders of CVRs and (ii) registering CVRs and
Permitted Transfers thereof.

  


 

  

(c) Without limiting the restriction on transferability set forth in _Section
2.2_ , every request made to transfer a CVR must be in writing and accompanied
by a written instrument of transfer and other requested documentation in form
reasonably satisfactory to the Rights Agent, duly executed by the registered
Holder or Holders thereof, or by the duly appointed legal representative,
personal representative or survivor of such Holder or Holders, setting forth
in reasonable detail the circumstances relating to the transfer demonstrating
that such proposed transfer is a Permitted Transfer. Upon receipt of such
written notice, the Rights Agent shall notify Parent that it has received such
written notice. Upon receipt of such notice from the Rights Agent, Parent
shall in good faith reasonably determine whether the transfer is a Permitted
Transfer and otherwise complies with the other terms and conditions of this
Agreement, and if Parent so reasonably determines that such transfer does so
comply, Parent shall instruct the Rights Agent in writing to register the
transfer of the applicable CVRs in the CVR Register. All duly transferred CVRs
registered in the CVR Register shall be the valid obligations of Parent,
evidencing the same right, and entitling the transferee to the same benefits
and rights under this Agreement, as those held by the transferor. No transfer
of a CVR shall be valid until registered in the CVR Register in accordance
with this Agreement. Any transfer or assignment of CVRs shall be without
charge (other than the cost of any transfer tax or similar tax or charge) to
the applicable Holder. Parent and the Rights Agent may require payment of a
sum sufficient to cover any stamp or other tax or charge that is imposed in
connection with any such registration of transfer.

  

  

 

5  

  

(d) A Holder may make a written request to the Rights Agent to change such
Holder's address of record in the CVR Register. Such written request must be
duly executed by such Holder. Upon receipt of such written request, the Rights
Agent shall promptly record the change of address in the CVR Register.

  


 

  

SECTION 2.4 _Payment Procedures_.

  


 

  

(a) _Milestone 1_. If the Milestone 1 Target is achieved during the Milestone
Achievement Period, then no later than the fifth (5th) Business Day after
Parent files its first Quarterly Report on Form 10-Q, or Annual Report on Form
10-K, as applicable ("SEC Report"), with the Securities and Exchange
Commission (the "SEC") following the end of the four (4) consecutive calendar
quarters during which the Milestone 1 Target is achieved, Parent shall deliver
to the Rights Agent (i) a certificate (the "Milestone 1 Compliance
Certificate") certifying that the Holders are entitled to receive the
Milestone 1 Payment and (ii) an amount in cash equal to the aggregate
Milestone 1 Payment with respect to the CVRs held by all Holders. The Rights
Agent shall promptly (and in no event later than five (5) Business Days after
receipt thereof by the Rights Agent) send to each Holder at its address set
forth in the CVR Register a copy of the Milestone 1 Compliance Certificate and
an amount in cash equal to the Milestone 1 Payment with respect to each CVR
held by such Holder. In the event that the Milestone 1 Target is not achieved
prior to the end of the Milestone Achievement Period, the Holders shall have
no right to receive the Milestone 1 Payment with respect to their CVRs.

  


 

  

(b) _Full Milestone 2_. If the Milestone 2 Target is achieved during the
Milestone Achievement Period, then no later than the fifth (5th) Business Day
after Parent files its first SEC Report following the end of the four (4)
consecutive calendar quarters during which the Milestone 2 Target is achieved,
Parent shall deliver to the Rights Agent (i) a certificate (the "Milestone 2
Compliance Certificate") certifying that the Holders are entitled to receive
the Full Milestone 2 Payment and (ii) an amount in cash equal to the aggregate
Full Milestone 2 Payment with respect to the CVRs held by all Holders. The
Rights Agent shall promptly (and in no event later than five (5) Business Days
after receipt thereof by the Rights Agent) send to each Holder at its address
set forth in the CVR Register a copy of the Milestone 2 Compliance Certificate
and an amount in cash equal to the Milestone 2 Payment with respect to each
CVR held by such Holder. In the event that the Milestone 2 Target is not
achieved prior to the end of the Milestone Achievement Period, the Holders
shall have no right to receive the Full Milestone 2 Payment with respect to
their CVRs. For the avoidance of doubt, if both the Milestone 1 Target and the
Milestone 2 Target are achieved based on Net Sales in overlapping four (4)
consecutive calendar quarters during the Milestone Achievement Period, both
the Milestone 1 Payment and the Full Milestone 2 Payment shall be made to
Holders in accordance with _Section 2.4(a)_ and _(b)_.

  


 

  

(c) _Partial Milestone 2_. If the Milestone 2 Target is not achieved during
the Milestone Achievement Period, but the Net Sales during the final full
calendar year of the Milestone Achievement Period exceed Fifty Five Million
Dollars ($55,000,000), then no later than the fifth (5th) Business Day after
Parent files its 2017 Annual Report on Form 10-K with the SEC, Parent shall
deliver to the Rights Agent (i) a certificate (the "Partial Milestone 2
Compliance Certificate") certifying that the Holders are entitled to receive
the Partial Milestone 2 Payment and (ii) an amount in cash equal to the
aggregate Partial Milestone 2 Payment with respect to the CVRs held by all
Holders. The Rights Agent shall promptly (and in no event later than five (5)
Business Days after receipt thereof by the Rights Agent) send to each Holder
at its address set forth in the CVR Register a copy of the Partial Milestone 2
Compliance Certificate and an amount in cash equal to the Partial Milestone 2
Payment with respect to each CVR held by such Holder. The Holders shall have
no right to receive any or all of the Partial Milestone 2 Payment in the event
that (A) the Milestone 1 Target is not achieved within the Milestone
Achievement Period or (B) the Milestone 2 Target is achieved during the
Milestone Achievement Period. For the avoidance of doubt, if the Milestone 1
Target is achieved during the Milestone Achievement Period but not until the
end of the Milestone Achievement Period based on the Net Sales during the
final full calendar year of the Milestone Achievement Period, and the Net
Sales during the final full calendar year of the Milestone Achievement Period
exceed Fifty Five Million Dollars ($55,000,000) but are less than Sixty Five
Million Dollars ($65,000,000), then the Holders shall have a right to receive
both the Milestone 1 Payment in accordance with _Section 2.4(a)_ and the
Partial Milestone 2 Payment in accordance with this _Section 2.4(c)_.

  

  

 

6  

  

(d) _Net Sales Statements_. No later than the fifth (5th) Business Day after
Parent files its first SEC Report following the end of each calendar quarter
during the Milestone Achievement Period commencing with the fourth (4th) full
calendar quarter after the Effective Time, Parent shall deliver to the Rights
Agent a Net Sales Statement for the four calendar quarters most recently
ended. Upon the written request of any Holder, the Rights Agent shall deliver
to such Holder a copy of any Net Sales Statement so requested.

  


 

  

(e) _Non-Compliance Certificate_. If Parent determines that the Holders are
not entitled to receive (i) the Milestone 1 Payment or (ii) either the Full
Milestone 2 Payment or the Partial Milestone 2 Payment, pursuant to the terms
of this Agreement, then no later than the fifth (5th) Business Day after
Parent files its 2017 Annual Report on Form 10-K with the SEC, Parent shall
deliver to the Rights Agent a certificate ("Non-Compliance Certificate")
setting forth such fact and indicating which Milestone Payment(s) the Holders
are not entitled to receive. The Rights Agent shall promptly (and in no event
later than five (5) Business Days after receipt thereof by the Rights Agent)
send to each Holder at its address set forth in the CVR Register a copy of the
Non-Compliance Certificate.

  


 

  

(f) _Independent Accountant Review_. Within ninety (90) days after the
delivery of a Non-Compliance Certificate by the Rights Agent pursuant to
_Section 2.4(e)_ (the "Non-Compliance Certificate Review Period"), the Acting
Holders may deliver to Parent and the Rights Agent a written objection notice
to such Non-Compliance Certificate (an "Objection Notice") and retain the
Independent Accountant to verify the accuracy of the Net Sales during the
Milestone Achievement Period. If the Acting Holders elect to deliver an
Objection Notice, they shall appoint one Holder (the "Holder Representative")
to represent them with respect to the review of the Independent Accountant.
Upon the written request to Parent by the Holder Representative, Parent shall
permit the Independent Accountant, at the Acting Holders' expense, to have
access upon reasonable notice and during normal business hours to such of the
records of the Company or other applicable Selling Entity as are reasonably
necessary to verify the accuracy of the Net Sales during the Milestone
Achievement Period. Each Person seeking to receive information from Parent in
connection with an audit shall enter into, and shall cause its accounting firm
to enter into, a reasonable and mutually satisfactory confidentiality
agreement with Parent obligating such party to retain all such financial and
other information disclosed to such party in confidence pursuant to such
confidentiality agreement. The Independent Accountant shall provide Parent
with a copy of all disclosures made to the Holder Representative. No later
than thirty (30) days following access to such records of Parent as are
reasonably necessary to verify the accuracy of the Net Sales, the Independent
Accountant shall deliver a written report to Parent and the Holder
Representative of its preliminary findings regarding the Net Sales during the
Milestone Achievement Period and any potentially applicable Milestone Payments
(the "Preliminary Statement"). Parent and the Holder Representative shall have
thirty (30) days following receipt of the Preliminary Statement from the
Independent Accountant (the "Preliminary Statement Review Period") to review
and comment upon the Preliminary Statement. The Independent Accountant shall
take into consideration in good faith any comments received from Parent or the
Holder Representative during the Preliminary Statement Review Period. No later
than ten (10) Business Days after the expiration of the Preliminary Statement
Review Period, the Independent Accountant shall deliver a final written report
to Parent and the Holder Representative (the "Final Statement"). If the
Independent Accountant in the Final Statement concludes that the Holders are
entitled to one or more Milestone Payments (and such payment has not been made
by Parent), then no later than ten (10) days following its receipt of the
Final Statement, Parent shall deliver an amount in cash to the Rights Agent
sufficient to pay to the Holders such Milestone Payment(s), together with
interest at the "prime rate" as published in the Wall Street Journal from time
to time, from the date that the applicable Milestone Payment was due. The
Final Statement shall be final, conclusive and binding on Parent and the
Holders, shall be nonappealable and shall not be subject to further review,
absent manifest error. If the Rights Agent has not received a written
objection to a Non-Compliance Certificate within the Non-Compliance
Certificate Review Period, the Milestone Payment(s) to which the Non-
Compliance Certificate relates shall not be due and payable to the Holders,
and Parent and the Rights Agent shall have no further obligations with respect
to the Milestone Payment(s) to which the Non-Compliance Certificate relates.

  

  

 

7  

  

(g) _Payments to Holders_. With respect to any Milestone Payment that is
payable pursuant to this Agreement, the Rights Agent shall pay the applicable
amount to each of the Holders (the amount to which each Holder is entitled to
receive will be based on the number of CVRs held by such Holder as reflected
on the CVR Register) by (i) check mailed to the address of each Holder as
reflected on the CVR Register as of the close of business on the last Business
Day prior to such payment date or (ii) with respect to Holders that are due
amounts in excess of $1,000,000 in the aggregate who have provided Parent with
wire transfer instructions in writing, the Rights Agent will make payments by
wire transfer of immediately available funds to the account specified in the
written instructions of Parent. Parent shall cause the Rights Agent, on behalf
of and at the expense of Parent, to mail with (or, in the case of payments
made to Holders who have provided Parent with wire instructions, at the same
time as) each payment made a copy of each compliance certificate (whether the
Milestone 1 Compliance Certificate, the Full Milestone 2 Compliance
Certificate or the Partial Milestone 2 Compliance Certificate) to which such
payment relates.

  

  

 

8  

  

(h) _Withholdings_. Parent, the Company and the Rights Agent shall be entitled
to deduct and withhold, or cause to be deducted or withheld, from any amounts
otherwise payable pursuant to this Agreement, such amounts as it is required
to deduct and withhold with respect to the making of such payment under the
Internal Revenue Code of 1986, as amended (the "Code"), or any provision of
state or local tax law. To the extent that amounts are so withheld or paid
over to or deposited with the relevant governmental entity, such withheld
amounts shall be treated for all purposes of this Agreement as having been
paid to the Holder in respect of which such deduction and withholding was
made.

  


 

  

(i) _Investment of Funds_. The Rights Agent shall invest any cash held by it
for payment to the Holders in a [Custodial Account] or as reasonably directed
by Parent in writing. Any interest and other income resulting from such
investment shall promptly be paid to Parent or an Affiliate of Parent, as
directed by Parent. Notwithstanding anything to the contrary herein, Parent
shall be responsible for providing the Rights Agent with sufficient funds to
satisfy its payment obligations to Holders.

  


 

  

(j) _Treatment of Undistributed Funds_. Any cash that remains undistributed to
the Holders of CVRs twelve (12) months after such payment is due in accordance
with the terms of this Agreement, shall be delivered to Parent, upon demand
and shall be held in trust by Parent in a segregated account for the benefit
of the Holders. Any Holders of CVRs who have not theretofore received cash
with respect to such CVRs shall thereafter look only to Parent for payment of
their claim therefor. Notwithstanding any other provisions of this Agreement,
any portion of the cash provided by Parent to the Rights Agent that remains
unclaimed after termination of this Agreement in accordance with _Section
6.13_ (or such earlier date immediately prior to such time as such amounts
would otherwise escheat to, or become property of, any governmental entity)
shall, to the extent permitted by Law, become the property of Parent free and
clear of any claims or interest of any Person previously entitled thereto.

  


 

  

(k) The Rights Agent shall keep copies of this Agreement available for
inspection by the Holders during normal business hours at its office. Parent
shall supply the Rights Agent from time to time with such numbers of copies of
this Agreement as the Rights Agent may request.

  


 

  

SECTION 2.5 _No Voting, Dividends or Interest; No Equity or Ownership
Interest_.

  


 

  

(a) CVRs shall not have any voting or dividend rights, and, except as set
forth in this Agreement, interest shall not accrue on any amounts payable in
respect of CVRs.

  


 

  

(b) CVRs shall not represent any equity or ownership interest in Parent, any
constituent company to the Merger or any of their respective Affiliates.

  


 

  

SECTION 2.6 _Ability to Abandon CVRs_. A Holder may at any time, at such
Holder's option, abandon all of such Holder's remaining rights in a CVR by
transferring such CVR to Parent without consideration therefor. Nothing in
this Agreement shall prohibit Parent or any of its Affiliates from offering to
acquire or acquiring any CVRs for consideration from the Holders, in private
transactions or otherwise, in its sole discretion. Any CVRs acquired by Parent
or any of its Affiliates shall be automatically deemed extinguished and no
longer outstanding for purposes of the definition of Acting Holders, _Article
V_ and _Section 6.4_.

  

  

 

9  

  

ARTICLE III

  


 

  

 _THE RIGHTS AGENT_

  


 

  

SECTION 3.1 _Certain Duties and Responsibilities of the Rights Agent_.

  


 

  

(a) The Rights Agent shall not have any liability for any actions taken or not
taken in connection with this Agreement, except to the extent such liability
arises as a result of the willful misconduct, bad faith or gross negligence of
the Rights Agent.

  


 

  

(b) The Acting Holders may direct the Rights Agent to act on behalf of the
Holders in enforcing any of their rights hereunder. All rights of action of
any or all Holders under this Agreement may be enforced by the Rights Agent,
and any action, suit or proceeding instituted by the Rights Agent shall be
brought in its name as the Rights Agent and any recovery in connection
therewith shall be for the proportionate benefit of all the Holders, as their
respective rights or interests may appear.

  


 

  

SECTION 3.2 _Certain Rights of the Rights Agent_.

  


 

  

(a) The Rights Agent undertakes to perform such duties and only such duties as
are specifically set forth in this Agreement, and no implied covenants or
obligations shall be read into this Agreement against the Rights Agent.

  


 

  

(b) The Rights Agent may rely and shall be protected in acting or refraining
from acting upon any resolution, certificate, statement, instrument, opinion,
report, notice, request, direction, consent, order or other paper or document
believed by it in good faith to be genuine and to have been signed or
presented by the proper party or parties.

  


 

  

(c) The Rights Agent may engage and consult with counsel of its reasonable
selection and the written advice or opinion of such outside counsel shall be
full and complete authorization and protection in respect of any action taken,
suffered or omitted by it hereunder in good faith and in reliance thereon.

  


 

  

(d) Any permissive rights of the Rights Agent hereunder shall not be construed
as a duty.

  


 

  

(e) The Rights Agent shall not be required to give any note or surety in
respect of the execution of such powers or otherwise in respect of such
powers.

  


 

  

(f) Parent agrees to indemnify the Rights Agent for, and to hold the Rights
Agent harmless from and against, any loss, liability, damage or expense
("Loss") suffered or incurred by the Rights Agent and arising out of or in
connection with the Rights Agent's performance of its obligations under this
Agreement, including the reasonable costs and expenses of defending the Rights
Agent against any claims, charges, demands, actions or suits arising out of or
in connection with such performance, except to the extent such Loss shall have
been determined by a court of competent jurisdiction to have resulted from the
Rights Agent's gross negligence, bad faith or willful misconduct. Parent's
obligations under this _Section 3.2(f)_ to indemnify the Rights Agent shall
survive the resignation or removal of any Rights Agent and the termination of
this Agreement.

  

  

 

10  

  

(g) In addition to the indemnification provided under _Section 3.2(f)_ , but
without duplication, Parent agrees (i) to pay the fees of the Rights Agent in
connection with the Rights Agent's performance of its obligations hereunder,
as agreed upon in writing by the Rights Agent and Parent on or prior to the
date of this Agreement, and (ii) to reimburse the Rights Agent promptly upon
demand for all reasonable and documented out-of-pocket expenses, including all
Taxes (other than income, receipt, franchise or similar Taxes) and
governmental charges, incurred by the Rights Agent in the performance of its
obligations under this Agreement.

  


 

  

SECTION 3.3 _Resignation and Removal; Appointment of Successor_.

  


 

  

(a) The Rights Agent may resign at any time by giving written notice thereof
to Parent and the Holders specifying a date when such resignation shall take
effect, which notice shall be sent at least sixty (60) days prior to the date
so specified.

  


 

  

(b) Parent shall have the right to remove the Rights Agent at any time by
specifying a date when such removal shall take effect. Notice of such removal
shall be given by Parent to the Rights Agent, which notice shall be sent at
least sixty (60) days prior to the date so specified.

  


 

  

(c) If the Rights Agent shall resign, be removed or become incapable of
acting, Parent shall promptly appoint a qualified successor Rights Agent. The
successor Rights Agent so appointed shall, forthwith upon its acceptance of
such appointment in accordance with this _Section 3.3(c)_ and _Section 3.4_ ,
become the Rights Agent for all purposes hereunder.

  


 

  

(d) Parent shall give notice of each resignation or removal of the Rights
Agent and each appointment of a successor Rights Agent by mailing written
notice of such event by first-class mail, postage prepaid, to the Holders as
their names and addresses appear in the CVR Register. Each notice shall
include the name and address of the successor Rights Agent. If Parent fails to
send such notice within ten (10) Business Days after acceptance of appointment
by a successor Rights Agent, the successor Rights Agent shall cause the notice
to be mailed at the expense of Parent.

  


 

  

SECTION 3.4 _Acceptance of Appointment by Successor_. Every successor Rights
Agent appointed hereunder shall, at or prior to such appointment, execute,
acknowledge and deliver to Parent and to the retiring Rights Agent an
instrument accepting such appointment and a counterpart of this Agreement, and
thereupon such successor Rights Agent, without any further act, deed or
conveyance, shall become vested with all the rights, powers, trusts and duties
of the Rights Agent; _provided_ that upon the request of Parent or the
successor Rights Agent, such resigning or removed Rights Agent shall execute
and deliver an instrument transferring to such successor Rights Agent all the
rights, powers and trusts of such resigning or removed Rights Agent.

  

  

 

11  

  

ARTICLE IV

  


 

  

 _COVENANTS_

  


 

  

SECTION 4.1 _List of Holders_. Parent shall furnish or cause to be furnished
to the Rights Agent the names and addresses of the Holders within thirty (30)
Business Days following the Effective Time. The CVRs shall, in the case of the
holders of Shares, be registered in the names and addresses of the holder as
set forth in the applicable letter of transmittal accompanying the Shares
surrendered by the holder thereof in connection with the Offer or the Merger
pursuant to the Merger Agreement and in a denomination equal to the number of
Shares so surrendered, and in the case of Company Options and Company
Restricted Stock Award, be registered in the name and address of the holder
set forth in the books and records of the Company at the Effective Time and in
a denomination computed in accordance with the terms of the Merger Agreement.

  


 

  

SECTION 4.2 _Efforts_.

  


 

  

(a) Parent shall procure that during the period from and after the Closing
Date through the end of the Milestone Achievement Period, Parent shall operate
the business of the Company in good faith, consistent with Parent's general
business practices, and shall exercise commercially reasonable efforts to sell
the Ophthalmology Products and achieve the Milestone 1 Target and the
Milestone 2 Target, and shall not act in bad faith or take any action with the
purpose of reducing Net Sales or any Milestone Payments hereunder. For
purposes of this _Section 4.2(a)_ , "commercially reasonable efforts" shall
mean the efforts and resources customarily applied by companies developing and
marketing, in those countries in which the Company currently markets,
ophthalmic surgical medical devices in selling similar products with similar
market potential and at a similar stage of commercial development or product
life as the Ophthalmology Products, taking into account all relevant factors,
including as appropriate, any of the devices' commercial profile (taking into
account the devices' features and selling points), competitiveness of
alternative products in the marketplace or under development, the proprietary
position of the devices (taking into account how customers view the Company's
devices as compared to similar devices), the actual or projected profitability
of the devices, the regulatory environment and other technical, commercial,
legal, scientific and/or medical factors. "Commercially reasonable efforts"
shall not include, and nothing herein shall require Parent or the Company to,
accelerate the timing of any sales or when the revenues from such sales would
be booked (in each case as compared to the timing that would otherwise occur
in the ordinary course of business) or provide rebates, returns, charge-backs,
discounts or reductions outside the ordinary course of business in each case
in order to increase Net Sales, sell the Ophthalmology Products and/or achieve
the Milestone 1 Target and the Milestone 2 Target.

  


 

  

(b) Parent shall impose the foregoing obligations set forth in this _Section
4.2(b)_ on each Selling Entity as applicable to such entity and as required
for Parent to satisfy its obligations hereunder.

  

  

 

12  

  

ARTICLE V

  


 

  

 _AMENDMENTS_

  


 

  

SECTION 5.1 _Amendments Without Consent of Holders or Rights Agent_.

  


 

  

(a) Parent, at any time or from time to time, may unilaterally enter into one
or more amendments hereto for any of the following purposes, without the
consent of any of the Holders or the Rights Agent, so long as, in the cases of
clauses (ii) through (iv), such amendments do not, individually or in the
aggregate, adversely affect the interests of the Holders:

  


 

  

(i) to evidence the appointment of another Person as a successor Rights Agent
and the assumption by any successor Rights Agent of the covenants and
obligations of the Rights Agent herein in accordance with the provisions
hereof;

  


 

  

(ii) to add to the covenants of Parent such further covenants, restrictions,
conditions or provisions as Parent shall determine to be for the protection of
the Holders;

  


 

  

(iii) to cure any ambiguity, to correct or supplement any provision herein
that may be defective or inconsistent with any other provision herein, or to
make any other provisions with respect to matters or questions arising under
this Agreement;

  


 

  

(iv) as may be necessary or appropriate to ensure that CVRs are not subject to
registration under the Securities Act or the Exchange Act; or

  


 

  

(v) any other amendment hereto which would provide any additional rights or
benefits to the Holders or that does not adversely affect the legal rights
under this Agreement of any such Holder.

  


 

  

(b) Promptly after the execution by Parent of any amendment pursuant to the
provisions of this _Section 5.1_ , Parent shall mail (or cause the Rights
Agent to mail) a notice thereof by first class mail to the Holders at their
addresses as set forth on the CVR Register, setting forth in general terms the
substance of such amendment.

  


 

  

SECTION 5.2 _Amendments with Consent of Holders_.

  


 

  

(a) In addition to any amendments to this Agreement that may be made by Parent
without the consent of any Holder or the Rights Agent pursuant to _Section
5.1_ , with the consent of the Holders of not less than a majority of the
outstanding CVRs, whether evidenced in writing or taken at a meeting of the
Holders, Parent and the Rights Agent may enter into one or more amendments
hereto for the purpose of adding, eliminating or changing any provisions of
this Agreement, even if such addition, elimination or change is adverse to the
interests of the Holders.

  


 

  

(b) Promptly after the execution by Parent and the Rights Agent of any
amendment pursuant to the provisions of this _Section 5.2_ (but prior to the
effectiveness of such amendment), Parent shall mail (or cause the Rights Agent
to mail) a notice thereof by first class mail to the Holders at their
addresses as set forth on the CVR Register, setting forth in general terms the
substance of such amendment. Any amendment to this Agreement made pursuant to
this _Section 5.2_ shall become effective fifteen (15) Business Days following
the mailing of such notice.

  

  

 

13  

  

SECTION 5.3 _Amendments Affecting Rights Agent_. The Rights Agent may, but is
not obligated to, enter into any such amendment that affects the Rights
Agent's own rights, powers, trusts, privileges, covenants or duties under this
Agreement or otherwise.

  


 

  

SECTION 5.4 _Effect of Amendments_. Upon the execution of any amendment under
this _Article V_ , this Agreement shall be modified in accordance therewith,
such amendment shall form a part of this Agreement for all purposes and every
Holder shall be bound thereby.

  


 

  

ARTICLE VI

  


 

  

 _MISCELLANEOUS_

  


 

  

SECTION 6.1 _Notices to Rights Agent and Parent_. All notices, requests,
claims, demands and other communications between the parties under this
Agreement shall be in writing and shall be deemed given if delivered
personally, sent via electronic mail (receipt confirmed), facsimile (with
automated confirmation of receipt) or sent by a nationally recognized
overnight courier (providing proof of delivery) to the parties at the
following addresses (or at such other address for a party as shall be
specified by like notice):

  


 

  

    | (a) | if to the Rights Agent to:  
---|---|--- 
  

  


 

  

[]

  

[]

  

[]

  

Fax No: []

  

Attention: []

  


 

  

E-mail address: []

  


 

  

with a copy to:

  


 

  

[]

  

[]

  

[]

  

Fax No: []

  

Attention: []

  


 

  

E-mail address: []

  

  

 

14  

  

    | (b) | if to Parent to:  
---|---|--- 
  

  


 

  

Valeant Pharmaceuticals International

  

400 Somerset Corporate Boulevard

  

Bridgewater, NJ 08807

  

Fax No: (949) 315-3590

  

Attention: General Counsel

  


 

  

E-mail address: Robert.Chaionn@valeant.com

  


 

  

with a copy to:

  


 

  

Skadden, Arps, Slate, Meagher and Flom LLP

  

Four Times Square

  

New York, NY 10036

  

Fax No: (212) 735-2000

  

    | Attention: | Stephen F. Arcano, Esq.  
---|---|--- 
  

  

Marie L. Gibson, Esq.

  


 

  

    | E-mail address: | Stephen.Arcano@skadden.com  
---|---|--- 
  

  

Marie.Gibson@skadden.com

  


 

  

SECTION 6.2 _Notice to Holders_. All notices, requests and communications
required to be given to the Holders shall be given (unless otherwise herein
expressly provided) in writing and mailed, first-class postage prepaid, to
each Holder affected by such event, at his, her or its address set forth in
the CVR Register, not later than the latest date, and not earlier than the
earliest date, prescribed for the giving of such notice. In any case where
notice to the Holders is given by mail, neither the failure to mail such
notice, nor any defect in any notice so mailed, to any particular Holder shall
affect the sufficiency of such notice with respect to other Holders.

  


 

  

SECTION 6.3 _Entire Agreement_. This Agreement, together with the Tender
Agreements, the Confidentiality Agreement, the Merger Agreement, the exhibits
hereto or thereto, the Company Disclosure Letter and the other documents and
certificates delivered pursuant to the Merger Agreement constitute the entire
agreement between the parties with respect to the subject matter of this
Agreement and supersede all prior agreements and understandings, both written
and oral, among or between any of the parties with respect to the subject
matter of this Agreement. Notwithstanding the foregoing, as between the Rights
Agent, on the one hand, and any Holder or Parent or any other person or
entity, on the other hand, this Agreement alone constitutes the entire
understanding and agreement of such parties with respect to the subject matter
of this Agreement.

  


 

  

SECTION 6.4 _Successors and Assigns_. Parent may assign, in its sole
discretion and without the consent of any other party, any or all of its
rights, interests and obligations hereunder to one or more its Affiliates
(that are wholly owned direct or indirect Subsidiaries of Parent) (each, an
"Assignee") and any such Assignee may thereafter assign, in its sole
discretion and without the consent of any other party, any or all of its
rights, interests and obligations set forth hereunder to one or more
additional Assignees; _provided_ , _however_ , that in connection with any
assignment to an Assignee, Parent shall agree to remain liable for the
performance by Parent of its obligations hereunder. This Agreement shall be
binding upon, and shall be enforceable by and inure solely to the benefit of,
the parties hereto and their respective successors and assigns. The Rights
Agent may not assign this Agreement without Parent's consent. Except as
otherwise permitted herein, Parent may not assign this Agreement without the
prior written consent of the Holders of not less than a majority of the
outstanding CVRs. Any attempted assignment of this Agreement or any of such
rights in violation of this _Section 6.4_ shall be void ab initio and of no
effect.

  

  

 

15  

  

SECTION 6.5 _Benefits of Agreement_. Nothing in this Agreement, express or
implied, shall give to any Person (other than the parties hereto, the Holders
and their permitted successors and assigns hereunder) any benefit or any legal
or equitable right, remedy or claim under this Agreement or under any covenant
or provision herein contained, all such covenants and provisions being for the
sole benefit of the parties hereto, the Holders and their permitted successors
and assigns. The Holders shall have no rights hereunder except as are
expressly set forth herein.

  


 

  

SECTION 6.6 _Governing Law_. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS,
INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF
DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND TO BE PERFORMED WHOLLY WITHIN
SUCH STATE WITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE
THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.

  


 

  

SECTION 6.7 _Consent to Jurisdiction; Service of Process; Venue_. Each of the
parties hereto (a) consents to submit itself to the personal jurisdiction of
any federal court located in the State of Delaware or any Delaware state court
for the purpose of any action or proceeding arising out of this Agreement or
any of the Transactions, (b) agrees that it will not attempt to deny or defeat
such personal jurisdiction by motion or other request for leave from any such
court, (c) consents to the service of process by first class certified mail,
return receipt requested, postage prepaid, to the address at which such party
is to receive notice in accordance with _Section 6.1_ and (d) agrees that it
will not bring any action relating to this Agreement or any of the
Transactions in any court other than a federal court located in the State of
Delaware or a Delaware state court, and irrevocably and unconditionally waives
(and agrees not to plead or claim) any objection to the laying of venue of any
action, suit or proceeding arising out of this Agreement or the Transactions
in a federal court located in the State of Delaware or a Delaware state court
or that any such action, suit or proceeding brought in any such court has been
brought in an inconvenient forum.

  


 

  

SECTION 6.8 _WAIVER OF JURY TRIAL_. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL
RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER
BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY
OR THE COMPANY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT
OF THIS AGREEMENT.

  


 

  

SECTION 6.9 _Further Assurances_. Subject to the provisions of this Agreement,
the parties hereto will, from time to time, do all acts and things and execute
and deliver all such further documents and instruments, as the other parties
hereto may reasonably require to effectively carry out or better evidence or
perfect the full intent and meaning of this Agreement.

  

  

 

16  

  

SECTION 6.10 _Severability_. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule of Law or
public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect, insofar as the foregoing can be
accomplished without materially affecting the economic benefits anticipated by
the parties to this Agreement. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible to the fullest
extent permitted by applicable Law in an acceptable manner to the end that the
Transactions are fulfilled to the extent possible.

  


 

  

SECTION 6.11 _Headings_. The headings and table of contents contained in this
Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement.

  


 

  

SECTION 6.12 _Counterparts_. This Agreement may be executed in two or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other parties.

  


 

  

SECTION 6.13 _Termination_. This Agreement shall be terminated and of no force
or effect, and the parties hereto shall have no liability hereunder (other
than to the extent of any obligations which expressly survive or provide for
performance following termination), upon the earliest to occur of (a) the
payment of the Milestone 1 Payment and either (i) the Full Milestone 2 Payment
or (ii) the Partial Milestone 2 Payment, (b) if Parent delivers a Non-
Compliance Certificate and the Acting Holders fail to deliver a written
objection within the Non-Compliance Certificate Review Period, upon the
expiration of the Non-Compliance Certificate Review Period, (c) if Parent
delivers a Non-Compliance Certificate, and the Acting Holders deliver an
objection within the Non-Compliance Certificate Review Period, upon delivery
of a Final Report that determines that no Milestone Payment referenced in the
Non-Compliance Certificate is owed by Parent to the Holders and (d) if Parent
delivers a Non-Compliance Certificate, and the Acting Holders deliver an
objection within the Non-Compliance Certificate Review Period, upon payment by
the Rights Agent to the Holders of all Milestone Payments which the Final
Statement determines are payable by Parent.

  


 

  

SECTION 6.14 _Legal Holidays_. In the event that the day on which any
Milestone Payment is due shall not be a Business Day, then, notwithstanding
any provision of this Agreement to the contrary, any payment required to be
made in respect of the CVRs on or prior to such date need not be made on or
prior to such date, but may be made on the next succeeding Business Day with
the same force and effect as if made on the last day on which such Milestone
Payment is due.

  


 

  

SECTION 6.15 _Interpretation_. When a reference is made in this Agreement to
an Article or Section, such reference shall be to an Article or Section of
this Agreement unless otherwise indicated. Whenever the words "include,"
"includes" or "including" are used in this Agreement, they shall be deemed to
be followed by the words "without limitation." The words "hereof," "herein"
and "hereunder" and words of similar import when used in this Agreement shall
refer to this Agreement as a whole and not to any particular provision of this
Agreement. All terms defined in this Agreement shall have the defined meanings
when used in any certificate or other document made or delivered pursuant
hereto unless otherwise defined therein. The definitions contained in this
Agreement are applicable to the singular as well as the plural forms of such
terms and to the masculine as well as to the feminine and neuter genders of
such term. Any agreement, instrument or statute defined or referred to herein
or in any agreement or instrument that is referred to herein means such
agreement, instrument or statute as from time to time amended, modified or
supplemented, including (in the case of agreements or instruments) by waiver
or consent and (in the case of statutes) by succession of comparable successor
statutes and references to all attachments thereto and instruments
incorporated therein. References to a Person are also to its permitted
successors and assigns. References to clauses without a cross-reference to a
Section or subsection are references to clauses within the same Section or, if
more specific, subsection. References from or through any date shall mean,
unless otherwise specified, from and including or through and including,
respectively. The symbol "$" refers to United States Dollars.

  

  

 

17  

  

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

  

  

 

18  

  

  

IN WITNESS WHEREOF, Parent, and the Rights Agent have each caused this
Agreement to be executed as of the date first written above by their
respective officers thereunto duly authorized.

  


 

      |  

VALEANT PHARMACEUTICALS

   
---|--- 
     |  

INTERNATIONAL

   
     |  |   
     |  

By:

  |  

   
     |  |  

Name:

   
     |  |  

Title:

   
     |  |   
     |  

[RIGHTS AGENT]

   
     |  |   
     |  

By:

  |  

   
     |  |  

Name:

   
     |  |  

Title:

   
   


 

  

[Signature Page to Contingent Value Rights Agreement]

  


 

    

  

  

  

  

      '

